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ABSTRACT 
Ankylosing Spondylitis (AS) is a highly heritable condition characterised by excessive bone 
formation and stiffness of the spine and pelvis causing functional impairment.  Functional 
impairment is strongly correlated with radiographic signs of bone formation.  Clinicians can 
accurately measure bone formation but have a limited ability to predict or prevent it.   
 
A small number of non-genetic factors have been identified that explain approximately one 
third of the variation in radiographic severity.  No genetic predictors of radiographic 
severity have consistently been identified.   
 
This work investigates the contribution of non-genetic and genetic factors to radiographic 
severity.  Knowledge of causal genetic variants could be used to predict prognosis or to 
design therapeutics.  Spinal radiographs were scored using the modified Stoke Ankylosing 
Spondylitis Severity Score (or a modified version of this score), mostly by a single 
calibrated reader.   
 
Observed modified Stoke Ankylosing Spondylitis Severity Scores were compared between 
males and females.  Cross-sectional modelling was performed on 1392 subjects by 
comparing previously recorded clinical covariates and demographics with the latest 
radiographic score for each patient, using a negative binomial model.  Residuals from this 
model were considered to be the phenotype corrected for known covariates.  A 
quantitative Genome Wide Association Study (GWAS) was performed on 1253 cases, 
comparing the corrected phenotype with millions of genetic markers per subject.  Genome-
wide Complex Trait Analysis (GCTA) was used to estimate the contribution of common 
variants with small effect sizes to the phenotype.  An allelic risk score approach was used 
to examine the hypothesis that known bone mineral density, height, AS susceptibility and 
smoking dependence related loci also affect AS radiographic severity. 
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Known contributors to radiographic severity - gender, smoking and symptom duration were 
found to explain approximately one-third of phenotypic variation.  GCTA estimated that 
common variants contribute at least 33% of phenotypic variation.  No signal was identified 
to link known contributors to AS susceptibility, including the MHC region, with radiographic 
severity.  Known AS susceptibility, BMD, height and smoking dependence loci were not 
associated with severity upon allelic risk score analysis.  GWAS suggested that loci 
involved in bone metabolism and innate inflammation may influence radiographic severity.  
Some genes in the same pathways as AS susceptibility loci, including the TNF pathway, 
had a suggestive association with the phenotype.  Additionally suggestive associations 
between loci related to bone formation and immune-microbiota interactions in the gut were 
present, which, if confirmed, may provide a mechanism for observed patterns of microbiota 
in human AS cases.   
 
This study did not definitively associate any specific loci with the phenotype, probably due 
to its low power and limitations of the phenotype modelling.  Modelling was limited to a 
cross-sectional analysis, slightly underestimated the frequency of ankylosis and did not 
correct for some known influences of radiographic severity such as medication use and 
occupation.  Robustness of the model to the effects of confounders was assessed by local 
sensitivity analysis. 
 
As the first comprehensive study of the relationship between genotype and radiographic 
severity, this study confirms that genetic factors make a significant contribution.  
Involvement of loci highlighted by this study should be confirmed by larger genetic 
association studies and functional profiling of the new candidate genes in AS cases.  Once 
identified, genetic determinants of radiographic severity would make attractive targets for 
therapeutic intervention and prediction of prognosis. 
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Thesis Introduction 
 
Ankylosing Spondylitis is a highly heritable condition characterised by excessive bone 
formation of the spine and pelvis.  A small number of non-genetic factors have been 
identified that explain less than one third of the variation in radiographic severity.  
Numerous studies have investigated genetic contributors to susceptibility. Few studies 
have compared genotype with radiographic severity and none have scanned the whole 
genome.   
 
This study investigates the contribution of non-genetic and genetic factors to this 
phenotype with the aim of identifying causal variants that could be used to predict 
prognosis or as therapeutic targets. 
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1. Literature Review  
 
This literature review will discuss the nature of radiographic signs of Ankylosing Spondylitis 
(AS).  It will cover AS pathology related to radiographic changes, predictors of radiographic 
severity and the most appropriate method of assessing radiographic severity in AS.  
Identification of limitations of current knowledge will aid in focussing future research into 
AS severity. 
 
AS is a chronic form of autoinflammatory arthritis which affects approximately 0.5-0.86% of 
Europeans, and is two to three times more common in males (1, 2).  The predominant 
symptoms of axial pain, stiffness and fatigue usually develop in the late teens or early 
twenties.  These symptoms result from inflammation and bone formation of the spine, 
which is typically first evident in the sacroiliac joints.  Entheseal inflammation occurs in the 
axial spine and many extra-axial locations, including the hip and knee joints, the plantar 
fascia and the insertion of the Achilles tendon.  Other sites of inflammation can include:  
the anterior uvea, the intestines, the proximal aorta and the lungs.  One third of sufferers 
will progress to complete bony fusion of the spine within thirty years of symptom onset, 
which confers significant disability.  Recent Genome Wide Association Studies (GWAS) 
have identified genetic loci that contribute to AS susceptibility, but as yet few investigations 
have examined loci associated with AS severity.  AS cohorts have been examined for non-
genetic predictors of AS severity, but they explain only 23% of phenotypic variation in 
severity (3).  Clinicians therefore have very limited ability to estimate prognosis in this 
commonly disabling condition. 
 
The location of many prognostic factors is expected to be within the genome.  Twin studies 
demonstrate more than 90% of AS susceptibility is explained by genetic variation (4).  
Pedigree studies of AS severity have estimated the heritability, or variation due to genetic 
factors, of a functional score, Bath Ankylosing Spondylitis Functional Index (BASFI),  a 
symptom score, the Bath Ankylosing Spondylitis Activity Index (BASDAI), and score of 
radiographic severity, the Bath Ankylosing Spondylitis Radiology Index (BASRI).  BASFI 
has an estimated heritability of 0.76, BASDAI 0.49, and BASRI 0.62 (5, 6).  An alternate 
model of AS severity would be that while susceptibility is genetic, the progression of the 
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disease depends upon non-genetic factors present at the time.  The limited amount of 
variation in AS severity explained by non-genetic factors, and the existing estimates of 
BASFI and BASRI heritability make this model unlikely.  Thus the influence of genetics on 
AS severity is likely to be substantial, mirroring the magnitude of the influence of genetics 
on AS susceptibility. 
  
Functional deficit from AS is mostly due to pain, stiffness, limitation of joint movement and 
fatigue.  Serial symptom scoring of AS sufferers demonstrates large temporal variation in 
the symptoms of pain and stiffness (7).  Current treatment of AS relieves axial pain, 
stiffness and associated fatigue in most patients.  Restricted range of movement, 
measured by metrology, is  not completely relieved by pharmacologic therapy and is highly 
correlated with radiographic signs of ankylosis.  It remains the main cause of disability that 
clinicians are unable to treat.  As radiographic signs of ankylosis are progressive and 
irreversible, they provide a replicable phenotype which can be objectively measured and is 
proportionate to disability.   
Figure 1.1.  Progression of spinal disease in AS  (8) 
 
 
The Pathology of Progression in AS  
 
The pathological characteristics of AS and their progression have been investigated by 
Magnetic Resonance (MR) studies and histology.  The sequence is believed to start with 
autoinflammatory osteitis, progresses to erosion of cartilage and bone, and is replaced by 
loose fibrous repair tissue which eventually ossifies (9).  If this occurs at a vertebral corner 
a spur-like bony protrusion, termed a syndesmophyte, may form.  Histological examination 
at autopsy has demonstrated that squared and sclerosed vertebrae on radiography are 
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sites of osteitis, infiltrated with neutrophils, lymphocytes and monocytes (10).  Some areas 
of vertebral cortex were replaced by granulation tissue.  Osteoclasts and osteoblasts were 
present, and woven bone was seen to be replaced by lamellar bone.  Biopsy of tender 
entheses and ligaments from AS patients also has demonstrated inflammatory infiltrate.  
Entheseal erosions were present, and appeared to be repaired with woven bone without 
cartilage formation, then presumably was later replaced by lamellar bone forming a bony 
prominence at the site of former erosion (11).  A similar process was observed at anterior 
vertebral corners, with the additional feature of endochondral ossification of the vertebral 
end plate.  Some syndesmophytes were noted to have bases of lamellar bone and apices 
of woven bone.  Given that lamellar bone usually replaces reactive woven bone after some 
time, this indicates intermittent bone formation.  Fewer histological signs of inflammation 
were present at sites of new bone formation.  These findings have been supported by MR 
studies of osteitis, which demonstrate syndesmophyte formation is more common in 
vertebral corners with observed osteitis at baseline (12).  It is also more common at 
corners where inflammation has resolved, as evidenced by a fatty lesion or resolution of 
osteitis (13).  These studies have also implied that syndesmophytes are more likely to 
occur at sites of advanced osteitis, called ‘type B’ corner inflammatory lesions (CIL), rather 
than acute ‘type A’ CIL, and where osteitis persists for the entire duration of the study.  
One study found a persistent CIL to be six times more likely, and a resolved CIL twice as 
likely to progress to a syndesmophyte than a vertebral corner with no CIL and no fatty 
lesion (13).  This was in the context of an overall syndesmophyte formation rate of 3.7%, 
which is consistent with previously observed rates.  Notably 40% of syndesmophytes in 
this two year study arose from corners with no observed inflammatory or fatty lesion (14).  
The lack of immediate bone formation at inflamed vertebral corners can be explained by 
the ‘TNF brake hypothesis’, where active inflammation and osteoclast stimulation 
temporarily inhibit bone formation (15).  This may explain why an MR study comparing the 
syndesmophyte predictive value of two osteitis based scores did not find any benefit of 
including erosion information (16).   
 
An alternative explanation for the lack of observed coexisting bone formation and 
inflammation would be that erosions do not progress to sites of bone formation.  Lories et 
al. tested this theory in a mouse model by observing whether pathological bone formation 
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occurs when inflammation is treated with Tumour Necrosis Factor α (TNF) inhibitors and 
dexamethasone.  Pathological bone formation from existing bone, termed 
osteoproliferation, was not affected (17, 18).  The authors also suggested that a lack of 
inhibition of bone formation by glucocorticoids is a sign that osteoproliferative signals in AS 
differ from physiological bone remodelling signals, which are inhibited by glucocorticoids.  
Supporting the uncoupled theory, a subsequent mouse trial found that blockade of the 
osteoclastogenic signals TNF and RANKL did not affect bone formation, and sites of 
osteoclast infiltration were seen to progress to bony spurs.  Sites where osteoclast 
infiltration breached the cortex and formed an erosion were observed to not progress to 
bony spurs (19).  This mouse model develops an ankylosing enthesopathy focused around 
the ankle, and it is known that trauma (such as fighting between male mice) is involved its 
pathogenesis.  Unlike most human AS cases, the mice involved do not carry HLA-B27, 
and do not develop axial arthritis.  Thus the relevance of these mouse model findings to 
human AS is uncertain.  Under the assumption that in this model bony spur formation 
occurred despite thorough suppression of all inflammation, the authors proposed an 
alternate model.  This model treats inflammation and ankylosis as uncoupled processes, 
and states that biomechanical stress or damage triggers a local reaction that may result in 
either osteogenesis or inflammatory cell infiltration.  At this point there is no human 
radiographic data to support this model, and the strong link between CIL and 
syndesmophyte formation suggests a coupled process.  Changes to bone including 
osteitis, vertebral erosion, sclerosis and squaring have been implicated in the 
pathogenesis of syndesmophyte formation, but the exact pathological process that leads 
to their formation is not clear. 
 
The only known mechanism of bone resorption is by osteoclasts.  Osteoclasts are 
overactive in AS, demonstrated by a greatly increased incidence of trabecular 
osteoporosis.  Osteoblast precursors, lymphocytes, Natural Killer (NK) cells and synovial 
cells all express RANKL, a signal which promotes osteoclast differentiation from monocyte 
lineage precursors and stimulates resorption (20). This process is directly inhibited by 
osteoprotegrin.  Another inhibitor of osteoclast differentiation is IL-12 (21), which is 
associated with Single Nucleotide Polymorphisms (SNPs) in AS (22).  RANKL production 
is induced by TNF, IL-1, IL-6 and IL17/23 with IL-6 also exerting a direct inhibitory effect on 
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osteoclasts.  Apart from IL-17, the receptors for these cytokines have been associated with 
SNPs in AS.  TNF also acts synergistically with RANKL on osteoclast precursors to 
promote osteoclast differentiation.  Osteoclast formation in response to TNF is 2.5 fold 
higher in HLA-B27 positive monocytes, an allele present in most AS patients (23).  IL-12 
and IL-23 inhibit osteoclast formation by inducing production of Granulocyte Macrophage 
Colony Stimulating Factor (GMCSF) which promotes mononuclear cell differentiation into 
dendritic cells rather than osteoclasts (24).  Thus the spondyloarthropathies, which are 
mediated by a Th17 response involving IL-12, IL-23, IL-17, IL-1, TNF and IL-6, produce a 
mixture of inhibitory and stimulatory osteoclast signals.  Bone resorption is regulated by 
complex overlapping cytokine pathways. 
 
Bone formation is also regulated by the same pathways.  Some cytokines involved in the 
Th17 response, such as IL-23, also stimulate bone formation (25).  TNF and IL-6 inhibit 
bone formation by upregulating DKK-1 and sclerostin, negative regulators of the ‘wingless’ 
(Wnt) pathway, a pathway central to osteoblast differentiation and function (21).  Blocking 
these inhibitory signals promotes bone formation, as evidenced by increased osteophyte 
formation, by endochrondral ossification, upon combined DKK-1 and TNF blockade (26).  
Wnt dysregulation in AS has been demonstrated by the observation that DKK-1 and 
sclerostin levels are lower in subjects who develop syndesmophytes over a two year 
period.  DKK-1 levels in the AS subjects were not correlated with CRP, and were noted to 
be stable over three measurements spanning two years (27).  Kwon et al. found that DKK-
1 levels in AS cases are almost half that in healthy controls, and are unresponsive to three 
months of TNF blockade (28).  This suggests DKK-1 levels are independent of acute 
inflammation, and may be instead influenced by other signalling mechanisms, host factors 
such as genetics or may display a delayed rise after inflammation. A similar study by 
Daoussis et al. found the opposite – with DKK-1 levels higher in AS cases than controls, 
and DKK-1 levels higher in the TNF treated group (29). This study also found DKK-1 levels 
in RA subjects to be lower than in controls, which is highly inconsistent with previous 
studies of DKK-1 levels, and the fact that DKK-1 blockade induces sacroiliac fusion in TNF 
transgenic mice (30).  Bone Morphogenic Proteins (BMP), members of the Transforming 
Growth Factor β family, stimulate physiological chondrogenesis and bone formation.  BMP 
dysregulation is evident in mouse models (17, 18), and one study of human AS cases 
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suggests BMP is elevated relative to controls in AS subjects with spinal fusion but not AS 
subjects without fusion (31).  Matrix Metalloproteinases (MMPs) break down extracellular 
matrix during remodelling, and may be a marker of AS activity.  Elevated levels of MMP3 
have been linked to radiographic progression over two years (32).   A follow up study did 
not find MMP levels elevated in the bone or synovium of AS cases, leaving their role in AS 
undefined (33).  Dysregulated bone formation and remodelling pathways are implicated in 
syndesmophyte formation, and appear to be influenced by inherent host factors and 
inflammatory pathways. 
 
Numerous inflammatory pathways have been implicated in AS pathogenesis.   Studies 
from AS cases and mouse models have strongly implicated Th17 cytokines IL-17 and IL-
23.  They are produced at sites of inflammation, mostly by innate immune system cells 
including mast cells and γ/δ T cells (25, 34).  This response is also seen in immune 
response to Chlamydial infections, a trigger of reactive arthritis.  IL-23 triggers 
inflammation of entheses and the proximal aorta in mouse models, and promotes IL-22 
expression which in turn upregulates Wnt and BMP (25).  Overactivity in these pathways is 
deliberately introduced into mouse models, while its origin in humans is believed to be 
mostly inherited.  Genetic studies have found association between AS susceptibility and 
SNPs in receptors for IL-23, IL-6, IL-12, IL-27 and prostaglandin E2 (35, 36).  TNF, IL-1, 
IL-6, IL-17 and IL-23 are considered shared pathways of multiple physiological 
inflammatory responses (34).  Elevated IL-1 and IL-6 levels are seen in gout, while 
rheumatoid arthritis is associated with increased production of TNF, IL-6, IL-17 and IL-23.  
Prostaglandin E2 is produced at sites of inflammation, and promotes osteoblast 
differentiation via Wnt activation.  Non Steroidal Anti-Inflammatory Drugs (NSAIDs) limit 
radiographic progression in AS, an action attributed to decreased prostaglandin production 
(37-39). Other loci implicated in AS pathogenesis include those involved in lymphocyte 
differentiation and function, peptide handling and extra-cellular matrix interaction.  A 
GWAS of Han Chinese cases associated HAPLN1, an extra-cellular matrix linker protein 
associated with osteophyte formation in postmenopausal women (40). This study also 
associated EDIL3, also known as DEL1, which inhibits bone resorption in a periodontitis 
mouse model by downregulating IL-17 and subsequently RANKL (41).  No association 
with either HAPLN1 or EDIL3 was found in two GWAS of AS susceptibility in Europeans 
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and another study including 2 998 East Asian cases and 5 547 East Asian controls (22, 
35, 36).  Other immunological genes associated with AS susceptibility include the 
aminopeptidases ERAP1, ERAP2, LNPEP and NPEPPS (22).  They cleave antigens 
before presentation in HLA I and have been hypothesised to increase AS risk by 
endoplasmic reticulum stress or aberrant antigen presentation to T lymphocytes and 
Natural Killer cells.  AS pathogenesis involves a prominent Th17 response as well as 
production of cytokines common to multiple autoimmune diseases.  This is reflected by the 
susceptibility loci identified on GWAS. 
 
Identifying Genetic Variation 
 
GWAS is an efficient method of identifying cellular mechanisms responsible for disease.  
GWAS measure hundreds of thousands of SNPs across the genome, and compare this to 
a known reference sequence or haplotype map to infer the sequence of nearby variable 
regions.  Measured SNPs display high Linkage Disequilibrium (LD) to nearby loci.  Distant 
loci are less likely to be inherited together, as the chance of recombination is proportionate 
to genetic distance.  A SNP is considered associated with a disease if there is a significant 
difference in allele frequency between cases and controls, or between subjects with 
different levels of a quantitative phenotype.  Variation in a SNP or in the surrounding 
region with high LD may contribute to pathogenesis.  These regions are examined for 
coding or regulatory sequences related to the affliction.  This method allows examination 
of most of the European genome while genotyping fewer than a million SNPs, despite over 
38 million human SNPs being identified (42).  This high throughput approach is cheaper 
and faster than an equivalent proteomics based approach, where a small number of 
candidate pathways are identified through slow, costly and laborious examination of case 
and mouse model tissue.  The search for diseased mechanisms in human cases and 
mouse models usually requires knowledge of where to look, what to measure, and 
depends on mouse models that accurately reflect the disease in humans.  GWAS does not 
investigate ‘rare variants’, it excludes SNPs with a Minor Allele Frequency (MAF) <1%.  
The total contribution of rare variants to polygenic disease is controversial.  Rare variants 
of genes CARD9, IL23R, LNPEP and TYK2 have been found to contribute to AS 
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susceptibility (22).  Most GWAS testing does not include specific tests for sporadic 
mutations, epigenetic changes or genomic structural features such as Copy Number 
Variants (CNV) and insertions and deletions.  Despite this, GWAS tag most CNV variation, 
meaning that most disease associated CNV should appear as disease associated SNPs 
on GWAS (43).  GWAS is an efficient method of identifying pathological processes, but 
has limitations and has only identified 24.4% of the heritability of AS susceptibility, 
compared to an estimated total heritability of >90% from twin studies (4, 22). 
 
Heritability estimates from twin studies and pedigree data are considered robust 
calculations.  The heritability with no identified source is termed ‘missing heritability’.  
While some ‘missing heritability’ may exist undiscovered in rare variants, epigenetics and 
other known non-SNP sources of variation, an effort is being made to quantify the 
contribution of common variants with small effects (44).  It has been suggested that much 
of the missing heritability is spread across hundreds or thousands of common SNPs, each 
with an effect size too small to pass the stringent genome wide significance tests used to 
limit false positives in GWAS (45).  Advocates of this hypothesis have developed a method 
of estimating heritability from additive genetic variants (narrow sense heritability) using 
SNP data, called Genome Wide Complex Trait Analysis (GCTA).  This method, which 
estimates relatedness by allele sharing, has less error than similar methods that estimate 
relatedness using detected Identity By Descent segments (46).  Application of GCTA to 
Parkinson’s Disease attributed 27% of narrow sense heritability to SNPs, a figure much 
closer to estimates from family studies than the 3-5% from GWAS hits (47).  This analysis 
allows researchers to quantify variation responsible for heritability without specific 
knowledge of which SNPs are contributing.  Comparisons of narrow sense heritability 
estimated by GCTA and heritability calculated from familial studies can partly answer the 
problem of missing heritability, confirming that common SNPs are a major source of 
phenotypic variation. 
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Measuring the Radiographic Severity of AS 
 
Symptoms and radiographic changes in AS are predominantly related to the axial 
skeleton.  Initial symptoms of buttock and lower lumbar pain coincide with sacroilitis, 
initially visible on MR imaging, which is followed over years by sclerosis, erosion, 
osteoproliferation and joint fusion on plain radiography.  These contrasting signs of erosion 
and bone formation reflect the complex signals that promote bone resorption while also 
promoting bone formation, and provide specific criteria for radiologic diagnosis.  For over 
twenty-five years, definite AS has been diagnosed by the modified New York Criteria, 
which require typical symptoms or changes in metrology plus definite sacroilitis bilaterally 
or severe changes unilaterally (48). 
 
Early radiographic changes seen at vertebral corners include erosions, sclerosis and 
squaring, with syndesmophytes and bony bridges between vertebrae occurring later.  The 
modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) has been validated as a 
reproducible severity score which is strongly correlated with metrology, progression and 
functional scores (14, 49-51).  mSASSS has been endorsed as the most appropriate 
scoring method for trials by the Assessment in Ankylosing Spondylitis working group (52).  
It scores one point for any erosion, sclerosis or squaring at twenty-four anterior vertebral 
corners in the cervical and lumbar spine, two points for a syndesmophyte and three for 
ankylosis.  The omission of posterior corners is valid – as anterior vertebral fusion is more 
strongly correlated with BASFI than posterior fusion, and posterior corners are often not 
clearly visible on plain radiograph (50).  Facet joint ankylosis is a prominent, function 
limiting feature of AS, but their use in scoring systems has been limited as lateral views 
are not the best angle for assessment (51, 53).  Studies have consistently found strong 
correlation between mSASSS and outcomes including BASFI, AS metrology, and hip 
damage measured by the BASRI hip score, and the BASRI spine score, a four level 
severity score (49, 50, 54).  Due to its reproducibility and correlation with functional 
outcomes, mSASSS is the preferred method of scoring spinal changes in AS trials (52).    
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Figure 1.2.  Radiographic disease progression in a single patient.  Zero syndesmophytes 
progress to complete ankylosis. 
  
Figure 1.3. The mSASSS scoring system (48).  
   
An ideal score of cumulative AS severity should be based on features that directly 
contribute to functional impairment.  Presence of osteoproliferation, indicated by 
syndesmophytes and bony fusion, directly decrease spinal range of movement and 
therefore function.  Removal of ambiguous syndesmophytes from mSASSS scoring by not 
counting any bony protrusions growing greater than 45° from the anterior plane of the 
vertebra improved the ability of mSASSS to predict progression (14).  Numerous 
researchers have suggested removing scores for cervical squaring as it is not consistent 
between scorers, and occurs in <1% of vertebral corners.  They have also criticised the 
scoring of erosions as erosions may represent a pathologic process separate to or distant 
from syndesmophyte formation, and have minimal impact on mSASSS as they occur in 
<5% of changes over two years (14, 55, 56).  The only studies that examine the future of 
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erosions, sclerosis and squaring (all from the OASIS cohort) suggest that erosions and 
sclerosis but not squaring have an odds ratio of 2 for progressing to syndesmophytes over 
a twelve year period (57, 58).  Despite these criticisms, the reliability of total mSASSS has 
been repeatedly demonstrated, with high intra- and inter-observer correlations for cross-
sectional data (49, 51, 54).  Longitudinal data measured as change in score between films 
demonstrate higher inter-observer correlation (55, 59).  To minimise error, it has been 
suggested that the use of multiple scorers minimises bias from a single scorer (51).  To 
improve sensitivity to change, films from all timepoints from the same subject should be 
scored at the same time (60).  While the mSASSS is a reproducible score predictive of 
future progression, scoring of non-syndesmophyte elements may detract from its role as a 
measure and predictor of ankylosis. 
 
Many of these studies aiming to validate mSASSS have also provided data into the natural 
history of AS.  It has been observed that 27.9% of subjects progress to complete spinal 
fusion after thirty years, and 42.6% after forty years (61).  Progression has been noted to 
be linear, irrespective of disease duration or age, and the proportion of patients with 
lumbar, cervical and hip involvement has been demonstrated to increase linearly over time 
(62).  The average rate of progression has repeatedly been found to be approximately one 
mSASSS point per year, with 33% of subjects progressing within two years of observation, 
48% within four years and 82% after twelve years in the OASIS cohort.  As scores of one 
are uncommon, one mSASSS point per year is equivalent to one new syndesmophyte 
every two years.  While many subjects did not progress, a subset progress rapidly, with 
22% of subjects in OASIS cohort and 38% of a German cohort progressing at least twice 
as fast as average (63-65).  As progression is almost universal, mSASSS is proportionate 
to disease duration.  The recommended film interval is every two years to provide 
sensitivity to change and adequate time for progression.  Two cohorts scored with BASRI 
spine have demonstrated a predominance of syndesmophytes in the lumbar compared to 
cervical spine in the first twenty years of symptoms  (61, 62).  The natural history of AS is 
slow, linear progression for most patients. 
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Determinants of Radiographic Severity 
 
The HLA-B27 allele is the largest identified genetic contributor to AS susceptibility, and 
has repeatedly been investigated for a link to AS radiographic severity.  Exactly how it 
predisposes individuals to AS, or why the majority of B27 positive individuals do not 
develop AS is not clear.  Theories of its mechanism of action in AS pathogenesis include 
that it may present a particular arthritogenic peptide to induce autoimmunity, that its 
subunits may be targeted by antigen presenting cells, or that it may contribute to 
endoplasmic reticulum stress and trigger IL-23 production (66).  HLA-B27 variants, and the 
presence of B27 heterozygosity or homozygosity has not consistently been linked to AS 
severity.  Boonen et al. found no association between HLA-B27 positivity and 
syndesmophyte presence or spinal fusion in 498 subjects (67).  Ward et al. found no 
association between HLA-B27 and BASRI spine score in a cross sectional study of 398 
subjects.  Studies of Finns demonstrated no relationship of HLA-B27 positive 
homozygotes with BASFI or BASDAI, but confirmed increased risk of AS susceptibility 
compared to HLA-B27 heterozygotes (68).  A cross sectional Turkish study found of more 
severe spinal disease in HLA-B27 positive males compared to negative males on BASRI, 
but only in the lumbar spine (69).  A recent longitudinal Korean study of 127 homozygous 
positive and 241 heterozygous cases found no influence on mSASSS progression, BASFI 
or BASDAI, after a mean follow up of 2.86 years and correction for clinically relevant 
covariates (70).  The longest longitudinal data is from the OASIS cohort of 186 subjects, 
with an average follow up point of 7.9 years.  HLA-B27 positive men were found to 
progress faster than HLA-B27 negative men at rates of 1.18 and 0.69 mSASSS units per 
year respectively upon univariate regression (65).  The authors provided no values 
corrected for the influence of the other covariates.  The lack of a corrected progression 
rate, the fact that it only occurs in males, and the absence of this finding on multiple 
previous cross sectional and one corrected longitudinal study mean that the body of 
evidence does not support a major role for HLA-B27 in the variation of AS radiographic 
severity.  While HLA-B27 is clearly involved in AS susceptibility, it remains unclear whether 
it is associated with the radiographic severity of established AS. 
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No genetic association studies into determinants of AS radiographic severity have been 
performed on a genome wide scale.  Candidate gene studies have attempted to associate 
this quantitative trait with genetic loci, termed QTLs (Quantitative Trait Loci).  A candidate 
gene study of 398 subjects compared the HLA-DRB1, -DQA1, -DQB1 and -DPB1 alleles to 
BASRI spine scores by multivariate logistic regression.  This cross sectional study found 
HLA-DRB1*0801 to be protective, and DQB1*0603 and DQB1*0401 to predict severe 
disease.  These alleles were present in 6%, 8.3% and 9.5% of subjects respectively (71).  
Another candidate gene study that examined 384 SNPs from immunological and bone 
related loci found significant associations with:  a β adrenergic receptor ADRB1,  the 
osteoblast stimulator NELL1, and SNPs near HLA-B, -DRB1 and -DQA1, whereas  HLA-
B27 did not display a significant association (72).  The third candidate gene study of 
radiographic severity compared thirteen SNPs tagging five genes, with mSASSS scores 
from 241 Canadian cases, with a mean follow up of 2.4 years.  This study demonstrated 
an association with LMP2 and baseline mSASSS, after correction for gender and disease 
duration.  This association did not exist with mSASSS progression, in fact only baseline 
mSASSS had a significant predictive value (73).  LMP2 is also known as PSMB9, and is a 
proteasome subunit involved in peptide handling and antigen processing.  The significance 
of these candidate gene study results is difficult to interpret given that none of these loci 
have been identified as susceptibility loci in genetic studies of AS susceptibility.  A recent 
Immunochip study with good HLA coverage, found an association with HLA-A*0201 and 
HLA-B27 and AS susceptibility, but not with HLA-DRB1 or the other HLA-B alleles found in 
the candidate gene study of radiographic severity (22).  The non-HLA QTLs found by 
these studies have not been associated by AS susceptibility GWAS or Immunochip either.  
This implies that either these reported QTLs were false negatives on the susceptibility 
GWAS, false positives as QTLs, or influence severity but not susceptibility.  The latter 
possibility is unlikely - QTLs are expected to be related to disease pathogenesis and so 
should also contribute to disease susceptibility.  A QTL that does not contribute to 
susceptibility would have to affect a disease related pathway many steps away from the 
initiating pathological events.  To date, GWAS of other autoimmune diseases have not 
definitely identified such an entity, with QTLs being previously identified susceptibility loci, 
as in an asthma severity GWAS (74), or no QTLs being found at all, as in Multiple 
Sclerosis (75, 76).  These inconsistent findings, the patchy haplotype coverage of 
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candidate gene studies and a lack of correction for population stratification and multiple 
testing make the relevance of these loci uncertain (77).  Candidate gene studies have 
pointed to a number of QTLs which should be investigated as determinants of severity by 
a more comprehensive genetic study. 
 
The most visible genotype that predicts severity in AS is the male gender.  Many cross-
sectional and longitudinal studies, after correcting for relevant covariates, have found the 
male gender to be associated with more severe radiographic disease and faster 
progression (3, 62, 65, 69, 71, 78).  The rate of progression (before correction) was found 
to be significantly higher in males, at 1.11 mSASSS units per year compared to 0.69 in 
females (65).  Conversely two longitudinal studies and one cross-sectional study analysing 
predictors of progression found no association with gender after correcting for other 
factors, despite the largest having 334 subjects, including 22% females (63, 71, 79).  The 
reason why such a strong effect was found in most but not all studies is not clear.  Gender 
based differences in the immune system are well described, and are attributed to 
regulatory effects of oestrogen on leukocytes and X inactivation.  Notably, decreased IL-1 
and IL-6 production occurs in the presence of oestrogen (80).  Many of the genetic causes 
of immunological gender differences, such as dosage compensation of X linked genes 
may also apply to AS related loci.  Oestrogens are also known to inhibit osteoclast function 
and to stimulate bone formation by stimulating Wnt in osteoblasts, while androgens 
stimulate bone formation in men (81).  This anabolic effect of androgens in males may add 
to other osteogenic signals in AS, favouring osteoproliferation.  Gender based patterns of 
severity exist in AS. Presence of lumbar syndesmophytes is less common in females, but 
peripheral arthritis is more common (61).  Some studies have demonstrated a 
predominance of cervical spine disease in females, while others have found no difference 
(61).  Females have slightly higher BASFI for equivalent BASRI scores compared to 
males, which has been attributed to the higher incidence of peripheral arthritis (78).  
Gender is strongly associated with AS radiographic severity, which is presumably due to 
recognised effects on the immune system and bone.   
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Cigarette smoking has also been strongly linked to dysregulation of the immune system 
and bone metabolism.  Current smoking has repeatedly been associated with mSASSS 
progression, in a dose dependent fashion (71, 79).   Analysis of subjects with AS within the 
GESPIC cohort found that current heavy smokers (>10 cigarettes per day) progressed 
significantly faster than others, increasing their mSASSS on average 3.1 units over two 
years compared to 0.57 units over two years for moderate and non-smokers (82).  In 
another early spondyloarthritis cohort, which contained subjects with and without definite 
AS, higher mSASSS scores and spinal inflammation on MR were more common in current 
smokers (83).  Smoking has long been recognised as a proinflammatory factor, and it also 
causes elevated IL-1, IL-6 and GMCSF, all of which inhibit osteoclast formation (21).  
Clinical evidence and knowledge of immunological and bone metabolism pathways 
support the notion that smoking is a determinant of radiographic severity in AS. 
  
Prostaglandin signalling is an immunological pathway involved in bone metabolism.  
NSAIDs have been used to treat inflammation and pain in AS, and have been 
demonstrated to limit radiographic progression over a two year period (37-39).  Recently 
published data from two longitudinal cohorts found no impact of NSAID intake, as 
measured by the ASAS NSAID index, on radiographic progression (65, 79).  The three 
studies that demonstrated an effect of NSAIDS found a large effect size, with the odds 
ratio of risk of progression being 0.15-0.36.  The first study had a borderline p value of 
0.045 (37), the first and second studies only found an effect in subjects with raised 
inflammatory markers (37, 38), and the third did not match cohorts for baseline mSASSS 
(39), thus leaving the greatest predictor of mSASSS progression (65, 79), as a 
confounding factor.  While NSAID induced inhibition of radiographic progression is 
consistent with theory, further longitudinal studies should be conducted to confirm the 
effect size of this medication. 
  
The other major class of medication used in AS is TNF inhibitors.  If TNF induced 
inflammation is an immediate trigger of osteoproliferation, TNF inhibition should impair 
radiographic progression.  Randomised Control Trials (RCTs) of etanercept and 
golimumab and case control studies of adalimumab and infliximab found no effect on 
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mSASSS progression after two years (59, 84-86).  Haroon et al. examined the effect of 
any TNF inhibitor use in a propensity score matched observational study, with a mean 
follow up of 2.9 years.  TNF inhibitor use was found to be protective in multivariate logistic 
regression assessing risk of progression, with subjects commencing TNF inhibitors >10 
years after symptom onset more likely to progress.  Longitudinal analysis only revealed an 
effect in subjects followed up for more than 3.9 years (79).  This study suggests that TNF 
may limit mSASSS progression, especially if started soon after symptom onset, and that 
the effect may only be evident after 3-4 years, explaining why the two year randomised 
control trials found no effect.  The theory that only suppression of early inflammatory 
lesions with TNF inhibits bone formation is consistent with findings that advanced ‘type B’ 
CIL are more likely to progress to syndesmophytes than early ‘type A’ CIL (13).  Thus if 
TNF inhibitor use prevents type A CIL from progressing to type B CIL, it may only inhibit 
bone formation if commenced early in the disease.  TNF inhibition has been demonstrated 
to decrease erosions in rheumatoid arthritis, and to improve trabecular osteoporosis in AS, 
but its overall effect on the complex, interacting erosive and osteoproliferative pathways of 
AS is controversial (87-89).  Given the conflicting clinical evidence and different theories 
regarding its effects on bone metabolism, further longitudinal and animal studies are 
needed to reveal the exact effects of TNF treatment. 
 
Multiple clinical parameters have been repeatedly associated with mSASSS progression.  
After disease duration, presence of syndesmophytes at baseline appears to be the second 
best predictor of mSASSS progression (14, 63, 64, 79).  This consistent finding, coupled 
with the average rate of mSASSS progression suggests that absence of syndesmophytes 
after sufficient disease duration is a protective prognostic marker.  Severe hip disease is 
strongly correlated with BASRI spine score (3, 61, 62).  This close relationship is 
presumed to be an extension of the AS disease process that affects the axial spine, 
although hip osteoarthritis is common and has a similar radiographic appearance.  Hip 
disease in AS exhibits almost the same correlation with BASFI as mSASSS (50), making it 
an important functional outcome as well as a predictor of spinal disease.   
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Disease activity has been inconsistently linked with risk of syndesmophyte formation.  ESR 
or CRP elevation indicate inflammation as part of an acute phase response.  As discussed 
earlier the pathological relevance of acute inflammation to syndesmophyte formation is 
poorly understood.  Bone formation and overactivity of the IL-17/23 pathways can occur 
without ESR or CRP elevation, and small clinical trials of IL-6 blockade in AS have not 
demonstrated any symptomatic benefit (90, 91).  Nevertheless ESR and CRP may be 
markers of syndesmophyte formation, without being part of the causal pathway 
themselves.  mSASSS progression has been associated with baseline inflammatory 
markers in a Canadian AS RCT and German AS RCT, and baseline and time averaged 
inflammatory markers in AS cases from the observational GESPIC cohort.  No association 
with BASDAI was found in any of these studies (79, 85, 92).  A recent update from the 
OASIS cohort, analysing longitudinal data found ESR, CRP, BASDAI and ASDAS (another 
a disease activity score) were associated with radiographic progression over the 
subsequent two to twelve years (93, 94).  A report from this cohort at four years, found that 
BASDAI and CRP had no association with cross-sectional mSASSS univariate modelling, 
while ESR and ASDAS had p values of borderline significance (0.07 and 0.06 respectively) 
(64).  An RCT on NSAID use found no effect of ASDAS, BASDAI or time averaged CRP 
on radiographic progression, but time averaged ESR was significant (38).  Thus the 
association between measures of disease activity and radiographic progression, even from 
within the same cohort, are inconsistent.  Further investigation is needed into these 
markers, along with whether inflammation precedes syndesmophyte formation. 
 
Lifestyle factors may also influence radiographic severity.  Physical activity and AS specific 
stretches are cornerstones of AS multidisciplinary management.  They have been shown 
to improve symptom scores but not radiographic severity (3, 95).  Conversely, occupations 
that require frequent bending, stretching, twisting or exposure to whole body vibration have 
been associated with higher BASFI and BASRI scores.  Work environments involving 
sitting, stranding and kneeling did not demonstrate any association (96).  A previous study 
that classified occupations as sedentary, active or manual, found no association with 
BASRI (3).  Conversely a recent report (published only as an abstract to date) from the 
OASIS cohort found that blue-collar workers had higher rates of progression than white-
collar workers (97).  Level of education has recently been linked to mSASSS progression, 
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with individuals with university degrees having the lowest risk of progression (98).  The 
authors have suggested that level of education is a proxy for socio-economic status, which 
may explain the association.  However level of education may also be representative of job 
activity level, exercise, medication and stretching compliance and other healthcare related 
behaviour.  Occupational and social factors that affect disease progression are important 
to identify as they may be modifiable. 
  
Extra-spinal manifestations of AS, including anterior uveitis, psoriasis and peripheral 
arthritis have not consistently been linked to radiographic severity.  A past history of uveitis 
has been associated with radiographic severity in three observational studies examining 
subjects from Bath (3, 62, 99).  An effect persisted after multivariate analysis which 
corrected for gender, disease duration, and smoking status.  Other cohorts do not 
demonstrate a correlation, even one cohort with a mean follow-up of 7.9 years (65, 67, 69, 
72, 82).  Comorbidity of AS and psoriasis is common, with 9.3% of AS sufferers reporting 
psoriasis (100).  Follow up of the OASIS and two smaller cohorts has not demonstrated an 
impact of psoriasis on radiographic severity (65, 92, 101).  An earlier study comparing 
matched controls to 91 AS subjects with psoriasis, and to 23 AS subjects with 
Inflammatory Bowel Disease (IBD) found no difference in BASRI spine scores (99).  Two 
recent small studies have found peripheral arthritis (with or without psoriasis), affecting 
joints other than the spine or hips, to be predictive of slower spinal radiographic 
progression (69, 102).  Given the closely related genetic risk factors for susceptibility of 
AS, psoriatic arthritis and IBD (103, 104), a subset of patients may have a mixed 
phenotype, involving features uncommon in AS but common in psoriatic or IBD associated 
arthritis, such as upper limb arthritis and an absence of spinal ankylosis.  These patients 
might meet the modified New York criteria for AS but progress slowly.  Presence of extra-
spinal manifestations allows identification of subgroups with different pathology that may 
experience different degrees of ankylosis. 
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Patterns of Severity 
 
Juvenile onset AS, defined as onset before age seventeen, has been linked to higher 
BASRI hip scores, a higher rate of hip replacement and lower BASRI spine scores (105).  
While the finding of lower lumbar spine BASRI in this subgroup was replicated in a 
Taiwanese cohort, worse BASRI hip and cervical spine scores were not (106).  Two further 
studies found the association between juvenile onset and lower overall mSASSS scores 
(without reporting cervical and lumbar scores), but no significant association with BASRI 
hip score (107, 108).  An increased prevalence of peripheral arthritis and dactylitis has 
been noted in juvenile onset AS (106, 107).   In adult onset AS, multiple cross-sectional 
studies have found more severe disease in subjects with an older age of onset (71, 72).   
This has not been demonstrated in longitudinal studies dedicated to identifying risk factors 
for progression (14, 65, 79, 95).  Factors associated with a late age of onset include 
absence of HLA-B27 and the male gender (68, 78).  Patterns of AS severity appear to vary 
with age of onset, which may represent overlapping pathological mechanisms. 
 
mSASSS modelling 
 
Count data, including radiographic scores, often involve large proportions of low scores.  
Analysis of non-parametric count data requires the use of less commonly used modeling 
methods.  Analysis of radiographic severity in AS has only been performed in a few 
cohorts, utilizing three distinct approaches.  The first approach involves purely descriptive 
and observational statistics.  Baraliakos et al. reported observed rates of syndesmophyte 
formation in a German cohort, and did not mention the distribution of the data (14).  This 
study reported descriptive statistics (eg the mean) that do not require the data to be 
normally distributed.  The second approach has been used to analyse the OASIS cohort of 
AS.  Rates of change were reported, with no assumption of a normal distribution.  
Modeling was performed using Generalised Estimating Equations (GEE) (57).  GEE can 
be used to analyse repeated measurements where there is correlation between 
observations (eg longitudinal data) but the distribution of correlation is unknown (109).  
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GEE require correlated response variables and so are not appropriate for analysis of 
cross-sectional data.    
 
The third method used to analyse mSASSS was first used for this condition by Haroon et 
al. in a longitudinal study (79).  Notably the cohort studied by Haroon et al. overlaps the 
cohort analysed in this MPhil project. Haroon et al. used a Zero Inflated Negative Binomial 
(ZINB) regression model for cross-sectional and longitudinal analysis of mSASSS. The 
authors justified the choice of model with the finding that change in mSASSS was over-
dispersed and zero-inflated, with 55.4% of delta mSASSS values being zero. Parameters 
describing the goodness of fit of this model were not published. 
 
Overdispersion, where the variance is higher than the mean of the observations, is a 
common problem when modeling count data (110, 111).  If not corrected, overdispersion 
can cause model misspecification.  Apparent overdispersion can result from model 
misspecification issues such as a missing covariate or interaction, outliers of the response 
variable and non-linear predictor effects. Real overdispersion may result from truly large 
variance, an excess of zeros, correlation between observations or clustering of 
observations (112, 113). 
The Poisson distribution is equidispersed, where the variance equals the mean. In the 
negative binomial distribution the variance may exceed the mean.  The Negative Binomial 
(NB) distribution is a mixture of the Poisson and gamma distributions (112, 113).  It is 
appropriate for count data that consists of non-negative integers, in which the 
overdispersion is believed to occur in a gamma distribution.  Gamma distributions include 
a wide range of shapes including a Gaussian distribution and left and right skewed bell 
shaped curves. If the overdispersion forms a recognizable distribution such as an inverse 
Gaussian distribution, modeling is typically performed by simulation (113). Otherwise “If 
overdispersion in the data takes no identifiable shape, most statisticians employ a negative 
binomial” (113)(Hilbe, p2). 
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Overdispersion in Poisson or NB models that persists after revision of the model terms and 
investigation into the previously mentioned causes over overdispersion is commonly 
caused by excessive counts of zero (zero inflation).  The best method of addressing zero 
inflation is to use a zero inflated model (113).  Zero inflated models are mixture models.  
They combine two models – one predicts the outcome of a zero vs a non-zero value 
(binomial model), and the other predicts the outcome for a range of non-zero (‘count’) 
values.   
 
Assessment of model fit for Poisson and NB models differs from that of other models 
types.  Notably these models allow a large amount of variance, allowing a greater 
difference between fitted and observed values than is present in other model types.  The 
residuals must be considered in proportion to the variance, and so are scaled by the 
square root of the variance as Pearson residuals.  Common methods of model validation 
for negative binomial models include observed vs fitted plots, plots of predictors vs 
residuals, and residuals vs predicted plots (112).  These should be assessed for 
homogeneity.  Importantly, plots of residuals should not be expected to be normally 
distributed. “As we are now using techniques that do not need a normal distribution, a 
normal distribution of the residuals is no longer of concern” (110) (Zuur et al.,  p86). 
Instead residuals may be assessed by comparing them with an envelope of bootstrapped 
confidence intervals (114, 115).  If the confidence interval completely contains the 
residuals the model is likely adequate. This method assesses for incorrect model 
specification of error distribution, the influence of outliers and for missing explanatory 
variables. 
 
Summary 
Individuals with AS experience symptoms across numerous areas of their body, and 
experience great variation in severity.  More than a third develop complete spinal fusion, 
almost a third grow syndesmophytes twofold faster than average while many never 
develop spinal fusion.  The pathophysiology that leads to osteoproliferation is only partly 
understood, leaving no definite explanation for features seen on MR and radiographic 
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studies.  This leaves clinicians with very little ability to predict which patients will progress 
to spinal or hip ankylosis.   
 
The slow rate of radiographic progression of AS and the relatively small size of AS cohorts 
has limited identification of determinants of severity. The established determinants of 
radiographic progression are existing syndesmophytes, genetics, disease duration, 
gender, smoking and continuous NSAID use.  TNF inhibitor use may slow progression, 
while raised inflammatory markers and occupation-induced mechanical stress appear to 
be associated with mSASSS progression.   
 
Previous research suggests the greatest determinant of AS severity is within the genome.  
No study has compared comprehensive genetic data with AS radiographic severity.  
Research in to genetic and non-genetic determinants of radiographic severity should 
provide valuable prognostic information and therapeutic targets that will improve the lives 
of AS patients. 
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2.   Cross-Sectional Analysis of Radiographic Severity in AS 
2.1 Introduction 
 
Radiographic severity in AS varies from no spinal changes to complete ankylosis, and 
known factors explain a minority of this variation.  Previous research has repeatedly 
identified a number of factors – symptom duration, gender, smoking status, continuous 
NSAID treatment, existing syndesmophytes, specific bone metabolism markers, and AS 
hip involvement to be predictive of radiographic severity.  There are also select reports that 
TNF inhibitor use, occupation, AS symptom scores and inflammatory markers may predict 
radiographic severity. 
 
This cross-sectional analysis aims to describe patterns of severity, and to assess the 
influence of recorded covariates on a cohort of over 1000 subjects.  After removing the 
influence of these covariates, the data could be used as a phenotype for genetic 
association testing.  With adequate power and replication, this could be used to create a 
prognostic model of AS radiographic severity, or to identify genetic and non-genetic areas 
for further research. 
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2.2  Methods   
2.2.1  Radiographic and Clinical Data 
Subject data were included from The University of Queensland Diamantina Institute 
(UQDI), and The Australo-Anglo-American Spondylitis Consortium (TASC). All subjects 
had definite AS by the modified New York criteria (48).  UQDI films were scored with 
mSASSS by either Steven Truong (ST), or Linda Bradbury (LB) with Matthew Brown 
(MAB). TASC films were scored once by LB, MAB, Thomas J Learch (TJL), Millicent Stone 
(MS), Michael Ward (MMW) or Michael Weisman (MHW).  Written informed consent was 
obtained from each subject and the data collection was approved by the ethics committee 
at each centre. 
 
mSASSS scoring by ST was compared to other TASC scorers using twenty-two TASC 
reference films and thirty-nine UQDI films, each from a different subject.  ST was blinded 
to previous scores at the time of scoring.  When scoring multiple films from the same 
subject, ST scored films chronologically and was not blinded for their date.  Blinding for 
date is technically difficult (they are date stamped) and was not considered necessary by 
mSASSS validation studies (49, 51, 60). The most recent mSASSS for each subject was 
used, unless it indicated complete cervical or lumbar ankylosis.  In these cases, where 
possible the score from the film preceding complete ankylosis was used to avoid a ‘ceiling 
effect’. 
In the case of mSASSS a ‘ceiling effect’ can exist because scores are right censored in a 
biological sense. mSASSS scores cannot be greater than 72 but clinical severity continues 
to worsen after mSASSS reaches 72.  Once a subject has an mSASSS of 72, even if the 
disease is progressing in terms of other radiographic and clinical measures, mSASSS 
cannot increase past 72.  Cross-sectional modeling should attempt to avoid using 
observations where a score of 72 has been present for many years.  A more accurate 
representation of this subject’s disease state is the score preceding complete ankylosis.  
For example, consider a subject with symptom duration of 30 years who has had an 
mSASSS of 72 for the last 10 years.  The relationship between symptom duration and 
mSASSS for this subject should be considered as an mSASSS of 72 attained after 20 
years, rather than an mSASSS of 72 attained after 30 years.  Ignoring the ceiling effect 
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would underestimate the severity of disease in this subject, making estimates of fixed 
effects (eg smoking, gender) falsely low. 
 
The mSASSS measure scores twenty four anterior vertebral corners, from the inferior 
aspect of C2 to the superior aspect of T1, and from the inferior aspect of T12 to the 
superior aspect of S1.  Vertebral corners are often obscured on lateral radiographs leaving 
an incomplete set of scores.  Cervical or lumbar films lacking scores for four or more 
vertebral corners were deemed invalid.  Consistent with mSASSS validation studies, if less 
than four corners were lacking scores, they were given the mean score for that vertebral 
segment (cervical or lumbar)  (51).  A ‘contracted mSASSS’ (cmSASSS) was used, 
scoring 0 for normal vertebral corners, erosion, sclerosis or squaring, 1 for a definite 
syndesmophyte, and 2 for each corner with a total bony bridge  (116).  Scores for erosion, 
and squaring were removed as they reduce inter-rater reliability (55, 56).  Scores for 
sclerosis are rare and have poor inter-rater reliability (117).  Syndesmophyte formation is 
not consistently preceded by observed erosion, sclerosis or squaring, making their 
biological relevance unclear.  A recent study found that use of the cmSASSS rather than 
mSASSS increased complete agreement of scores from 69.7% to 81.4% (116).  This study 
also found that cmSASSS remained highly correlated with mSASSS (r2 > 0.96). 
 
Inter-rater reliability was assessed using a two-way mixed effect Intra-Class Correlation 
Coefficient (ICC).  The ICC is a widely accepted measure of inter-rater reliability suitable 
for non-normal ordinate data, and is considered the best comparator in radiographic 
scoring studies (118-120).  Longitudinal mSASSS were only available for a few hundred 
subjects, which would not have provided enough subjects for covariate regression.  
Scoring of longitudinal mSASSS has been demonstrated to improve inter-rater reliability 
(55, 59).  Sacroiliac joints were scored according to the New York classification (48). 
 
Clinical covariates including co-morbidities had previously been collected by UQDI and 
TASC.  Uveitis, IBD and psoriasis status were physician diagnosed for US subjects and 
self-reported or physician diagnosed for UK and UQDI subjects.  US subjects with uveitis 
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were ophthalmologist diagnosed, which has a similar rate to self-reported uveitis (121).  
Data for each covariate were not available for all subjects with mSASSS.  Each covariate 
based analysis used the maximum number of subjects with data on that covariate. 
 
Some covariates vary greatly between clinic visits, and do not lend themselves to cross-
sectional analysis.  The highly variable covariates ESR, CRP, BASDAI and some symptom 
scores were included in the univariable analysis as analyses of other cohorts have 
suggested they have predictive value (65, 92). 
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2.2.2  Regression Analysis 
Regression analysis was used to assess and correct for the influence of measured clinical 
covariates on the most recent cmSASSS.  cmSASSS were not normally distributed due to 
an extreme left skew.   
 
The NB distribution was the most suitable distribution for modeling cmSASSS. Other 
distributions commonly used to model count data, such as the Poisson, Gaussian, 
Gamma, Binomial and exponential distributions are either nested within the NB distribution 
or do not resemble the distribution of observed data on visible inspection (Fig 2.1).  The 
NB distribution has a high probability when the mean is small, resulting in a left skewed 
distribution.  The most common cmSASSS score was zero, and low cmSASSS were far 
more common than high cmSASSS, producing a left skewed distribution.  The Poisson 
distribution also includes left skewed distributions, but all Poisson distributions can be 
produced by the NB function, as they are NB distributions where variance is equal to the 
mean.  Additionally the NB model is favored over Poisson models for analysis of 
overdispersed data (112, 113). For these reason, models based on the NB distribution was 
developed.  ZINB models have previously been chosen by other researchers for 
regression analysis of rheumatoid arthritis and mSASSS (79, 109).  
 
Dispersion parameters α and φ were used to assess overdispersion in the NB model.  The 
fit of NB and zero-inflated negative binomial (ZINB) models to the cmSASSS distribution 
was compared using methods suggested by Hilbe (113) – goodness of fit plots (using 
Pearson residuals), Vuong’s test (a Likelihood Ratio based test used to compare zero-
inflated and non-zero-inflated models) and the Akaike Information Criterion (AIC).  These 
goodness-of-fit plots and tests of the NB and ZINB models can be found the Appendix A.4 
and A.5.  They demonstrate the superior fit of the ZINB model. 
 
Overdispersion in the NB model was assessed by the overdispersion parameter, φ.  
Unfortunately φ could not be calculated for the ZINB model to allow a straightforward 
comparison with the value of φ for the NB model.  Calculation of φ requires calculation of 
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the residual deviance of the model, which is then divided by the residual degrees of 
freedom.  Residual deviance cannot be reliably estimated for ZINB as it is a mixture model 
with a highly non-normal outcome (122).  A related and alternative measure of dispersion 
is the Pearson Dispersion Statistic, PDS (110, 113).  This is statistic is calculated by 
dividing the Pearson Chi Squared Statistic by the residual degrees of freedom of the 
model, and ideally should be 1.00. In this case, as expected the extra modelling of zeros 
results in less overdispersion in the ZINB model (PDS  = 0.99) compared to the NB model 
(PDS  = 1.03).  The superior handling of dispersion by the ZINB model is also reflected by 
its better results in the goodness-of-fit analysis (Table 2.5, Appendix A.4 and Appendix 
A.5). 
 
All statistical analyses were performed in R using the packages: COUNT,  pscl, MASS and 
lmtest (123-127).  pscl is the most commonly used ZINB package for R and is considered 
the most reliable (112, 113).  gamlss is an R package that is used less commonly for 
ZINB, but allows random effects (128). Attempts to use gamlss with a random effect for 
Scorer failed due to model non-convergence.  A pscl ZINB using only fixed effects was 
used.   
 
Predictors of cmSASSS were assessed using univariable ZINB regression, and were then 
added by stepwise multivariable regression.  The mSASSS scorer of each film was 
included as a predictor in multivariable analysis, to account for possible minor inter-
observer variation.  Predictors involving time were allowed to interact with symptom 
duration to prevent expected collinearity (eg AS symptom duration is believed to interact 
with smoking duration as they increase equally with age).  Covariates which reveal 
themselves over time were also allowed to interact with symptom duration to account for 
the cumulative incidence of the covariate over time.  For example, AS symptom duration is 
allowed to interact with uveitis status, a feature of AS with cumulative incidence.  An 
interaction allows uveitis status to have no effect at disease onset (when lifetime uveitis 
status is inaccurate) and a definite effect after many years of symptoms.  Covariates were 
added stepwise, in order from the most to least significant on univariable analysis.  
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Superior models were identified by pairwise likelihood ratio tests, AIC and Wald tests on 
models with the same number of subjects.   
A comparison of different measures of smoking was undertaken to identify the best 
predictor for modeling.  Smoking duration, pack year history and 3 level (current/ex-/never) 
smoking status were not entered into the model at the same time as they are collinear. 
Use of an interaction term in R maintains the presence of the fixed effects as well as the 
interaction term.  In this example there would be four effects in the model: symptom 
duration, uveitis (present/absent), symptom duration with uveitis present and symptom 
duration with uveitis absent. 
One method of limiting the effect of collinearity in a model is to combine highly correlated 
predictors into a single predictor (110, 112, 129).  This approach can involve linear 
combinations of variables or a regression function that describes their distribution relative 
to the outcome (110, 130).  Horton et al. describe using of this method to combine 
collinear binary, categorical, ordinal and continuous predictors. 
 
As cmSASSS is right censored, use of a model that specifies right censorship may 
improve fit, including the underestimation of ankylosis.  Construction of a right censored 
ZINB is not currently a feature available in R, and upon perusal of the manuals of SPSS, 
Stata and SAS this type of model does not appear to be an option usable with the usual 
ZINB functions.  As a future project, a statistician may be able to write their own function 
that constructs a ZINB that specifies right censorship. 
The potential of bias from each scorer was a significant concern during the design of this 
study.  Inter-scorer variation has been a significant concern in previous studies using 
mSASSS and was a significant predictor in the univariable analysis.  The validation studies 
of mSASSS require calibration of scorers and analysis to assess inter-reader variation.  
Due to the many scorers across four countries, any inter-reader variation would cause bias 
in all subjects from an entire site.   
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The potential influence of scorer was investigated further by generation of confidence 
intervals for all fixed effects (Table 2.14). The confidence intervals suggested that despite 
a non-significant effect size in the model, the true effect size of certain scorers may be 
significant.  Bias attributed to scorer may also result from site specific factors.  Scorers 6 
and 7 scored films from the same hospital, but all other scorers work at different hospitals 
across the United States, Canada and the United Kingdom.  Local factors including 
genetic variation, radiographic methods, occupational or other environmental factors may 
vary between these sites. 
 
2.2.3  Sensitivity Analysis of the Cross-Sectional Model 
The main goals of sensitivity analysis are to identify if variability and uncertainty of input 
parameters have significant and relevant effects, (131) and to quantify the requirements of 
an unmeasured confounder large enough to alter the conclusions of a study (132).   
 
Terminology for sensitivity analyses varies between authors, due to the overlapping nature 
of statistical techniques each uses.  This study used a combination of techniques which 
are described by various authors as one-at-a-time analysis, local sensitivity analysis, 
range sensitivity analysis, confounder analysis, regression sensitivity analysis and 
graphical analysis. 
 
Local sensitivity analysis can be performed by varying one predictor at a time by a 
plausible range of variation or within the known range of input values (133).  Range 
sensitivity analysis examines model sensitivity across the entire range of input variable 
values. 
 
Local sensitivity analysis was performed by simulation, using either all observed data or a 
reference dataset of all possible combinations of observed values.  For example, 
considering only 3 level smoking status, scorer and gender, there were 3 smoking statuses 
x 7 scorers x 2 genders = 42 possible combinations  42 entries in the reference 
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population, which cover the entire probability space of observed data.  The ZINB model 
was run on this reference population, generating the entire range of possible predicted 
cmSASSS.  
 
To generate confidence intervals for model predictors, observed data (not reference data) 
underwent bootstrap resampling to create a simulated population size of 10 000, and the 
model rerun.  Bootstrapped confidence intervals are one method of demonstrating that a 
predictor has a significant effect on the model, and of quantifying the uncertainty of its 
effect size.   
 
The relative contributions of predictors to model outcome were assessed with r2 and 
pseudo-r2 values, calculated by linear regression of the model predicted value against 
each predictor.  
 
The effect of possible unknown confounders was performed by simulating the effect of 
adding a synthesised confounding covariate.  Two synthesised confounders were made: a 
present/absent factor and a normally distributed continuous covariate.  Both were created 
from normalised ranked values of each subject’s New York sacroiliac joint score, a metric 
highly correlated with mSASSS.  The confounders were given a range of effect sizes (0-1 
standard deviation per unit), and the present/absent factor a range of prevalence (0-
100%), and the effect on predicted cmSASSS was simulated.  
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2.3  Results 
2.3.1  TASC Cohort Characteristics  
Clinical data on gender and symptom duration were available on 1392 subjects with valid 
cmSASSS (Table 2.1).   
 
Table 2.1.  Available covariate data 
Covariate 
Subjects with covariate 
and a valid mSASSS 
Subjects with Gender, 
symptom duration, valid 
mSASSS and covariate 
Film scorer 1464 1392 
Gender 1417 1392 
Symptom duration 1411 1392 
BASDAI ever 1006 986 
BASFI ever 1176 1143 
Age of symptom onset 1231 1204 
3 level Smoking (ex-, 
current, never) 
1135 1117 
Age 1228 1207 
Smoking duration 1135 1113 
Pack year history 908 896 
ESR ever 384 371 
CRP ever 361 354 
IBD 166 165 
Psoriasis 538 536 
Uveitis 538 536 
Mean recorded 
Visual-Analogue Scale 
(VAS) stiffness* 
568 548 
Patient Stiffness* 580 557 
Exercise Number/wk* 567 547 
Exercise minutes/wk* 557 538 
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Regular Back Exercises* 566 546 
Back Exercises days per 
wk* 
566 546 
*  See appendix A.1  for description 
 
The cohort had similar rates of male gender, uveitis, IBD and psoriasis to other AS cohorts 
(Table 2.2).  The average subject was aged in their forties, had symptoms for twenty-one 
years, and was an ex-smoker.  There is a trend towards a lower age of symptom onset 
lower in males than females, with overlapping 95% confidence intervals (p=0.02 by t test, 
male mean 24.7, 95% CI 24.28-25.13, female mean 25.6, 95% CI 24.95-26.30).  
 
Table 2.2.  Cohort Profile  
Covariate TASC Cohort 
OASIS Cohort  
(at baseline) (64) 
Other cohort meta-
analysis (100) 
Subjects 1392 217  
Gender (% male) 74.4% 70%  
Mean symptom duration 
(yrs) 
21.5 11  
Mean age of symptom 
onset 
25.0   
Mean follow up (yrs) 2.7 7.9  
Mean age 47.5 43  
Mean latest mSASSS 10.9 11.6  
Mean sacroiliac score 3.2   
Pack year history 
Mean 6.7* 
Median 0 
  
3 Level Smoking 
16% Never 
29% Current 
54.8% Ex- 
  
Uveitis ever 32.6%  25.8% 
Uveitis in subjects with 
symptom duration 10-15 
26.0%  23.3% 
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yrs 
Uveitis in subjects with 
symptom duration > 20 
yrs 
35.6%  38.5% 
Diagnosed IBD 8.1%  6.8% 
Diagnosed psoriasis 11.3%  9.3% 
* use of mean is inappropriate given the non-normal distribution (Figure 2.3B) 
The contracted mSASSS distribution was left skewed with 509 scores of zero and 
cmSASSS range 0 to 48.   
Figure 2.1.  Distribution of cmSASSS  
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Figure 2.2.  cmSASSS vs symptom duration.  Males in blue, females in red.  cmSASSS 
increases with symptom duration, but large variation exists.  Use of correlation 
(Spearman’s rho = 0.49) is poorly descriptive – it belies the abundance of scores of zero. 
 
Figure 2.3.  Histograms of symptom duration and smoking duration.  There is skew 
towards lower symptom duration and lower smoking duration.  Notably only 16% of 
subjects self-report never smoking, yet 63% report a smoking duration of 0 years.  This 
suggests most ex-smokers have a very limited smoking duration. 
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Figure 2.4.  Boxplot comparing cmSASSS by gender.  Across symptom duration, males 
have higher cmSASSS. 
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Figure 2.5.  cmSASSS vs Smoking Duration across four bins of symptom duration.  Each 
range of smoking duration has a different panel. Males are represented by black circles, 
females by red. For each panel, a blue line represents a simple linear model fit to 
cmSASSS vs smoking duration (gradient at the bottom right of each panel).  cmSASSS 
appears to be proportionate to smoking duration across symptom duration.   
 
 
 
Many observations of zero exist for smoking duration which was the chosen value for 
subjects who have never smoked.  These ‘never smoker’ subjects were included in the 
analysis to allow for a spectrum of smoking exposure from never smoked to heavy 
exposure. The use of zero for never smokers is a commonly used value for smoking 
history (eg pack year history, cigarette year history) (134).   
The use of zero for never smokers assumes a quantitative rather than qualitative 
relationship, where the effect size per year of smoking is equal (ie a linear relationship).  
The effect size for smoking duration is averaged so that the effect of smoking for 0 vs 10 
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years is the same as smoking for 40 vs 50 years.  If the effect size of smoking is not 
constant, use of a smoking duration of zero for never smokers may under or overestimate 
the effect of smoking for some individuals.  Importantly in this case, plots of cmSASSS vs 
smoking duration do not demonstrate any definite non-linear relationship with the 
cmSASSS vs smoking gradient remaining similar across symptom durations >10 years 
(Fig 2.5).   The gradient of the 0-10 smoking duration bin is higher, which would suggest 
that the effect size between never smokers and low duration smokers is higher than the 
gradient for short vs long duration smokers. 
 
Cervical cmSASSS scores contribute more to total cmSASSS than lumbar scores (Table 
2.3). 
Table 2.3.  Correlation between observed values 
 
Observation 1 Observation 2 Spearman 
Correlation 
Cervical cmSASSS Lumbar 
cmSASSS 
0.61 
Cervical cmSASSS Total cmSASSS 0.91 
Lumbar cmSASSS Total cmSASSS 0.88 
 Mean BASFI  Total cmSASSS 0.23 
Total mSASSS Total cmSASSS 0.99 
Cervical mSASSS Total cmSASSS 0.98 
Lumbar mSASSS Total cmSASSS 0.99 
VAS Stiffness Total cmSASSS 0.27 
Early Morning Stiffness Total cmSASSS 0.14 
NY Sacroiliac Score Total cmSASSS 0.54 
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2.3.2  Inter-rater Reliability  
 
The ST-UQDI ICC was 0.968 (95% CI 0.935 – 0.984, p=2.06 x 10-20) and the ST-TASC 
ICC was 0.985 (95% CI 0.965-0.994, p=3.56 x 10-17).  These ICC indicate good to 
excellent reliability (135).  The inter-rater reliability of scorers MAB, TJL, MMW and MHW 
were found to be high in a previous study that used the same TASC reference films (116). 
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2.3.3  Cervical and Lumbar score comparison 
In both genders, across almost all points of symptom duration, syndesmophyte presence 
was more common in the cervical spine (Figure 2.6).  Presence of lumbar 
syndesmophytes was far more common in males. 
Figure 2.6.  Frequency of cervical and lumbar syndesmophyte across symptom duration. 
A) Males       
 
 
 
B) Females  
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Males are more likely to have syndesmophytes in the cervical or lumbar spine.  Males 
have a markedly higher rate of lumbar syndesmophyte presence (Figure 2.7). 
 
Figure 2.7.  Presence of cervical and lumbar spine syndesmophytes by gender.   
A) Cervical Spine     
  
 
B) Lumbar Spine 
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Table 2.4.  Inter-gender comparison.  Comparison of results from Figures 2.7A and 2.7B 
by Chi Squared testing.  Males have more severe cervical and lumbar disease at almost 
all points of symptom duration. 
 
Symptom 
duration 
Cervical syndesmophyte 
presence is higher in males  
(p value) 
Lumbar syndesmophyte 
presence is higher in males  
(p value) 
0-10   0.03  2.1 x 10
-5
 
10-20   0.3  2.3 x 10
-5
 
20-30 1.4 x 10
-4
 4.1 x 10
-4
 
30-40 3.2 x 10
-4
 9.3 x 10
-4
 
40-50 0.04 7.25 x 10
-5
 
>50 Not calculated as female n=4, male n=21 
 
Cervical predominant disease, as defined by previous authors was more common in males 
than lumbar or equal predominance after forty years of symptoms (61).  Most females did 
not display a cervical or lumbar predominance. 
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Figure 2.8.  Predominance of cervical and lumbar disease by gender.  Predominant 
disease is defined by a cervico-lumbar difference >2 cmSASSS.  The proportions of 
cervical and lumbar predominant disease are different between genders at all points of 
symptom duration (p<0.02 in five separate Chi Squared tests, for five symptom duration 
bins). 
A) Males      
 
 
B) Females 
 
 
Over a lifetime, cervical cmSASSS generally rise before lumbar cmSASSS.  The rise of 
cmSASSS in females is mild compared to males (Figure 2.9). 
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Figure 2.9.  Distribution of cervical and lumbar mSASSS by gender.  Early in the disease 
course, cervical cmSASSS are markedly higher than lumbar cmSASSS, in both genders. 
A) Males      
 
B) Females 
 
 
After forty years of symptoms, complete lumbar ankylosis is rare in females, but occurs in 
30% of males. Complete cervical ankylosis also occurs in ~30% of males after forty years, 
and 13% of females (Figure 2.10). 
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Figure 2.10.  Rates of ankylosis across symptom duration.  Subject numbers: 973 males 
and 316 females.     
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2.3.4  Regression Analysis 
The cmSASSS distribution resembled the negative binomial distribution (Figure 2.11).  
 
Figure 2.11.  A negative binomial distribution overlaid on observed cmSASSS counts.  
Notably cmSASSS approaching 48 (complete ankylosis) were underestimated by this 
distribution.  The there is an extreme observed cmSASSS count of zero – zero inflation.  
The NB distribution under-predicts the observed number of zeros. 
 
 
A basic negative binomial (NB) model using symptom duration and gender as predictors of 
cmSASSS was fitted to the data.  It displayed significant overdispersion, demonstrated by 
dispersion parameters:  α = 2.64 and φ = 1.067 (calculations in Appendix A.2) (112, 113).  
Correctible causes of real and apparent overdispersion, such as missed 
predictors/covariates, outliers, missed predictor interactions, or a predictor or response 
requiring transformation were investigated with multiple NB models.  All displayed 
overdispersion.  Overdispersion can also be caused by excessive counts of zero, which 
are present in this case.  Overdispersion due to excessive counts of zero can be 
addressed with a zero-inflated negative binomial model, which is a two component mixture 
model of the negative binomial distribution and a zero model that estimates how many 
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counts of zero are likely due to covariate influence  (112, 113).  In this case, many 
cmSASSS of zero are attributable to low symptom duration, making this model biologically 
relevant.  Comparison testing, including Vuong’s test, AIC and goodness-of-fit plots 
demonstrate the superior fit of the ZINB model over the NB  (Table 2.5. See Appendix A.4 
and A.5 for goodness-of-fit plots). 
 
The cause of the real overdispersion was most likely the excessive counts of zero.  This 
particular cohort and this condition include many patients with mSASSS of zero.  The only 
other relevant cause of real overdispersion, data clustering from population heterogeneity, 
is not present in this case.  There is no evidence of clusters of scores representing sub-
populations in the cmSASSS histogram (Fig 2.11). 
 
 
ZINB and NB models are based on the distribution seen in Figure 2.11, which decreases 
at higher values.  Thus both model types are likely to underestimate the number of 
individuals with complete ankylosis.  This is seen in Figure 2.12, where predicted values 
are significantly lower than observed values.  For the purpose of this modelling, this 
underestimation is acceptable, so long as the and the predicted scores represent the 
relative differences between the severity of individuals. 
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Figure 2.12.  The ZINB distribution overlaid onto observed cmSASSS. The ZINB 
distribution allows for a higher count of zero. 
 
 
Figure 2.13.  Predicted vs observed values from the ZINB model – Boxplot and scatterplot.  
Predicted values increase as observed values increase, but their size is less than 
expected.  For example, the median predicted cmSASSS for an observed cmSASSS of 20 
is 15. 
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ZINB and NB models are based on the distribution seen in Figure 2.11, which decreases 
at higher values.  cmSASSS is interval censored, so individuals with severe disease 
become ankylosed and never change their score, causing a ‘ceiling effect’.  This results in 
a peak in the histogram at the maximum cmSASSS of 48.  To minimize the ceiling effect, if 
available, the observation immediately before complete ankylosis was used instead of the 
latest score of 48.  Unfortunately no statistical distribution that I have read about has a 
peak at extreme low and high values.  The ideal distribution to model this data might be a 
distribution which has a peak at zero and at 48.  I have not encountered such a 
distribution.  In my reading of modeling count data, apart from longitudinal modeling, I 
have seen no more appropriate distribution or method than ZINB model, and this method 
has been used by previous authors for mSASSS (79) and other musculoskeletal radiology 
papers (109).  Consequently we must accept that this model will underestimate the 
number of individuals with complete ankylosis, and keep this in mind when interpreting the 
result. 
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Table 2.5.  Vuong’s test and AIC favour the ZINB model.  Lower AIC indicates superior fit. 
Model Vuong’s test AIC 
NB ZINB superior  
p < 2.2 x 10-16 
8358.96 
ZINB 8138.72 
 
Univariable regression analysis was used to assess the predictive value of recorded 
covariates (Tables 2.6, 2.7).  pscl reports ZINB results for both the zero and count 
components of the model.  The ‘count model’ assesses which covariates predict higher 
cmSASSS other than zero (ie 1 vs 48).  The ‘zero model’ assesses which covariates 
predict scores of zero.  Thus a covariate which predicts higher cmSASSS should have a 
positive effect size for the count model, and a negative effect size for the zero model.  
Covariates which are only significant in the zero model may only be significant because of 
this two component approach, or may truly predict scores of zero without influencing 
further syndesmophyte formation, which is of little clinical relevance. 
 
Univariable analysis indicates scorers 4 and 5 scored higher mSASSS (Table 2.6) than 
other scorers.  Symptom duration, male gender and pack year history predicted higher 
cmSASSS.  Current smoking and age predicted higher cmSASSS, and were collinear with 
smoking duration and symptom duration respectively.  The effect of gender on cmSASSS 
was similar at all levels of symptom duration, as indicated by the absence of significant 
interaction between gender and symptom duration.  Cross-sectional measures of disease 
activity, including ESR, CRP and mean recorded BASDAI were not significant, while 
BASFI had a significant association.  Two stiffness related scores had significant p-values, 
though one of these had confidence intervals overlapping zero.  Higher age of symptom 
onset was only significant in the zero model.   
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Table 2.6.  ZINB univariable analysis of film scorer influence. All values are relative to 
Scorer 2 who scored the most films used in this study, 607. 
Scorer 
Count Model Zero Model 
Films Effect 
Size 
95% CI P value 
Effect 
Size 
95% CI P value 
1 -0.024 
-0.33, 
0.29 
0.88 -0.52 -1.08, 0.04 0.07 107 
2 - - - - - - 607 
3 -0.021 
-0.23, 
0.19 
0.84 -0.66 -1.04, -0.28 7.5 x10-4 302 
4 0.34 0.10, 0.58 5.3x10-3 -1.08 -1.62, -0.55 7.6x10-5 173 
5 0.48 0.13, 0.83 6.5x10-3 -1.71 -2.87, -0.55 3.87x10-3 63 
6 0.54 
-0.14, 
1.22 
0.12 -1.41 -3.35, 0.53 0.15 15 
7 
(ST) 
-0.15 
-0.43, 
0.12 
0.29 -0.89 -1.51, -0.28 4.5x10-3 125 
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Table 2.7.  Results of covariate univariable regression analysis.  Ordered by count model p 
value.  Signficant p-values are shaded. 
Covariate Count Model Zero Model 
Effect 
Size 
95% CI P value Effect 
Size 
95% CI P value 
Symptom duration 0.03 0.02,   0.03 <2x10
-16
 -0.09 -0.10  -0.07 <2x10
-16
 
Age 0.03 0.02, 1.54 <2x10
-16
 -0.09 -0.1, -0.07 <2x10
-16
 
Male Gender 0.63 0.42, 0.84 2.98 x 10
-9
 -1.28 -1.59, -0.97 1.06 x 10
-15
 
Smoking duration 
(yrs) 
1.6x10
-2
 0.01, 0.02 5.29 x 10
-6
 -0.08 -0.1, -0.05 3.76 x 10
-8
 
Mean recorded 
VAS stiffness 
0.01 0.01, 0.02 2.35 x 10
-5
 -0.01 -0.02, -0.01 3.6 x 10
-4
 
Mean recorded 
BASFI 
6.1 x 10
-3
 3x10
-3
, 0.01 8.35 x 10
-5
 -0.01 -0.02, -0.01 1.37x10
-4
 
Pack year history 
(20 / pack) 
0.01 
4.9x10
-3
, 
0.02 
5.2 x 10
-4
 -0.14 -0.23, -0.06 7.4x10
-4
 
Current smoker vs 
never 
0.28 
2.1 x 10
-3
, 
0.55 
0.048 -0.62 -1.12, -0.12 0.015 
Mean recorded 
BASDAI 
-0.03 
-0.06, 
2.2x10
-3
 
0.07 0.05 -0.01, 0.11 0.089 
Age of symptom 
onset 
6.85 x 10
-3
 
2.1 x 10
-3
, 
0.02 
0.14 -0.02 
-0.04, -3.9 x 
10
-3
 
0.02 
Early Morning 
Stiffness 
5 x 10
-4
 0, 0 0.27 
-2.5 x 
10
-3
 
0, 0 5.9 x 10
-3
 
Regular Back 
Exercises 
-0.21 -0.6, 0.17 0.28 -0.12 -0.65, 0.4 0.64 
Exercise 
Number/wk 
0.02 -0.03, 0.07 0.35 -0.06 -0.14, 0.02 0.17 
Ex-smoker vs 
never 
0.12 -0.15, 0.38 0.39 -0.14 -0.57, 0.3 0.53 
Latest ESR 4 x 10
-3
 -0.01, 0.01 0.4 -0.02 -0.05, 0.01 0.2 
IBD 0.19 -0.52, 0.9 0.6 -1.4 -4.25, 1.42 0.32 
Back Exercises: 
days per wk 
0.02 -0.07, 0.1 0.67 -0.03 -0.15, 0.08 0.57 
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Latest CRP 2 x 10
-3
 2.24, 2.75 0.68 -0.11 -0.29, 0.06 0.21 
Uveitis -0.03 -0.22, 0.16 0.74 0.07 -0.27, 0.4 0.69 
Psoriasis -0.03 -0.24, 0.19 0.81 0.21 -0.17, 0.59 0.29 
Exercise 
minutes/wk 
-1.8 x 10
-4
 0, 0 0.88 -2 x 10
-3
 -0.01, 0 0.35 
 
Covariates with univariable count model p-value < 0.1 were progressed to multivariable 
analysis.  Age was not included as it is collinear with and of less clinical relevance than 
symptom duration.  VAS stiffness and BASFI were not progressed to multivariable analysis 
as they are outcomes or results of higher cmSASSS and not biological processes.  
Including them in the model would decrease variance attributed to other predictors.  Age of 
symptom onset was only significant in the zero model, but has been found to predict 
higher mSASSS in previous studies so was progressed to multivariable analysis (71). 
 
Some univariable results of borderline significance did not produce results consistent with 
known pathophysiology.  BASDAI had univariable p-values of borderline significance, from 
0.05 to 0.1, with a negative effect size in the count model, and an effect size in the zero 
model with a confidence interval overlapping zero.  The negative effect size suggests 
higher BASDAI predicts lower cmSASSS, which is not consistent with previous studies 
that suggest higher BASDAI, ESR and CRP predict radiographic severity (92, 93).  This 
effect might be explained by the protective effect of NSAIDs and TNF inhibitors, which are 
more likely to be initiated in subjects with high BASDAI. 
 
Comparison between no smoking status, 3 level smoking status, pack year history and 
smoking duration using model AICs indicate that smoking duration is the most predictive 
smoking metric (Table 2.8).  Pack year history is calculated by: smoking duration multiplied 
by reported cigarette intake per day ÷ 20.  To analyse whether cigarette intake per day 
holds any predictive value, it was assessed in the multivariable model in place of pack 
year history, and was found to be non-significant (p=0.55).  In terms of overall model fit, 
there is little difference between the smoking metrics listed in Table 2.8 (<1% of AIC).  The 
interaction between smoking duration and symptom duration was also significant with a 
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negative effect size, suggesting that as symptom duration and smoking duration increase, 
the effect size of smoking duration decreases very slightly (p = 0.045, effect size -3.6x10-4, 
95% confidence intervals -7.1 x 10-4, -7.6 x 10-6).  Only the most predictive smoking metric, 
smoking duration, was progressed to multivariable analysis. 
 
 
Table 2.8.  Multivariable analysis of smoking measures.  A multivariable model corrected 
for symptom duration, gender and scorer.  Each smoking measure was analysed in a 
separate model, and each model had the same 890 subjects, each with valid entries for 
smoking duration, 3 level smoking and pack year history. 
Smoking 
metric 
Count Model Zero Model 
AIC 
Effect 
size 
95 % CI 
on 
effect 
size 
P-
value 
Effect 
size 
95 % CI 
on effect 
size 
P-value 
No smoking 
status 
- - - - - - 5459 
3 level 
smoking: ex 
0.24 
-0.27, 
0.75  
0.35 0.14 -0.77, 1.06  0.75 
5449 
3 level 
smoking:  
current 
0.33 -0.2, 0.86  0.22 -1.31 -2.32, -0.32  9.9 x 10
-3
 
Pack year 
history 
0.01 
-0.01, 
0.04 
0.19 -0.13 -0.23, -0.04 7.1 x 10
-3
 5433 
Smoking 
duration 
0.024 
 0.01, 
0.04 
9.4 x 
10
-4
 
-0.08 -0.12, -0.04 1.35 x 10
-5
 5422 
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Figure 2.14.  Analysis of pack year history.  After correcting for smoking duration, gender 
and symptom duration, cigarettes per day are not associated with cmSASSS. 
 
 
Gender, symptom duration, smoking duration and age of onset remained significant on 
stepwise multivariable analysis.  Mean recorded BASDAI was not.   Symptom duration 
was calculated by subtracting current age from age of symptom onset, so age of symptom 
onset was allowed to interact with symptom duration.  The modelling software would not 
allow symptom duration to interact with smoking duration and age of onset at the same 
time, so two models, each interacting with one only were modelled.  Both found age of 
onset to be a significant predictor of cmSASSS, and the age of onset – symptom duration 
interaction model found no significant interaction between the two.  Surprisingly, age of 
onset was not significant in the count model upon univariable analysis, but became 
significant upon multivariable analysis.  This is likely because of its relationship to 
symptom duration.  Explanations for its newfound significance upon multivariable analysis 
are that it may be a genuine effect of small size, only detectable once symptom duration is 
corrected for, or it may be an artefact of this correction. 
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Table 2.9.  Stepwise selection.  Multivariable model comparison 
Model: 
cmSASSS vs 
New 
Covariate 
Count Model Zero Model 
Effect 
size 
95 % CI on 
effect size 
P value 
Effect 
size 
95 % CI on 
effect size 
P value 
Symptom duration + Scorer 
Symptom 
Duration 
0.03 0.02, 0.03 
4.73 x 10-
14
 
- 0.10 -0.12, -0.08 <2.2 x10-16 
Symptom duration + Scorer + Gender Gender 0.65 0.44, 0.86 2.24 x 10
-9
 -1.05 -1.44, -0.67 9.97 x 10
-8
 
Symptom duration * smoking duration + 
Scorer + Gender 
Smoking 
duration 
0.02 0.01, 0.04 1.53 x 10
-3
 -0.1 -0.14, -0.06 4 x 10
-7
 
Symptom duration * smoking duration + 
Scorer + Gender + BASDAI 
Mean 
BASDAI 
0.02 -0.01, 0.05 0.25 -0.07 
-0.15, 2.6 x 
10
-3
 
0.06 
Symptom duration * smoking duration + 
age of onset + Scorer + Gender 
Age of onset 0.02 3.8x10
-3
, 0.04 0.017 -0.05 -0.08, -0.02 1.7 x 10
-3
 
Symptom duration * age of onset + 
smoking duration + Scorer + Gender 
Age of onset 0.02 -0.1, -0.03 0.03 -0.06 
2.2 x 10
-3
, 
0.04 
3 x 10
-4
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Table 2.10.  Age of onset model comparison 
Model: 
cmSASSS vs 
New 
Covariate 
Count Model Zero Model 
Effect 
size 
95 % CI on 
effect size 
P value 
Effect 
size 
95 % CI on 
effect size 
P value 
Symptom duration * smoking duration + 
age of onset + Scorer + Gender 
Age of onset 0.02 3.8 x 10
-3
, 0.04 0.017 -0.05 -0.08, -0.02 1.7 x 10
-3
 
Age * smoking duration + age of onset + 
Scorer + Gender 
Age of onset 
-5.1 x 
10
-3
 
-0.01, 3.5 x 10
-3
 0.24 0.04 0.02, 0.06 1.2 x 10
-3
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The positive effect size of age of symptom onset in the count and zero models suggests 
that a later age of onset predicts a higher cmSASSS.  Proof of this relationship requires 
further investigation given that symptom duration and age of onset are known to interact.  
To test for a symptom duration – age of onset interaction, a multivariable model using age 
instead of symptom duration was run.  When age is used instead of symptom duration, 
age of onset is no longer significant.  A univariable model, comparing five age of onset 
‘bins’ (<16, 16-20, 20-30, 30-40, 40-50 years) to cmSASSS found no bin to be significant 
(p>0.05), and a multivariable model, correcting for symptom duration did not either.  
However, if the dataset is limited to subjects with symptom duration longer than twenty 
years, onset before age 16 becomes significant in univariable and multivariable models 
(p=0.002 and p=0.0002 respectively), suggesting there is a small yet significant effect of 
early age of symptom onset, which has a long lead time, and which is detectable without 
correction for symptom duration. 
 
Alternate explanations for the positive effect size of age of onset is that older age of onset 
subjects may have more syndesmophytes at baseline, or may more have recall bias.  
Initial cmSASSS is higher in subjects with a higher age of onset (Figure 2.14).  This is 
evident upon linear regression analysis and t testing between bins.  Linear regression 
demonstrates the higher initial cmSASSS in older subjects with symptoms for less than 5 
years : effect size 0.14 (95% CI 0.06, 0.22, p value 5 x10-5).  Comparison of decade of 
onset bins (Table 2.11) demonstrates higher cmSASSS at later ages of onset in recent 
onset AS. 
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Figure 2.15.  Plots of first recorded cmSASSS vs age of onset. Limited to subjects with 
symptom duration < 5 years.  Notably, some subjects are recorded as having age of onset 
> 50 years which is highly unusual in AS and suggests earlier asymptomatic disease. 
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Table 2.11.  Comparison of first recorded cmSASSS between age of onset bins.  Values 
are Mann-Whitney test p-values (for comparing non-normal data). 
Age of onset 
group (years) 
10-20 20-30 30-40 40-50 
10-20     
20-30 0.13    
30-40 3.56 x 10-5 2.7 x 10-3   
40-50 1.27 x 10-4 4.61 x 10-3 0.69  
 
 
This apparent effect of later age of onset causing higher cmSASSS is contributed to by the 
existence of multiple syndesmophytes in subjects with new onset AS symptoms.  Existing 
syndesmophytes at symptom onset may be caused by minimal symptoms or recall bias.  
The possibility of this effect being caused by rapidly progressing late-onset AS will be 
addressed in the longitudinal analysis.   
 
These analyses demonstrate that age of symptom onset is an inconsistent predictor of 
cmSASSS.  Its effect is only present when cmSASSS is corrected for by symptom duration 
or if symptom duration is limited to more than twenty years.  The effect size appears to be 
small over a lifetime.  Because of these inconsistences, and the desire to include subjects 
with symptom duration less than twenty years in this analysis, age of onset was not used 
in further multivariable analyses. 
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Figure 2.16.  Age of onset vs latest mSASSS. There is an appearance of lower cmSASSS, 
corrected for symptom duration, smoking duration, gender and scorer, for subjects with 
age of symptom onset before sixteen.  The difference in mean corrected cmSASSS for 
figure A is 5.16, significantly different by t test (p=4.4 x10-6).  However use of different 
sized bins Figure B finds no significantly difference between means (pairwise t tests, p>0.3 
in each case). 
 Figure 2.16 A       
 
Figure 2.16 B  
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The best fitting cross-sectional model used fixed effects to correct for symptom duration, 
male gender and smoking duration (Table 2.12).  Adding scorer as a predictor does not 
improve the fit of the model but would correct any possible scorer based bias, so was 
included.  These models attribute 30-40% of variation in cmSASSS to smoking, symptom 
duration and gender. 
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Table 2.12.  Model comparison after removal each significant covariate.  Model r2 was 
estimated by the square of spearman correlation of observed vs predicted values.   
Model:   cmSASSS vs 
Covariate 
Removed 
Estimated 
model r2 AIC  
LR test vs 
model A 
Wald 
test vs 
model A 
Symptom duration * smoking 
duration +  Scorer + Gender 
(Model A) 
- 0.389 6473 - - 
Symptom duration + Scorer + 
Gender (Model B) 
Smoking 
duration 
0.355 6516 
Inferior 
p= 1.65 x 10
-
10
 
Inferior 
p=1.54 x 
10
-8
 
Symptom duration*smoking 
duration + Scorer  (Model C) 
Gender 0.339 6531 
Inferior 
p<2.2 x 10
-16
 
Inferior 
p<2.2 x 10
-
16
 
 
  
  
66 
 
Table 2.13.  Parameter estimates for the count model portion of the final model (‘Model 
A’).   
Covariate  
Estimated 
Effect Size 
Standard 
Error 
P-value 
Intercept 1.28 0.20 2.0 x 10
-10
 
Male Gender 0.58 0.11 1.3 x 10
-7
 
Scorer 2 0.12 0.16 0.44 
Scorer 3 0.36 0.21 0.09 
Scorer 4 0.33 0.18 0.22 
Scorer 5 0.31 0.21 0.14 
Scorer 6 0.54 0.35 0.12 
Scorer 7 0.15 0.19 0.42 
Symptom Duration 0.03 3.9 x 10
-3
 2.0 x 10
-12
 
Smoking Duration 0.02 7.2 x 10
-3
 1.5 x 10
-3
 
Smoking duration – Symptom 
duration interaction 
3.6 x 10
-4
 1.8 x 10
-4
 4.5 x 10
-2
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2.3.5 Sensitivity Analysis of ZINB Model 
 
Local sensitivity analysis was used to assess the robustness of the model to variation and 
error in the predictors.  ‘Model A’ from Table 2.12 was chosen as the best model.  Notably 
recall bias could affect symptom duration and smoking duration, and scorers may exhibit 
bias.  The sensitivity analysis, but not multivariable analysis, found the Scorer to be 
responsible for significant variation in predicted score (Figure 2.16).  In the sensitivity 
analysis, the magnitude of variation is proportionate to the predicted value, and is 
significantly reduced if scorer 6 is excluded (Table 2.13).    
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Table 2.14.  Sensitivity to changes in Scorer 
Symptom 
duration 
Smoking 
duration 
Range of predicted 
scores: all Scorers  
Range of predicted 
scores: scorers other than 
scorer 6 
0 0 1.69 – 4.83 1.69 – 3.07 
0 10 4.25 – 9.52 4.25 - 6.27 
40 0  19.4 – 26.6 19.4 – 25.98  
40 10 22.95 – 35.5 22.95 – 28.3 
40 30 25.01 – 42.96  25.01 – 34.09  
 
A clinically plausible error in symptom duration from recall bias of five years would cause a 
difference of three cmSASSS points (assuming scorer 2, never smoker, male, symptom 
duration 20-25 years).  A plausible error in smoking duration of ten years would also result 
in a difference of three cmSASSS points (at symptom duration 0 or 40, male) (Figure 
2.16). 
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Figure 2.17.  Predicted cmSASSS over symptom duration.  Predicted cmSASSS exhibits 
inter-scorer variation.  Predicted scores for Scorer 6 are higher than the maximum possible 
cmSASSS of 48.  Predicted cmSASSS increases with smoking duration  (but smoking 
duration cannot increase independently of symptom duration). 
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Figure 2.18.  Predicted scores by gender. Predictor values used in this plot are real 
observed values.  Predicted zeros can be produced by either the zero model or the count 
model.  In the observed data, females have less severe disease than males for the same 
symptom duration. Consequently the count model adds a fixed effect for the average 
influence of male gender (0.6 model units).  This gives all males a predicted score slightly 
higher than zero. 
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Confidence intervals on effect sizes were refined by simulation.   
 
Table 2.15.  Results of confidence interval simulation for count and zero models.  As 
expected, factors such as a long symptom duration, the male gender and a long smoking 
duration predict higher counts and lower zeros.  The confidence intervals around their 
effect sizes do not cross zero, making them significant predictors according to this 
analysis.  Some of the confidence intervals for Scorers do not cross zero, indicating that 
they may in fact be significant effects, despite not being considered significant by the 
multivariable analysis.  Given this uncertainty Scorer should remain in the model. 
 
 Count Model Zero Model 
Predictor 
Effect 
Size 
Estimate  
95% Confidence 
Interval  
Effect Size 
Estimate  
95% Confidence 
Interval  
Symptom 
duration 
2.85 x 10
-2
 2.6 x10
-2
, 3.1 x10
-2
 -0.09 -0.1, -0.09 
Male  0.55 0.48, 0.62 -1.07 -1.2, -0.94 
Female Reference value 
Smoking duration 2.34 x 10
-2
 1.9 x10
-2
, 2.8 x10
-2
 -0.10 -0.11, -0.09 
Scorer 1 -0.12 -0.02, -0.01 -1.01 -1.4, -0.81 
Scorer 2 Reference value 
Scorer 3 0.22 0.11, 0.33 0.22 -0.2, 0.45 
Scorer 4 0.08 7.8 x10
-3
, 0.16 -0.25 -0.43, -0.07 
Scorer 5 0.16 0.06, 0.26 -0.4 -0.75, -0.05 
Scorer 6 0.4 0.21, 0.59 -1.1 -1.67, -0.55 
Scorer 7 (ST) 0.019 -0.07, 0.1 -0.86 -1.05, -0.65 
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The sensitivity analysis suggested that observations from Scorer 6 may be significantly 
higher than those of other readers.  Multivariable analysis (Table 2.6) did not find any 
significant effect of Scorer 6.  Multivariable analysis compared only Scorer 2 with Scorer 6, 
and found no significant difference in Scores.  Importantly Scorer 6 only scored 15 films 
used in this study.  Sampling bias may have caused an overestimation of Scorer 6’s 
influence in the sensitivity analysis. This small number of films is unlikely to cause bias in a 
study of almost 1400 films.  Importantly all scorers were calibrated, meaning that higher 
mSASSS from this Scorer may reflect a particular cohort or subset of subjects who Scorer 
6 was asked to score.  For these reasons films scored by Scorer 6 were not excluded from 
this study. 
 
Sensitivity analysis is often used to assess the relative contribution of predictors.  
Comparison of predictor effect sizes from Table 2.14 is inappropriate as the units for 
gender, symptom duration and smoking duration are not equivalent.  To address this 
issue, the predictive value of each covariate relative to symptom duration can be quantified 
by performing linear regression of predicted values against the covariate and symptom 
duration (Figure 2.18) and then comparing the total model coefficient of determination, 
termed a pseudo-r2.  This analysis was performed using observed values and mirrored 
Figures 2.15-2.16.  It demonstrates that the model attributes the most variation due to 
symptom duration, then gender, then smoking duration, then scorer. 
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Table 2.16.  Relative importance of covariates.  Ranked by pseudo-r2.  Pseudo-r2 = r2model 
– r2null model 
 
Model 
Linear r2 
Pseudo-r2 relative to 
symptom duration 
Symptom duration only 
 (Null model) 
0.71 0 
Symptom duration + Gender 0.86 0.16 
Symptom duration + Smoking 
duration 
0.82 0.12 
Symptom duration + Scorer 0.75  
(with or without scorer 6) 
0.04 
 
Figure 2.19.  Predicted cmSASSS by gender.  This null model + Gender was used to 
calculate pseudo-r2. 
 
  
The potential effect of unmeasured confounders was assessed by simulation.  For a 
continuous variable confounder to introduce clinically significant error into the model (eg 1-
2 cmSASSS at symptom duration of zero or 5-6 cmSASSS at symptom duration of 20) it 
would require an effect size of 0.34 model units per standard deviation (Table 2.16).This is 
approximately half the effect size of symptom duration (if one ‘standard deviation’ of the 
non-normal symptom duration is considered to contain 34% of values).  For confounding 
factors that are present or absent, variation in confounder prevalence caused only a few 
points of cmSASSS variation after twenty years of symptom duration.  For a common 
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confounding factor, with prevalence 43%, an effect size of 0.3-0.43 would be required to 
cause variation of 4-7 cmSASSS at a symptom duration of twenty years.  This is also a 
large required effect size, more than half that of male gender (0.58) in the same model. 
 
Table 2.17. Smoking metrics by Gender.  Males and females have similar rates of 3 level 
smoking status, with no significant difference upon Chi Squared testing of the 3 
proportions.  The mean smoking duration between males and females is significantly 
different by t test (p=1.3 x 10-6). 
 Females Males 
Never smoker (%) 13.9% 15.9% 
Current smoker (%) 25.8% 34.1% 
Ex-Smoker (%) 60.3% 50.0% 
Mean smoking duration 
(yrs) 
4.4 7.5 
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Table 2.18.  Sensitivity to unmeasured confounders.  Predicted cmSASSS assuming male 
gender, Scorer 2. The continuous confounder is normalised, thus a range of 0-1 is one 
standard deviation. 
Confounder 
type 
Effect 
Size 
(ES) 
Confounder 
Prevalence 
Symptom 
Duration  
Range of 
confounder 
size 
Range of 
predicted 
cmSASSS 
Comment 
Continuous 0.34 100% 0 0-1  2.27 – 3.96 Only very large ES 
cause significant 
change Continuous 1 100% 0 0-1 2.27 – 11.33 
Continuous 0.19 100% 20 0-1 9.45 – 12.47 
An ES of 0.34 
causes cmSASSS 
to vary by 5  
Continuous 0.34 100% 20 0-1 9.45 – 14.41 
Continuous 0.70 100% 20 0-1 9.45 – 21.65 
Present / 
Absent 
0.18 
25% 0 
Present  
or  
Absent 
1.90 – 2.70 
ES or prevalance 
variation has little 
effect at this 
symptom duration 
Present / 
Absent 
0.49 
60% 0 1.29 – 3.23 
Present / 
Absent 
0.88 
25% 0 0.89-2.89 
Present / 
Absent 
0.43 
27% 20 7.16 - 14.37 
Prevalence 
variation causes 
minor change Present / 
Absent 
0.43 
72% 20 5.26 - 11.12 
Present / 
Absent 
0.3 
43% 20 7.34 - 11.57 
ES > 0.3 required 
for significant 
change Present / 
Absent 
0.6 
75% 20 4.20 – 10.75 
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2.4 Discussion 
The TASC cohort is the largest AS cohort ever investigated for radiographic severity.  Its 
demographics and incidence of AS extra-articular manifestations are similar to other 
cohorts.  Uveitis is common and its cumulative incidence increases with symptom duration.  
Most subjects are ex-smokers who report a minimal smoking duration.   
 
Inter-rater reliability was high, likely aided by the removal of scores for erosion, sclerosis 
and squaring – the more subjective features of mSASSS.  Univariable, multivariable and 
sensitivity analysis all suggested that cmSASSS from particular scorers were higher than 
the reference scorer, Scorer 2.  This may be due to sampling error, more severe cohort of 
subjects, due to clinic or location related confounders, site specific variation in radiology 
equipment, or bias in cmSASSS scoring.  Sensitivity analysis indicated that the model 
predicts higher cmSASSS from Scorer 6, likely a result of sampling error as only 15 
cmSASSS from Scorer 6 were used.  Apart from a possible effect of Scorer 6, the model 
appears robust, or not overly sensitive, to plausible errors in input data.  Reasonable 
events such as a recall bias of 5 years for symptom duration would only result in a 3 point 
difference in predicted cmSASSS.   
 
The distribution of cmSASSS was zero-inflated.  The disproportionate number of subjects 
with a low symptom duration would have contributed to this, but many subjects with 
symptom duration > 30 had cmSASSS of zero.  The left-skewed, overdispersed, zero-
inflated distribution of cmSASSS greatly complicated statistical modelling.  Inclusion of 
cmSASSS of zero is important, as subjects with mild disease need to be compared for 
protective features.  Modelling of this cross-sectional data attributed 30-40% of variation in 
cmSASSS to gender, symptom duration, smoking duration, following correction for inter-
rater variation.  By this measure, this model is superior to previous efforts at modelling 
mSASSS. 
 
Cervical syndesmophytes were more common and appeared earlier than lumbar 
syndesmophytes in both genders.  Cervical ankylosis was far more common than lumbar 
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ankylosis.  The severity of cervical radiographic disease contrasts classical descriptions of 
AS, as reflected by the modified New York Criteria, which consider inflammatory lumbar 
pain but not cervical pain to be a sign of AS.  The reason why cervical radiographic 
disease is more severe than lumbar is not known, but may be related to biomechanical 
differences such as the higher mobility of the cervical spine, or possibly differential gene 
expression in bone or cartilage across the spine.   
 
The association between later age of onset and more syndesmophytes has been seen in 
previous studies (71, 105).  In this cohort the association was not consistently present.  In 
particular, models including all symptom durations and models that corrected for age 
instead of symptom duration found no effect of age of onset.  The association is 
contributed to by late onset AS subjects having multiple syndesmophytes present within 
five years of symptom onset.  This could be from recall bias, or may be because some 
subjects initially suffer minimal symptoms.  Nevertheless it is a sign that symptom duration 
can be an unreliable measure of AS disease duration, making symptom duration lower 
than true disease duration.  The presence of self-reported age of onset after 60 years in 
some subjects supports this.  This analysis found no consistent evidence of any effect of 
age of symptom onset, with any possible effect size being very small and only evident after 
twenty years of symptoms.  To answer the question of whether juvenile symptom onset is 
protective, future models should restrict symptom duration to over twenty years, separate 
age of onset into bins to isolate any protective effect of younger onset from the anomalous 
association of late onset symptoms with higher cmSASSS, and perform tests correcting for 
symptom duration and current age. 
 
Consistent with previous data, syndesmophyte formation increases with symptom 
duration, age and smoking dose.  Male gender predisposes to more severe disease at all 
points of symptom duration, with equal effects early and late in the disease.  Smoking is a 
significant predictor of cmSASSS in a dose dependent manner.  Smoking duration was 
more predictive than pack year history.  This comparison of pack year history to smoking 
duration has not been examined by previous publications.  The difference between the two 
measures may be due to less recall bias of smoking duration compared to cigarettes per 
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day, or could be caused by the stronger effect of smoking exposure than high smoking 
dose.  Smoking is believed to promote osteoproliferation by promoting systemic 
inflammation (82). 
 
Gender was seen to influence severity in a number of ways.  Males had more severe 
disease at all points of symptom duration, and were more likely to progress to ankylosis.  
In females, cervical ankylosis was uncommon and lumbar ankylosis rare.  The effect of 
gender on radiographic severity was greater than that of smoking.   Males were more likely 
to have lumbar or cervical syndesmophytes, and were more likely to have cervical 
predominant disease than females.  The prevalence of cervical predominant disease in 
females was affected by the high frequency of scores of zero in females.  Cervical 
predominant disease was more common than lumbar predominant disease, especially at 
low symptom duration.  Epidemiological studies that identify gender as a risk factor must 
consider the possibility that gender is an indirect risk factor with all or part of its effect 
mediated by a true biological determinant.  In this case, gender could act as an indirect 
marker of smoking status or occupational status, which are both associated with 
radiographic severity.  Gender is unlikely to be a marker for smoking status in this study, 
as 74% of subjects are male, the model corrects for smoking status, and the contribution 
of gender is greater than that of smoking.  In the 3 level smoking model, gender should not 
act as an indirect marker of smoking as there is no significant difference in rates of 3 level 
smoking between males and females.  The effect of gender may contain some occupation 
related effect, but this is likely to be limited – the effect of gender is already evident in 
subjects with low symptom durations.  This translates to early in subjects’ working lives as 
the mean age of onset is 25 years.  Gender is the most influential predictor of radiographic 
severity identified in this study, with particularly strong effects on lumbar syndesmophytes.  
Even in the cervical spine, for a given symptom duration the average male has more than 
twice as many syndesmophytes.  Gender related genetic and hormonal differences should 
be investigated to determine their potent disease influencing mechanisms. 
  
Some covariates are difficult to use as predictors in cross-sectional analyses, especially 
those that fluctuate regularly, as they may have only been recorded as a single 
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observation at one point in time. This applies to markers of disease activity such as ESR 
and CRP, symptom scores such as BASDAI and VAS stiffness, and quantification of 
weekly exercise. Usual analysis of disease activity markers involves quantifying their area-
under-the curve values which is used as a predictor for longitudinal analysis. Tests such 
as CRP also have large inter-institution variation due to different assay preparations. 
Symptom based scores, symptom duration and smoking duration can all exhibit recall 
bias. Recall bias may also be present in data on extra-axial manifestations of AS, as (for 
the TASC and SPARRC cohorts) these results contain a mixture of physician-diagnosed 
and self-reported uveitis, IBD and psoriasis. Functional scores are both markers and 
predictors of severe disease. Many are highly correlated with mSASSS, and in this 
analysis, outcome measures including BASFI were highly significant predictors of 
cmSASSS.   
Any significant association found between disease activity measures and radiographic 
severity must be interpreted with caution.  Measures of disease activity such as BASDAI 
are a phenotype or outcome, influenced by many factors including medications, physical 
factors such as occupation and exercise, and may be correlated with severe radiographic 
disease. 
 
Longitudinal analysis, which compares change in these scores to change in mSASSS, is 
the best method of demonstrating the significance of these covariates.  A recent cross-
sectional analysis of the OASIS cohort after twelve years did not find BASDAI to be 
predictive of mSASSS, but using a longitudinal analysis, the same data demonstrated that 
BASDAI was predictive of radiographic progression, after a two year time lag (93). 
Similarly, covariates such as recent stiffness and number of back exercises per week are 
best analysed in a longitudinal model, and were statistically not significant in the TASC 
cross-sectional model.  
 
Covariates in cross-sectional model must be provided to the model in a metric appropriate 
to the biological context and the features of that covariate.  Smoking is best measured by a 
cumulative metric such as pack year history or smoking duration if it is hypothesised that 
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cumulative smoking dose influences the outcome.  Covariates that fluctuate dramatically 
over time should also be considered using a cumulative measure such as the area-under-
the-curve over time.  Covariates that do not change such as gender or family history 
should not have a cumulative metric unless an interaction with time has been established.  
For example uveitis has a cumulative incidence, and a lifetime history of no episodes of 
uveitis in an 18 year old is not the same as no episodes of uveitis in an 80 year old. 
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2.5  Conclusion 
This study describes and quantifies patterns and predictors of cross sectional radiographic 
severity.  The previously identified predictors smoking, gender and symptom duration were 
found to explain about 40% of variation in radiographic severity.  Smoking duration, which 
has not previously been compared to pack year history, was found to be a more accurate 
predictor than pack year history.  Other covariates found to be significant by previous 
studies were either not recorded or not recorded in a form appropriate for cross-sectional 
analysis.  Syndesmophyte formation in males was far more severe, especially in the 
lumbar spine.  Even after attributing variation to gender, symptom duration and smoking 
duration, variation in radiographic severity is large.  The source of this variation as well as 
the mechanisms of gender based variation should be investigated to predict and prevent 
osteoproliferation. 
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3. Genetic Investigations 
3.1  Introduction  
 
Radiographic severity in AS is variable and highly correlated with functional ability.  One 
quarter to one third of variation in radiographic severity has previously been attributed to 
non-genetic factors.  The remaining variation remains unexplained.  A large proportion of 
variation in AS susceptibility is genetic and pedigree studies have found strong evidence of 
heritability of severity.  Consequently it is believed that much of the unattributed variation 
in radiographic severity is determined by genetic factors.  To date, a number of candidate 
gene studies have investigated suspected loci, but no results have been reproducible.  
Importantly researchers have specifically chosen these candidate genes for investigation.   
 
This study is the first genome wide search for determinants of this phenotype.  The 
extensive cost and logistics of collecting radiographs, clinical determinants of radiographic 
severity and genotypes from thousands of cases has been an enormous challenge in this 
area.  Description and analysis of this radiographic phenotype requires complex non-
parametric statistics that were developed in the 1990s.  The statistical genetic and 
genotyping tools used in this study were developed in the last ten years.  As a result this 
first GWAS of radiographic severity in AS was challenging in many respects.  This study 
and subsequent studies should provide insights into AS pathophysiology that will improve 
prognostication and treatment. 
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3.2 Methods 
3.2.1 Collection and Analysis of Phenotypic Data 
 
Radiographs and clinical covariates of >1000 TASC subjects were collected as outlined in 
Chapter 2. The Spondyloarthritis Research Consortium of Canada (SPARCC) collected 
mSASSS and clinical covariates on 274 Canadian subjects used in this study, with local 
ethics committee approval.  SPARCC subjects did not have per corner mSASSS available, 
thus scores for erosion, sclerosis and squaring could not be removed. Scores from 
SPARCC subjects were described as total mSASSS, cervical mSASSS and lumbar 
mSASSS.  Clinical covariates were only available for subjects from two centres.  168 
SPARCC subjects from one centre had smoking duration and pack year history while the 
remaining 106 subjects from the other centre had three level smoking status 
(current/ex/never) but not smoking duration.  All SPARCC subjects had gender and 
symptom duration, but data on other covariates were not available.   
 
The distribution of SPARCC mSASSS resembled that of TASC cmSASSS and the 
negative binomial distribution (Figure 3.1).  Modelling was performed using NB and ZINB 
models, as described in Chapter 2.  The ZINB model fit was superior as demonstrated by 
Vuong’s test, AIC and standard goodness-of-fit plots (Appendix A.5).  The TASC and 
SPARCC cohorts were modelled separately due to the use of cmSASSS and mSASSS 
respectively.  For the GWAS, the two datasets were only combined at the stage of GWAS 
meta-analysis, to use data using two different measures of the same trait. 
 
For the TASC cohort, the scoring sheets for mSASSS were available. This allowed scores 
of 1 to be removed for conversion to cmSASSS. As previously discussed, for reasons such 
as biological relevance, the cmSASSS score is preferable to mSASSS. Unfortunately the 
original scoring sheets for the SPARCC cohort were not available, and these scores were 
not able to be converted to cmSASSS.  For this reason association testing was performed 
on SPARCC scores separately, then meta-analysed with the TASC association testing 
results.  The two scoring systems, cmSASSS and mSASSS both describe the AS 
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phenotype, and scores of 1 are uncommon – they contribute to <5% of changes over a 
two year period (14, 55, 56).  This study performs independent association testing of each 
cohort to assesses the significance of each SNP.  Thus main role of the phenotype metric 
is to compare the severity of each subject with this sample of the entire AS population.  
The per SNP significance results can be meta-analysed so long as they are treated as 
different cohorts by the statistical analysis.  Even when the same phenotype metric is 
used, association testing is often performed on each cohort separately then meta-
analysed, which allows for variation between the cohorts caused by unmeasured effects 
and known cohort specific covariates (136).   
 
Figure 3.1.  Radiographic scores in each cohort.  The SPARCC mSASSS scores can be 
approximated to the negative binomial distribution.  The negative binomial distribution 
assumes higher scores are less likely.  NB and ZINB models will therefore predict lower 
values for subjects with the most severe disease.  The sample size of the TASC cohort is 
much larger than the SPARCC cohort with 979 and 382 subjects respectively.  Both 
distributions have a predominance of low scores. 
 
 
To maximise subject numbers in the GWAS, it was desirable to include subjects with three 
level smoking status but not smoking duration data.  Models using three level smoking 
status and smoking duration were previously compared by AIC, likelihood ratio tests and 
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Wald tests and were found to be almost the same as the smoking duration model (Table 
2.8).  Analysis comparing the three level smoking model with the smoking duration model 
found a Spearman correlation 0.97, and ICC 0.98 (95% CI 0.977-0.982).  As the residuals 
of these two models were almost identical, for subsequent steps the three level smoking 
status model was used. 
 
Figure 3.2. Comparison of residuals from different ZINB smoking models.  TASC cohort 
data.  There is little variation between the two models, as demonstrated by the proximity to  
perfect correlation (r = 1). 
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3.2.2  Genotyping and Data Preparation 
 
SNP genotyping was previously performed during multiple studies of AS susceptibility,  
involving subjects from TASC and SPARCC (22, 35, 36).  TASC subjects were genotyped 
on at least one of the Illumina HumHap370, Illumina Human660W-Quad or Illumina 
Infinium Immunochip platforms.  SPARCC subjects were genotyped on at least one of the 
Illumina Human OmniExpress or Illumina Infinium Immunochip studies.  
 
Genetic quality control of Immunochip genotypes using PLINK v1.07 (137) was performed 
by Adrian Cortes (AC), and for all other genotypes by ST.  Only autosomal SNPs were 
studied.  Genotypes from Immunochip control subjects were used for quality control of 
Immunochip genotypes, and genotypes from Wellcome Trust Case Control Consortium 
(WTCCC) controls for Illumina HumHap370 and Illumina Human660W-Quad data.  
Illumina Human Omniexpress genotypes underwent quality control using cases and 
controls genotyped on this chip.  Control data was used for heterozygosity and Hardy-
Weinberg Equilibrium testing.  SNPs with genotype call rates <99% were excluded.  
Individuals were excluded if their heterozygosity was greater than 2 standard deviations 
from the mean or if >3% of SNPs were missing.  Rare SNPs with Minor Allele Frequency 
(MAF) < 5% in cases were excluded.  SNPs not in Hardy-Weinberg equilibrium (p<1x10-5) 
were removed.      
 
AC assessed population stratification of Immunochip genotypes using 5 Principal 
Components (PCs) and removed non-Caucasian outliers.  ST combined these genotypes 
with the genotypes from the other SNP chips and recalculated PCs using the shellfish 
software package.   Shellfish has been validated against the commonly used PCA 
software and has been used in large GWAS (138, 139).  Non-Caucasian outliers were 
excluded if either of their first two PCs were greater than six standard deviations from the 
mean.  A six standard deviation cut-off is commonly used and is employed by 
EIGENSTRAT (140).  Non-Caucasians were excluded because population stratification 
could not be reliably corrected across different ethnicities. 
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Figure 3.3.   PC analysis displaying the first two eigenvectors.  Colours represent Hapmap 
ethnic groups.  Numerous cases (black circles) were clearly not of Causasian ethnicity.   
 
Identity By State calculation using PLINK (PI_HAT > 0.9) was used to identify duplicate 
samples and to match subjects who had been genotyped on multiple SNP chips.   
In total, QC removed 82 subjects from the TASC GWAS studies and 90 from the SPARCC 
GWAS study.  Twenty-one subjects from the Immunochip study who AC performed QC on 
were removed by the PC analysis.  The final counts of subjects with sufficient data for 
association testing are presented in Table 3.1. 
 
Table 3.1.  Subjects counts for association testing.  These subjects all have a genotype 
that has passed quality control, smoking data, gender, symptom duration and mSASSS. 
 
Cohort GWAS chip* 
only 
Immunochip 
only 
GWAS + 
Immunochip 
Total 
TASC 108 252 619 979 
SPARCC 75 21 286 382 
 
* GWAS chips: Illumina HumHap370, Illumina Human660W-Quad, Illumina Human 
OmniExpress. 
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Table 3.2.  Imputed SNPs available per subject. 
 
Cohort GWAS chip 
only* 
Immunochip 
only 
GWAS + 
Immunochip 
TASC 5-6 x 106 
500 000 
5-6 x 106 
SPARCC 7 x 106 7 x 106 
 
Haplotype phasing and imputation of nearby loci was performed using SHAPEIT and 
IMPUTE2 respectively. A merged reference sequence was used for imputation, consisting 
of 1000 Genomes phase 3 and UK10K.  Validation studies of the sequential SHAPEIT-
IMPUTE2 method (141) found that when using the 1000 Genomes reference panel, SNPs 
were imputed with high accuracy (Table 3.3).   
 
Table 3.3.  Imputation accuracy of SHAPEIT-IMPUTE2 (141).  Mean R2 refers to the 
coefficient of determination between a test panel of genotyped SNPs and SNPs imputed 
using data with the genotyped SNPs missing (‘masked genotyped SNPs’). 
 MAF 0.01 to 0.03 MAF 0.03 to 0.05 MAF > 0.05 
Mean r2  0.82 0.86 0.92 
 
Only high confidence imputed SNPs were included, by removing imputed SNPs with an 
imputation score <=0.8.  Imputed SNPs with a MAF <0.05 were removed due to the limited 
sample size and therefore power.   For example, a SNP with MAF 0.02 genotyped in 1000 
subjects would only be present in 20 subjects.  Comparing these 20 phenotypes with 980 
would be prone to error.  Following imputation, subjects genotyped on multiple SNP chips 
had their data merged into one subject entry.   
Imputed variants with MAF < 0.05 are often excluded from analysis due to significant 
uncertainty during imputation (142) and association testing (143).  SNPs with a population 
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MAF < 0.05 are more sensitive to outliers and have less reliable imputation, which is 
reflected by lower average imputation r2 values (144). 
 
Imputed ‘best-guess’ genotypes are not perfect, so measures must be taken to minimize 
genotype misspecification. Common techniques described by De Bakker et al. include only 
using SNPs genotyped on at least 1 platform and removal of SNPs with poor expected 
imputation performance (145). SNPs with poor expected imputation performance are those 
with a low imputation quality and those with MAF <0.05.  SNPs with a low imputation 
quality score are those that possess low LD with tag SNP.  These SNPs are not imputed 
with high certainty and clearly should be excluded.  Once MAF falls below 0.05, imputation 
accuracy (using Hapmap Phase II reference panel) falls dramatically (136).  This finding 
appears to occur even after the application of an imputation quality cutoff.  Howie et al. 
found a similar fall in accuracy when MAF falls below 0.05 when performing pre-phasing 
with SHAPEIT then imputation with IMPUTE2 using the 1000 Genomes reference panel 
(141).   
 
SNPs with low MAF may have imputation (confidence) scores that appear higher than 
those of common variants (143).  Most rare SNPs will be homozygotes for the common 
allele, making the genotype easier to predict which falsely elevating the r2.  Asimit and 
Zeggini suggest that alternative measures of imputation accuracy are required for rare 
SNPs to avoid genotype misspecification and an increase in false positive association 
(143). 
 
This study of AS radiographic severity imputed genotypes of AS subjects using a 
combined reference panel from 1000 Genomes and UK10K, which should include greater 
haplotype diversity than Hapmap phase II and 1000 Genomes. Nevertheless, the current 
study involves less than 1500 subjects in total, and many SNPs were imputed in <1000 
subjects.  This means that a SNP with MAF 0.03 which was imputed in 800 subjects would 
have the minor allele in only 24 subjects.  Any significant outliers or sampling bias in this 
population could create a false positive result.  Therefore in this case, the stringent 
  
90 
 
principles established by De Bakker et al., especially the exclusion of rare imputed SNPS, 
should be used in this study.  Additionally this analysis used the standard IMPUTE2 
protocol which treats imputed SNPs the same as genotyped SNPs during the association 
analysis.  All imputed SNPs need to be imputed with high confidence.  This concern is 
addressed by other imputation protocols, such as the MACH imputation package, by 
considering the uncertainty of imputed genotypes during association testing (using their 
r2).   
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3.2.3  A priori Power Calculation 
 
GWAS power was calculated using the quantitative trait disequilibrium test (146) employed 
by the Genetic Power Calculator (147).  This commonly used method compares the 
distribution of the test statistic under the null hypothesis with that under the alternate 
hypothesis and can be used for quantitative phenotypes that are not grossly non-normal 
(148).  Power to detect a range of MAFs and effect sizes were calculated for a scaled 
Linkage Disequilibrium coefficient (D’) of 0.8.  
 
A D’ value of 0.8 between tag SNPs and causal variants is a commonly used cutoff of 
significance (149).  The cutoff point is an arbitrary degree of linkage disequilibrium which 
allows for minimal loss of power.  As D’ approaches 1 there no loss of power in the 
assumption that the tag SNP perfectly tags the causal variant (144, 150).  Use of a higher 
D’ cutoff would decrease the number of imputed SNPs available for analysis.  In this case 
a D’ cutoff of 0.9 would decrease the number of imputed SNPs by 24%.  A lower D’ cutoff 
(eg 0.6) would increase the uncertainty of imputation which would increase the number of 
false negatives and positives upon association testing. 
The Genetic Power Calculator can be used for studies where the distribution of the test 
statistic is known under the null and alternate hypotheses (148).  Tests statistics in genetic 
association studies most commonly follow a normal or chi squared distribution.  This 
finding is consistent with the central limit theorem which states that a test statistic that 
consists of additive contributions from multiple observations will tend to have a normal 
distribution when the sample size is large (151).  To apply this principle to this study we 
should examine the expected test statistic.  As the genetic association test for this GWAS 
is a linear model, so long as the phenotype is not grossly non-normal, the expected test 
statistic from millions of SNPs should be normal.  The gross approximation the phenotype 
to a normal distribution is evident in Figure 3.4.  Post-hoc examination of the test statistic 
confirms that it is in fact normally distributed (Figure 3.5). 
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Figure 3.4.  Distribution of residuals from the 3 level smoking model.  The distribution is 
grossly bell shaped. 
 
Figure 3.5   QQ plot of association test statistic from the SPARCC cohort.  As predicted by 
the central limit theorem, the test statistic is normally distributed, indicating that use of the 
Genetic Power Calculator was appropriate. 
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3.2.4 Genome Wide Association Testing 
 
Residuals from the three level smoking TASC and SPARCC ZINB models discussed in 
Chapters 2 and 3.2.1 were used as quantitative phenotypes for association testing. For the 
TASC cohort, these residuals represent cmSASSS corrected for symptom duration, 
gender and three level smoking status.  For the SPARCC cohort, the residuals represent 
mSASSS corrected for the same covariates.  This phenotype represents radiographic 
severity within the population of AS subjects, so disease free controls cannot be assigned 
a phenotypic score.   
GWA testing was conducted to identify individual loci associated with severe disease.  
These loci, for example transcripts or regulatory elements, could in future be compared in 
vitro between AS subjects and healthy controls.  Unlike candidate gene studies, GWAS 
does not only examine loci hypothesised as being relevant.  Early candidate gene studies 
have also been criticized for lack of correction for population stratification and for 
inappropriate p-value thresholds (152).  GWAS is most able to detect common variants 
with large effect sizes, whereas candidate gene studies are often designed to detect the 
effects of rare variants. 
 
Association testing between the 3 level smoking model residuals and imputed genotypes 
was performed in PLINK separately for each cohort.  The first 3 PCs were used as 
covariates to control for subtle population structure, and the residuals were treated as a 
quantitative phenotype.  This study used an additive genetic model performed by linear 
regression.  The phenotype was regressed against the genotype of each SNP 
(homozygous minor, heterozygous, homozygous major).  This analysis treats all SNPs as 
biallelic, which is a common assumption in GWAS (152). 
 
 As per standard IMPUTE2 protocols, during association testing high quality imputed SNPs 
(‘info score’  >=0.8) were treated as if they were genotyped with 100% certainty (153).  
Other imputation protocols weight imputed SNPs by their confidence score (info score) to 
reflect uncertainty in their genotype, and weight genotyped SNPs as 1. 
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Association testing of genome wide imputed alleles was performed in PLINK using 3 PCs 
as covariates to control for subtle population structure.  The high confidence imputed 
SNPs were weighted equally to genotyped SNPs during association testing.  As the TASC 
cohort had cmSASSS values, while SPARCC had mSASSS values, the two datasets were 
analysed as two separate GWAS.  The Genomic Inflation Factor (λ) was calculated by 
PLINK. 
 
Multiple methods of GWAS meta-analysis have been developed.  The most common 
methods are: fixed effect meta-analysis, random effect meta-analysis and p-value meta-
analysis (also known as “z-score meta-analysis”).  Fixed effect meta-analysis assumes 
that the true effect of each risk allele is the same in each cohort, while random effect 
analysis does not (142).  P-value meta-analysis creates a z-score for the association for 
each SNP, representing the magnitude and direction of effect.  The score is compared to 
the average z-score for all SNPs, then weighted by the sample size of each cohort, and 
results from both cohorts are combined.  The comparison of each SNP’s effect to the 
average effect allows each cohort to have a unique scale of measurement (eg cmSASSS 
and mSASSS) (154).  Unfortunately this method provides no estimate of effect size for any 
SNP, only effect direction. The main benefit of p-value meta-analysis in this case is its 
ability to compare two cohorts using two different metrics for the same phenotype.  This is 
possible because it only compares the z-scores (which are standardised), not the effect 
size (which is scaled in the dimensions of the phenotype). 
 
P-value meta-analysis of the two datasets was performed using METAL (155).  METAL 
meta-analyses converts the direction of effect and observed p-value from each cohort into 
a signed z-score, and weights the score by the number of observations from each cohort.  
This method provides a meta-analysed p-value, but does not provide an effect size.  Other 
meta-analysis techniques would be inappropriate as they assume the effect size from each 
cohort uses the same scale.  Instead standardised effect size from the TASC cohort are 
reported.  Meta-analysis results were visualised by Manhattan plot and LocusZoom 
regional association plots (156).  Risk allele frequencies were reported from the 1000 
Genomes phase 3 dataset. 
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Gene, exon and expression data were collected from NCBI gene release 106 (157) and 
ENSEMBL build 78 (158) and FANTOM5 (159).  Structural and regulatory features were 
visualised using the UCSC genome browser (160).  
Figure 3.6.  Histogram of SNP count per subject after meta-analysis.  The vast majority of 
SNPs were imputed in at least 800 subjects.  These subjects also had data for symptom 
duration, smoking status, gender and mSASSS or cmSASSS.   
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3.2.5  HLA Imputation 
 
The HLA region is a unique and complex portion of the human genome.  Imputation of this 
region is best performed with specific techniques that impute HLA alleles using the LD 
patterns of multiple surrounding SNPs (161).   
 
Accurate genotyping of this region was considered important in this study due to the strong 
association between HLA-B27 and AS susceptibility.  Previous studies have suggested 
that HLA alleles other than HLA-B27 may be associated with bone formation in AS (71).   
 
The software SNP2HLA imputes SNPs in the HLA region and reports which classical HLA 
alleles and amino acids they encode.  SNP2HLA uses the Beagle software package (162) 
and a database of reference HLA genotypes from the WTCCC.  SNP imputation assumes 
that the haplotype distribution in cases and controls matches that of the reference 
population.  The most likely haplotype and genotype for each individual is modeled using 
methods specific to each software package (eg a Hidden Markov Model or a graphical 
model). 
 
Human Leukocyte Antigen (HLA) association testing was performed as multiple HLA 
alleles have been implicated in AS susceptibility.  Imputation of HLA alleles was performed 
using the SNP2HLA software package using a Type 1 Diabetes reference panel (163).  
SNP2HLA imputes classical HLA Class I and II alleles, as well as SNPs across the Major 
Histocompatibility Complex and where within HLA genes, the amino acids they encode.  It 
is used for high throughput HLA imputation and has successfully identified risk HLA alleles 
in IBD, AS, and lymphoma (164, 165). 
 
SNP2HLA imputation was only performed using Illumina Immunochip genotypes, from 
1144 subjects.  Genotyping and quality control was performed as detailed in Section 3.2.2.   
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Alleles with SNP2HLA imputation r2 <0.6 were excluded, leaving 7674 alleles (note this r2 
score is a different metric to the info score used by IMPUTE2).  The average accuracy of 
SNP2HLA imputation when using Immunochip genotypes and the Type 1 Diabetes 
reference panel was 96.7% for HLA alleles (4 digit resolution) and 99.3% for amino acid 
polymorphisms.   Association testing using PLINK was performed separately for the TASC 
and SPARCC cohorts. Residuals from the 3 level smoking model, which also had fixed 
effects for gender, symptom duration and reader was used as a phenotype.  Three PCs 
derived from genotypes were used as covariates to correct for population stratification.   
These association results were meta-analysed using METAL (155), with weighting based 
on cohort size (per SNP). 
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Table 3.4.  Accuracy of SNP2HLA imputation at selected loci.  SNP2HLA was used to 
imputed HLA alleles for an independent cohort (the British 1958 Birth Cohort) based on a 
reference panel from a Type 1 Diabetes.  The independent cohort and the reference panel 
were genotyped using the Illumina Immunochip platform.  The high accuracy of imputation 
in an independent cohort provides validation of SNP2HLA using this genotyping platform 
for these loci (adapted from Jia et al. (163)) 
Allele Genotyped-imputed r2  Accuracy (concordance) 
HLA-A*0201 0.99 99.4% 
HLA-B27 0.97 99.9% 
HLA-B40 0.96 99.7% 
HLA-DRB1*0801 0.92 99.8% 
HLA-DRB1*0804 0.68 99.9% 
 
A study of Hapmap phase II data by Conrad et al. concluded that tag SNPs are highly 
portable within three broadly related ethnic groups -  Africans, Asians and Europeans 
(166).  Importantly, tag SNPs were highly portable amongst the European ethnic groups in 
the study.  Tag SNPs from the CEU ethnic group tagged most polymorphic non-tag SNPs 
with r2 > 0.85.  Another study quantified the SNP coverage and power of CEU tag SNPs 
for multiethnic European populations (from Utah and Hawaii) (144).  For common, non-tag 
SNPs, the CEU tag SNPs had high coverage (>0.87) and power (>91%).   
 
Jia et al. compared reference panels from CEU and the Type 1 Diabetes Genetics 
Consortium with the 1958 British Birth Cohort and found imputation to be highly accurate 
(Table 3.4).  The TASC and SPARCC cohorts were limited to subjects of European 
ethnicity (by questionnaire and PC analysis) in Britain, Canada, the United States and 
Australia.  Consequently the accuracy of SNP2HLA imputation in the TASC and SPARCC 
cohorts should be considered similar to that of Jia et al.  
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3.2.6 Genome Wide Complex Trait Analysis   
 
Following the lack of significant GWAS results, Genome Wide Complex Trait Analysis  
(GCTA) was conducted to assess whether there was any evidence that genetic variation is 
associated with variation in severity.  Alternative methods of estimating heritability from 
GWA data include regression of phenotypic similarity on relatedness estimates from IBD 
segments (167).  One advantage of this method is that it can include the effects of rare 
variants within these IBD segments.  However IBD based methods are susceptible to error 
from IBD estimation in large cohorts of unrelated subjects.  GCTA primarily captures the 
effect of common variants and may be bias towards underestimating narrow sense 
heritability if rare variants are significant contributors to additive genetic variation (46).  
GCTA estimates relatedness based on allele sharing from SNP data.  One comparison of 
an IBD based regression method with GCTA found the standard error of its narrow sense 
heritability estimate to be 2-14 times as that of GCTA (46).  GCTA was chosen for the 
heritability analysis as the purpose of this study was to assess common variants, and 
because its developers (who work at the same institute) were available for support. 
GCTA was performed to estimate narrow sense heritability, the proportion of phenotypic 
variance explained by additive genetic factors.  In terms of genetic factors, this method 
only considers additive genetic variation tagged by analysed SNPs.  Consequently the 
estimate is expected to be lower than the true value.  GCTA regresses SNP alleles against 
the phenotype using a linear mixed model to account for relatedness and population 
stratification.  GCTA is able to quantify the effect of common causal variants with small 
effect sizes, which are usually not identified by GWAS due to stringent genome-wide 
significance levels.  GCTA has previously been applied to height, BMI, QT interval and 
Parkinson’s disease to demonstrate that a large narrow sense heritability is present in 
each case, despite not being identified by GWAS (45, 47, 168). 
 
The GCTA used 396 921 SNPs which were genotyped in at least one of the GWAS chips.  
Only 78 496 of the TASC SNPs were also directly genotyped in the SPARCC cohort.  For 
this reason imputed SNPs (see section 3.2.2) with an imputation score > 0.8 were 
included.  The use of 400 000 SNPs for GCTA is comparable to previous studies (47, 
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169).  Individuals with > 10% of SNPs missing were excluded, and SNPs underwent 
quality control as described previously (section 3.2.2).  Related individuals with an Identity 
By State > 0.08 were excluded. 
The GCTA analysis was performed only on genome-wide data from the GWAS platforms.  
Subjects who were genotyped using the Illumina Immunochip platform only were not 
included in this analysis as they had insufficient SNPs to allow GCTA – in principle and in 
practice.  The GCTA software would not fit a model for these subjects. 
 
The developers of GCTA recommend correcting the phenotype for known predictors and 
transforming it to a standardised z-score (170).  The phenotype used was the ZINB model 
residuals, the same phenotype used in the GWAS.  The phenotype of the TASC and 
SPARCC cohorts were standardised to z-scores then merged into one cohort.  
Phenotypes were regressed against the genotype using the default REstricted Maximum 
Likelihood (REML) method, while correcting for 3 PCs to account for subtle population 
structure.  A per chromosome analysis was also performed. 
 
To assess the robustness of the findings a basic sensitivity analysis used by previous 
authors was performed (169).  The GCTA was repeated with no PCs, with 10 PCs, and 
with the phenotype not corrected for smoking status, symptom duration or gender. 
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3.2.7  Allelic Risk Score Analysis 
 
Allelic risk score analysis was conducted to test the hypothesis that SNPs related to bone 
metabolism, AS susceptibility, smoking and height may also possess effects on 
radiographic severity in AS.  Comparison of multiple loci may identify variation from a 
collection of markers which in isolation do not achieve significance (171).  This method is 
useful for testing candidate SNPs when no individual locus is found to be significant upon 
independent association testing.  In this study, combining the effects of many SNPs into a 
single score increase the power to detect a small effect in an study otherwise poorly 
powered to detect independent effects across millions of markers.  A positive result would 
provide some signal that, for example, variation in bone metabolism loci can predispose 
more severe disease.  Such a signal would justify a candidate gene study of these loci.  
 
Allelic risk scores are limited by a number of assumptions, including that: the score 
contains SNPs in LD with causal variants, that many (and not few) alleles included in the 
score are in LD with causal variants and that the effect size is similar between the two 
phenotypes.  These limitations are discussed at length in section 3.4.4. 
 
Allelic risk scores were calculated to investigate whether SNPs associated with AS 
susceptibility, bone mineral density (BMD), height and nicotine dependence also 
predispose to AS severity.  Creation of an allelic risk score using SNPs associated with a 
related phenotype has been described previously (172).  For example polygenic risk 
scores have been used to predict blood pressure from an allelic risk score derived from the 
related phenotype of Body Mass Index (173). 
 
SNPs associated with AS susceptibility were identified from previous studies of AS 
susceptibility (22, 35, 36).  SNPs associated with BMD, height and nicotine dependence 
were identified by GWAS of these traits (174-177).   
 
In the case of nicotine dependence, two significant GWAS were identified, published in 
2007 and 2010 respectively (175, 177).  Without a meta-analysis, it would be difficult to 
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combine hits from each GWAS into a single score with a common effect size.  The latter, 
larger GWAS associated three SNPs with nicotine dependence.  Only two of these SNPs 
were imputed in the TASC or SPARCC cohorts, each of which tags a nicotinic 
acetylcholine receptor subunit locus.  One of these tag SNPs is in perfect LD with 
rs13277254, a SNP identified by the 2007 GWAS.  Thus for the purpose of choosing 
alleles for this allelic risk score analysis, the additional risk allele from the latter study adds 
little to the earlier 2007 study.  The latter GWAS only contributes one unique allele to the 
risk score, which corresponds to a subunit of a receptor that is tagged by other SNPs in 
the 2007 study.  For this reason, only risk alleles from the 2007 nicotine dependence 
GWAS were used. 
 
One SNP was included per risk locus – the SNP with the highest effect size.  For each 
subject, the number of risk alleles present was counted, and multiplied by the estimated 
effect size of the risk allele and aggregated to provide a weighted allelic risk score.  The 
effect size listed by the AS susceptibility GWAS and nicotine dependence GWAS were 
Odds Ratios (ORs) as they were case-control studies.  The BMD GWAS and height 
GWAS listed effect size as the linear regression coefficient β, as they were quantitative 
GWAS.  For the allelic risk score calculation, Odds Ratio (OR) effect sizes were converted 
to β coefficients by logarithmic transformation.  Only high confidence imputed SNPs with 
imputation score >0.8 were used.  Subjects missing > 5% of the SNPs used in that score 
were excluded from that analysis.  Separate allelic risk scores were created for AS 
susceptibility, BMD, height and nicotine dependence.   
 
For the BMD cohort, the effect size used was the mean effect size for femoral and lumbar 
spine BMD for each risk allele. 
 
HLA-B27 was not used in the analysis using the AS susceptibility allelic risk score, as its 
OR of 60 made all other SNPs irrelevant to the score.  The SNP with the next highest 
effect size was rs11209026 within IL23R with OR 1.6. 
 
Each score was then assessed for predictive ability by using it as a predictor in the ZINB 
model.  SPARCC subjects were analysed separately to TASC subjects as one cohort had 
  
103 
 
mSASSS data and the other cmSASSS.  The ZINB models (apart from the nicotine 
dependence score model) were corrected for the influence of symptom duration, gender 
and three level smoking status.  The nicotine dependence score model was not corrected 
for smoking status in any way, allowing the nicotine dependence score to influence 
severity via smoking.  In the case of nicotine dependence, only males were included in the 
allelic risk score.  The nicotine dependence paper listed separate OR for males and 
females, and there were too few females with risk scores for the model to calculate a result 
for them. 
 
Table 3.5.  Number of SNPs used for allelic risk scores.  Some risk loci could not be 
included because their risk SNPs were not imputed or genotyped. 
 
Allelic Risk Score SNPs in TASC cohort SNPs in SPARCC cohort 
AS susceptibility 41 41 
BMD 83 81 
Height 133 126 
Nicotine dependence 40 40 
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3.3 Results 
3.3.1  A priori Power Calculation Results  
 
Power was estimated over a range of trait heritabilities.  For interpretation, heritability was 
converted to a range of allele frequencies and effect sizes.   
 
The effect size cannot be converted to meaningful uncorrected (ie observed) cmSASSS or 
syndesmophytes, but represents variation in the phenotype after correcting for smoking 
status, gender and symptom duration.  The effect size should be considered as an additive 
effect present in each subject.  For example, an individual with 3 SNPs with effect size 
+0.1 would be expected to have a cmSASSS 0.3 standard deviations above the mean, 
after correcting for the effect of symptom duration, gender and smoking.   
 
The GWAS was powered to identify common SNPs with a large effect size.  The GWAS 
had 80% power to detect SNPs with MAF of 0.2 with an effect size of 0.49 standard 
deviations from the mean (of cmSASSS ZINB residuals) to the level of significance α = 5 x 
10-8.  Standardised effect sizes identified by similar GWAS have been much smaller than 
0.49.  The GEFOS2 study of BMD found dozens of SNPs with standardised effect sizes 
<0.1 and a few SNPs with standardised effect sizes of 0.1 – 0.15 (176).  The GIANT study 
identified 180 loci associated with height (p < 5 x 10-8), yet only one locus had 
standardised effect size > 0.1.  The interpretation of standardised effect sizes suggested 
by Cohen for general statistics, where 0.2 is small, 0.5 moderate and 0.8 large, is therefore 
not applicable to quantitative GWAS, as the effect sizes that are actually observed are 
much smaller than these thresholds.  Thus the GWAS was only powered to identify 
common SNPs with large effect sizes, in regards the known likely effect sizes of common 
genetic variants on bone phenotypes. 
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Figure 3.7.  Power for 1360 subjects. D’=0.8,  α= 5 x 10-8.  The dotted line represents a 
power of 0.8 (80%).  For common variants, only large effect sizes and common MAF 
(>0.05) are powered > 0.8. 
 
 
 
Figure 3.8.  Power for 3000 subjects. D’=0.8,  α= 5 x 10-8.  Doubling the sample size 
slightly improves the likelihood of detecting alleles with lower effect sizes. 
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Figure 3.9.  Power for 10 000 subjects. D’=0.8,  α= 5 x 10-8.  This large sample size still 
provides low power for effect sizes < 0.1 standard deviations. 
 
 
 
 
Power calculations demonstrate that even with a sample size of 10 000, there would only 
be adequate power for small effect sizes (<0.1) if MAF > 0.4. 
 
Power calculations for the HLA imputation step were performed 7674 SNPs from 1144 and 
876 subjects. Similarly association testing would only be well powered to detect large 
effects in common variants.   
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Figure 3.10.  Power for 1144 subjects.  D’=1,  α =  6.5 x 10-6. α is based on a Bonferroni 
correction for 7674 independent tests, assuming no LD.  The assumption of no LD for this 
HLA testing makes the correction overly stringent. 
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3.3.2  Genome Wide Association Study Results 
 
Following quality control and exclusion of subjects without mSASSS, symptom duration, 
gender, or smoking status, 979 subjects from the TASC cohort and 274 subjects from the 
SPARCC cohort were included.  For the TASC cohort, Genomic Inflation Factor (λ) = 1.01 
and for the SPARCC cohort, λ = 1.00.  Neither cohort had a SNP more significant than p < 
1 x 10-7.  SNP effect size in each cohort was approximately normally distributed (μ = 0, σ = 
1.7) with more extreme values than the normal distribution in the top and bottom quartiles.  
Standardised effect sizes from the TASC cohort are reported for comparison. 
 
After removal of rare SNPs (MAF < 0.05), 5 657 478 SNPs remained.  These SNPs were 
analysed by p-value meta-analysis using METAL (155).   
 
Figure 3.11.  QQ plots for each cohort.  SPARCC GWAS (left) and TASC GWAS (right).  
There is minimal inflation compared to the expected values by chance (black line, with 
95% confidence interval in grey).  Very few observed p-values were < 1x 10-5. 
 
 
 
 
After meta-analysis,  92.3% of SNPs were present in at least 800 subjects, while 507 910 
SNPs were present in more than 1000 subjects.  No SNP with MAF ≥0.05 met the 
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experiment wide significance cutoff p < 8.8 x 10-9,  based on a Bonferroni correction for 
5.66 Million tests, or the arbitrary genome wide significance cutoff of 5 x 10-8 (Bonferroni 
for 1 million SNPs). 
 
Figure 3.12.  Meta-analysis Manhattan plot.  The red line is at  p = 5 x 10-8.  The large 
centromere of Chromosome 9 is visible. 
 
 
 
Significant associations within the HLA region were not examined using this genome wide 
approach because the SNP2HLA program imputed the HLA region with much higher 
accuracy. 
 
Suggestive associations (p <1 x 10-6) were found at 10 loci.  A suggestive association was 
present at a TNFα receptor gene, Tumour Necrosis Factor Receptor Superfamily, Member 
  
110 
 
1B (TNFRSF1B).   The strongest association was at SNP rs79388457 which is located in 
an intron.  This gene is expressed in leucocytes.  Unlike TNFRSF1A, it has not been 
identified as a significant association in previous AS susceptibility GWAS or previous 
candidate gene studies of radiographic severity. 
 
Table 3.6.  TNFRSF1B association results.  Association was present in imputed SNPs 
from both cohorts and from a genotyped SNP.  The standardised effect size of the TASC 
SNP rs79388457 is 3.56. 
SNP Position 
(base 
pairs) 
MAF Subjects with 
SNP value and 
SNP type 
Effect 
Direction 
SPARCC 
cohort p-
value 
TASC 
cohort p-
value 
Meta-
analysis p-
value 
rs79388457 12243674 0.13 877 Imputed ++ 0.09 3.9 x 10
-6
 1.4 x 10
-6
 
rs235221 12263817 0.32 211 Imputed ++ 1.7 x 10
-4
 0.03 1.7 x 10
-4
 
rs1061622 12252955 0.23 877 Genotyped ++ 2.7 x 10
-3
 2.2 x 10
-3
 3.5 x 10
-5
 
*Risk Allele Frequency from 1000 Genomes dataset 
 
Figure 3.13.  Regional association plot for TNFRSF1B  (meta-analysed SNPs).  The 
strongest association signal is from the intronic SNP rs79388457. 
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An association signal was present at the NOD-Like Receptor Pyrin domain-containing 
protein 7 (NLRP7 also known as NALP7, NOD12, PYPAF3) locus, with peak association 5 
kb from the gene.  It is expressed in leucocytes and gastrointestinal and respiratory 
epithelium and plays a role in inflammasome regulation.  The lead SNP is between NLRP7 
and Natural Cytotoxicity Triggering Receptor 1 (NCR1), a receptor capable of triggering 
NK cell activation.  The lead SNP is in an intergenic region but many of the significantly 
associated imputed SNPs (from both cohorts) are within NLRP7, making NLRP7 the more 
likely source of association. 
 
Table 3.7.  NLRP7 association results.  Association was present in both cohorts and in a 
SNP genotyped in >1000 subjects.  Notably the lead meta-analysed SNP is a low 
frequency variant with MAF <0.1, and has a large effect size in the TASC cohort.  The 
standardised effect size of the TASC SNP rs139325508 was 4.01. 
 
 
SNP Position 
(base 
pairs) 
MAF Subjects with 
SNP value 
and SNP type 
Effect 
Direction 
SPARCC 
p-value 
TASC p-
value 
Meta-
analysis 
p-value 
rs139325508 55429591 0.06 974 Imputed ++ 0.31 6.3 x 10
-6
 8.6 x 10
-6
 
rs11668142 55900417 0.39 226 Imputed -- 4.8 x 10
-4
 0.15 2.6 x 10
-3
 
rs269933 55439166 0.46 1035 Genotyped -- 0.2 1.3 x 10
-4
 6.6 x 10
-5
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Figure 3.14.  Regional association plot for NLRP7 (meta-analysed SNPs). 
 
 
Figure 3.15. Regional association plot for NLRP7. Genotyped SNPs from TASC cohort.  
Multiple independently genotyped SNPs are in the association peak (p ~ 10-5).  Red 
indicates that these SNPs are in high LD with the lead SNP (purple). 
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A suggestive association was seen near the gene Fibroblast Growth Factor 4 (FGF4), with 
peak association 21kb from the final exon.  The peak could represent an insulator or 
enhancer of FGF4. Alternately the locus could regulate FGF19, which is 50kb from the 
association peak.  FGF4 is expressed in skeletal muscle, tendon, granulocytes, 
osteoblasts and respiratory epithelium.   
 
Table 3.8.  FGF4 association results.  A suggestive association was present upon meta-
analysis, but the most significant SNPs in each cohort and from genotyped data had p-
values of magnitude 10-4 and 10-3.  The standardised effect size of the lead TASC SNP 
rs1944131 was 1.84. 
SNP Position 
(base pairs) 
MAF Subjects 
with SNP 
value and 
SNP type 
Effect 
Direction 
SPARCC 
cohort p-
value 
TASC 
cohort 
p-value 
Meta-
analysis p-
value 
rs1944131 69572577 0.32 603 Imputed ++ 0.01 1.6 x 10
-4
 Not avail 
rs73518063 69879369 0.06 211 Imputed -- 1.2  x 10
-3
 Not avail Not avail 
rs9736587 69569224 0.31 
Geno: 603 
Imp: 485 
++ 0.01  5.0 x 10
-6
 
 
 
  
  
114 
 
Figure 3.16.  Regional association plot of FGF4  (meta-analysed SNPs).  The association 
peak demonstrates LD with FGF4, demonstrated by the recombination peak (peaked blue 
line) at 69.6 Mb. 
 
 
A suggestive association was seen within Bone Morphogenic Protein 2 (BMP2).  This 
association was only of magnitude 10-3 in each cohort but is notable because of the 
known involvement of BMP2 in bone metabolism.  Peak association was within an exon.  
All meta-analysed SNPs with p <1 x 10-4 had MAF of 0.07 in this cohort.  For example, the 
lead meta-analysed SNP had a Risk Allele Frequency 0.07, so would be present in 57 
individuals in this study.  The effect size of the lead TASC SNP is high, and of similar 
magnitude to the lead TASC TNFRSF1B SNP.  The small sample size of this GWAS, and 
peak association in genotyped SNPs of only 5 x 10-3 makes this association tentative. 
This association was only of magnitude 10-3 in each cohort but is notable because of the 
known involvement of BMP2 in bone metabolism. 
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Table 3.9.   BMP2 association results.  Association at BMP2 was present in both cohorts, 
with the strongest association in low frequency variants with MAF <0.1.  The standardised 
effect size of the lead TASC SNP rs13037675 was 5.9. 
SNP Position 
(base 
pairs) 
MAF Subjects with SNP 
value and SNP type 
Effect 
Direction 
SPARCC 
cohort 
p-value 
TASC 
cohort p-
value 
Meta-
analysis 
p-value 
rs13037675 6759706 0.07 814 Imputed ++ 0.037 7.8 x 10
-5
 8.1 x 10
-6
 
rs11697474 6722811 0.07 211 Imputed ++ 5.4 x 10
-3
 Not avail Not avail 
rs6910011 6877411 0.45 211 Genotyped   5.1 x 10
-3
 5 x 10
-3
 
 
Figure 3.17.  Regional association plot of BMP2 – meta-analysed SNPs. 
 
  
  
116 
 
Figure 3.18.  BMP2 regional association plot by cohort. TASC imputed SNPs (A) and 
SPARCC imputed SNPs (B).  Little association is seen in the SPARCC cohort. 
A) 
  
B) 
  
 
A suggestive association was seen at Orofacial Cleft Candidate 1 (OFCC1).  
Chromosomal breakpoints at this locus have repeatedly been associated with congenital 
orofacial cleft in humans, however OFCC1 knockout does not cause this malformation in 
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mice (178).  OFCC1 is expressed by respiratory epithelium, stimulated monocytes, bone 
marrow stromal cell lines and smooth muscle.  The peak association at OFCC1 is located 
in an intron.   
 
Table 3.10.  OFCC1 association results.  Association at OFCC1 is present in both cohorts.    
The standardised effect size of lead TASC SNP rs9383171 is 4.19. 
 
SNP Position 
(base 
pairs) 
MAF Subjects with 
SNP value and 
SNP type 
Effect 
Directi
on 
SPARCC 
cohort p-
value 
TASC 
cohort p-
value 
Meta-
analysis 
p-value 
rs9383171 9873422 0.17 1088 Imputed -- 0.18 4.4 x 10
-7
 1.1  x 10
-6
 
rs6914253 9824464 0.14 814 Imputed ++ 8.2 x 10
-6
 0.65 7.7  x 10
-3
 
rs9396671 9869358 0.12 1088 Genotyped -- 0.11  7.6  x 10
-7
 
 
Figure 3.19.  Regional association plot of OFCC1 (meta-analysed data). 
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Figure 3.20.  Regional association plot of OFCC1  (TASC cohort).  The association peak 
extends to either side of a recombination hotspot (peaked blue line).  Consequently there 
are two non-linked signals within OFCC1 (coloured red and navy), one on each side of the 
recombination hotspot. 
 
Figure 3.21.  Regional association plot of OFCC1 (SPARCC cohort).  The association 
peak is independently present the SPARCC cohort too. 
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A suggestive association is present at the protein kinase Vaccinia Related Kinase 2 
(VRK2).  Peak association is present in an intron.  VRK2 modulates transcription of 
cytokines including IL-1β and has been associated with schizophrenia and generalised 
epilepsy (179, 180).   VRK2 is expressed in stimulated monocytes, neutrophils, tendon and 
the substantia nigra.  Two independently genotyped SNPs in the TASC cohort were 
significant p ~ 10-6. 
 
Table 3.11.  VRK2 association results.  Association was predominantly in the TASC 
cohort, in imputed and genotyped SNPs.  The SPARCC imputed SNP is a low frequency 
variant with MAF <0.1.  The standardised effect size of lead TASC SNP rs2716999 is 2.36. 
 
SNP Position 
(base 
pairs) 
MAF Subjects 
with SNP 
value and 
SNP type 
Effect 
Direction 
SPARCC 
cohort 
p-value 
TASC 
cohort p-
value 
Meta-
analysis 
p-value 
rs2716999 58075743 0.3 
603 
Imputed 
++ 
0.48 1.1 x 10
-6
 8.7 x 10
-6
 
rs144500729 57003489 0.06 
211 
Imputed 
-- 
2.7 x 10
-3
 Not avail 2.6 x 10
-3
 
rs1607889 58073603 0.3 
603 
Genotyped 
++ 
0.55  1.8 x 10
-6
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Figure 3.22.  VRK2 regional association plot.  (meta-analysed data).  The strong p-values 
in the TASC cohort were diminished by the lack of association in the SPARCC cohort.  
The closest gene in the 5’ direction to the association peak is CCDC85A, an 
uncharacterised gene 1.5 MB distant. 
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Figure 3.23.  VRK2 regional association plot  (genotyped TASC SNPs).  This plot consists 
of genotyped SNPs from the TASC cohort only, and appears sparse compared to the 
imputed regional association plots.  Notably, two linked SNPs (purple and red) had p-
values of magnitude 10-6. 
 
 
 
A suggestive association was seen at 3p24.1.  Peak association was 216 bp upstream of a 
genscan predicted transcript and 23.5 kb downstream an ENSEMBL predicted gene 
(ENSG00000235493).  The transcripts at this locus are predicted to code for long 
intergenic non-coding RNA (lincRNA).  This peak is 255 kb from the gene eomesodermin 
(EOMES), which is a known AS susceptibility locus (22).  No regulatory features such as 
DNA methylation were present at this locus.  The association was strongest in low 
frequency and rare variants. 
 
  
  
122 
 
Table 3.12.  3p24.1 association results.  Association at this locus was predominantly in 
TASC subjects, in low frequency variants with MAF <0.1.  Genotyped TASC SNPs and 
SPARCC subjects only had association of 1 x 10-3.  The standardised effect size of lead 
TASC SNP rs77367404 is 3.18. 
SNP Position 
(base 
pairs) 
MAF Subjects 
with SNP 
value and 
SNP type 
Effect 
Direction 
SPARCC 
cohort 
p-value 
TASC 
cohort 
p-
value 
Meta-
analysis 
p-value 
rs77367404 28015174 0.08 
603 
Imputed 
++ 
0.01 
1.6 x 
10
-5
 
6.3 x 10
-7
 
rs7623233 27922474 0.12 
211 
Genotyped 
++ 
1.0 x 10
-3
 0.31 0.01 
 
 
A suggestive association was seen at 4q21.23, in the intron of ENSEBML predicted gene 
ENSG00000250546.  The transcript is expressed in muscle, leucocytes, fibroblasts and 
chrondrocytes, and is predicted to be lincRNA.  This pattern of expression is consistent 
with sites of inflammation and bone formation in AS. 
 
Table 3.13.  4q21.23 association results.  Association was present in each cohort and in a 
genotyped SNP.  The standardised effect size of the lead TASC SNP rs11099621 is 1.73. 
SNP Position 
(base 
pairs) 
MAF Subjects 
with SNP 
value and 
SNP type 
Effect 
Direction 
SPARCC 
cohort p-
value 
TASC 
cohort p-
value 
Meta-
analysis 
p-value 
rs11099621 84762151 0.4 
Geno: 603 
Imp: 211 
-- 0.002 1.4 x 10
-4
 1.23  x 10
-6
 
rs13147593 84756536 0.16 211 Imputed ++ 6.8 x 10
-4
 0.02 2.3 x 10
-4
 
 
A suggestive association was seen 82.5 kb from the last exon of 5-Hydroxytryptamine 
receptor 5A (HTR5A), a G-protein coupled receptor.  This gene is expressed in multiple 
cell types of the central nervous system. 
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Table 3.14.  HTR5A association results.  Association was present in both cohort and in 
genotyped SNPs.  The standardised effect size of the lead TASC SNP rs10260348 is 2.26.  
 
SNP Position 
(base pairs) 
MAF Subjects 
with SNP 
value and 
SNP type 
Effect 
Direction 
SPARCC 
cohort p-
value 
TASC 
cohort p-
value 
Meta-
analysis 
p-value 
rs10260348 154959965 0.45 
814 
Imputed 
-- 0.19 1.7  x 10
-6
 1.7  x 10
-6
 
rs1973359 154135286 0.18 
211 
Imputed 
 1.4  x 10
-3
 0.93 0.09 
rs1730175 154955663 0.29 
814 
Genotyped 
-- 0.017 2.4 x10
-4
 1.3x10
-5
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3.3.3   HLA Association  
 
7674 HLA SNPs were imputed for 1144 subjects who were genotyped on Immunochip.  
Association testing was performed using three level smoking status model residuals for 
each cohort, then meta-analysed.  Only 876 subjects had a three level smoking status. 
 
No HLA haplotype had a signification or suggestive association.  HLA-B27 had no 
significant association (p=0.34).  No HLA alleles or amino acid polymorphisms had a 
suggestive association, and no allelic association met significance using the Bonferroni 
correction for 7674 independent tests of 6.5 x 10-6.  The most significant p-value was 3.7 x 
10-4 for the intergenic SNP rs12203825.  No HLA allele listed by a previous candidate gene 
study by Ward et al. was significant with p < 0.1 (71). 
 
The process was repeated ignoring correction for smoking status, allowing 1144 subjects 
to be included.  Again, no significant association was found.  Peak association was at the 
intergenic SNP rs3130320 p= 2.0 x 10-4. 
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Figure 3.24.  Regional association plot at HLA B and C loci.  Only SNP associations are 
plotted – amino acid and HLA association results are not shown.  Not significant SNP 
association is present.  The nearest suggestive association is at OFCC1 (not shown). 
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Figure 3.25.  Regional association plot at HLA Class II loci.  No significant SNP 
association is present. 
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3.3.4  GCTA Results 
 
For the phenotype of mSASSS and cmSASSS, corrected for gender, symptom duration 
and smoking status, the estimated phenotypic variation due to genetic factors (VG / VP) 
was 0.330 or 33% (p = 0.006, standard error 0.136, using 984 subjects).   
 
The per chromosome analysis was limited by the small number of subjects and SNPs.  
Only two chromosomes had significant results – Chromosomes 3 and 5.   Chromosome 6, 
which includes the HLA, did not have a significant VG / VP. 
 
Table 3.15.  Significant per chromosome GCTA results. 
Chromosome SNPs 
included 
Significance VG/VP Standard Error 
3 20 414  p = 0.02 0.082 0.05 
5 18 070 p = 0.01 0.102 0.054 
18 9 857 p = 0.05 0.098 0.055 
     
6 31 497 p = 0.20 0.023 0.034 
 
The basic GCTA sensitivity analysis demonstrated that the results were robust to 
confounding covariates including population structure and model covariates.  The 
phenotype was found to be significantly heritable without correction for gender or smoking 
status (p = 0.03), without correction for PCs (p = 0.01) or while correcting for ten PCs (p = 
0.01). 
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3.3.5  Allelic Risk Score  
 
In the both cohorts, allelic risk scores for AS susceptibility, nicotine dependence and height 
were not predictive of radiographic severity.  In the SPARCC cohort only, the BMD score 
was a significant predictor of mSASSS, with a borderline level of significance (p=0.037). 
The SPARCC model reported a large positive effect size of 0.67 standardised units for 
BMD score, slightly greater than that of gender at 0.58 units.  In the TASC cohort the BMD 
score was not a significant predictor and had a positive effect size of 0.25 units.  If BMD 
score were a true predictor of magnitude greater than gender, it should be significant in 
both cohorts.  For this test, the TASC cohort was 1.8 times larger, so would be expected to 
identify a large predictor such as this.  The finding of significance in the SPARCC cohort is 
lost if the BMD score is split into multiple levels (ie high, medium, low BMD score).  For 
these reasons, the significance of the SPARCC BMD score is unlikely to be a true positive 
result. 
 
Figure  3.26.   AS susceptibility allelic risk scores (TASC cohort). 
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Figure 3.27.  Observed cmSASSS vs AS risk score.  There is no apparent relationship 
between the AS susceptibility based allelic risk score and observed cmSASSS.  This 
observation holds across symptom duration.  Attempts to fit a linear model (blue dotted 
line) find no significant linear relationship in any of these four symptom duration bin. 
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Table 3.16.  Significance of allelic risk scores.  P-value for signficance in the ZINB model.  
BMD was only significant in the SPARCC cohort. 
 
Score Cohort Subjects Score Significance 
AS susceptibility TASC 515 p > 0.59 
AS susceptibility SPARCC 201 p > 0.34 
BMD TASC 375 p > 0.27 
BMD SPARCC 210 p = 0.037 
Height TASC 374 p > 0.14 
Height SPARCC 210 p > 0.84 
Nicotine 
dependence 
TASC 387 p > 0.93 
Nicotine 
dependence 
SPARCC 260 p > 0.64 
 
Apart from the BMD based score, there was no significant or suggestive association in 
either cohort, making a significant association on meta-analysis impossible.  Additionally, 
meta-analysis would have decreased number of SNPs examined as they needed to be in 
common between the two cohorts. 
 
The BMD based score was only of borderline significance (p=0.037) in the smaller 
SPARCC cohort.  Even meta-analysis with an equal sized cohort would have yielded a p-
value >0.1.  Importantly, because this method uses many SNPs to create each score, 
significant associations in both cohorts would be required to justify further investigation. 
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3.4  Discussion 
3.4.1 GWAS Power and Limitations 
 
The power of this GWAS was determined by a number of factors, especially the expected 
heritability of risk SNPs, the number of subjects, and the number of SNPs genotyped.  The 
association analysis also relies on adequate phenotype modelling. 
 
The TASC and SPARCC cohorts had thousands of subjects with clinical covariates, 
mSASSS and genotypes, but when limited to subjects with all three forms of data, the 
number of subjects was reduced to a little over 1000. 
 
The power of this study limited its ability to investigate low frequency variants, and 
common variants with effect sizes <0.2 of a standardised phenotype.  From AS 
susceptibility GWAS and comparable quantitative GWAS of BMD, it would be expected 
that radiographic severity in AS is determined by numerous loci with a range of effect 
sizes.  For example, the GEFOS2 study of BMD found dozens of SNPs with effect sizes 
<0.1 standard deviations and a few SNPs with effect sizes of 0.1 – 0.15 standard 
deviations (176).  This indicates that bone metabolism is largely determined by SNPs with 
a small effect size. 
 
GWAS have an intrinsic inability to identify specific types of causal variants.  Variants with 
low heritability (ie low MAF or effect size) or in low LD with the nearest tag SNP are less 
significant on association testing.  Additionally it is not clear if an association signal is from 
a rare causal variant with a large effect size or from a common variant with a small effect 
size (181).  It could be argued that maximising LD between tag SNPs and causal variants 
by dense genotyping would reduce this problem and maximise power.  However 
simulations by multiple authors suggest that increasing sample size has a much greater 
effect on power than increasing SNP coverage (149, 181).  This GWAS had a limited 
ability to detect causal variants that have low heritability or are in low LD with tag SNPs. 
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Another factor that affects the power and accuracy of this study is the assumption that the 
ZINB model accurately represents the data.  As discussed in Chapter 2, the ZINB model is 
the best available model and is reasonably able to predict cmSASSS, as demonstrated by 
the estimated model r2 of 0.39.  Nevertheless, models of non-parametric data rarely 
describe observed data perfectly.  The challenge of modelling mSASSS has been 
addressed by previous authors either by longitudinal modelling that only examines change 
in score or by ZINB modelling (65, 79). 
 
This GWAS was adequately powered to detect common variants with large effect sizes, 
while the phenotype was expected to be determined by variants with predominantly small 
effect sizes.   
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3.4.2  GWAS Findings 
 
For the phenotype of radiographic severity, this GWAS identified no locus with significant 
association after Bonferroni correction for multiple testing (p < 8.8 x 10-9) or the arbitrary 
genome wide significance level of p < 5 x 10-8.  Less than ten loci had a suggestive 
association (p < 1 x 10-5).  None of these loci were identified by previous candidate gene 
studies of radiographic severity.  None of the suggestive loci were identified in previous AS 
susceptibility studies, although the effect size for susceptibility and radiographic severity 
are likely to be different.  The suggestive associations include loci with a range of 
functions, including some related to inflammation or bone metabolism. 
 
TNF inhibitors are commonly used treatment for AS.  Their ability to influence bone 
formation in AS is not currently clear, with one observational study finding a protective 
effect and multiple studies finding no effect.  TNFRSF1A and TNFRSF1B are the two main 
soluble TNF receptors.  A recent candidate gene study by Cortes et al. did not examine 
SNPs from either of these two loci, with the closest examined SNP to TNFRSF1B being 10 
Mb away (116). The receptor TNFRSF1A has repeatedly been identified as an AS 
susceptibility locus (22, 36), and the study by Cortes et al. associated RANK 
(TNFRSF11A) with radiographic severity in AS.  Polymorphisms in TNFRSF1B have been 
associated with response to infliximab in Crohn’s Disease (182, 183) and may play a 
similar role in AS.  The suggestive association of TNFRSF1B in this study reinforces the 
known involvement of the TNF pathway in the altered bone metabolism of AS.  The exact 
relationship between TNF and excessive bone formation in AS is controversial.  TNF 
inhibits the bone forming Wnt pathway by upregulating DKK-1 and sclerostin which inhibit 
the Wnt pathway (21, 26).  A simple loss of function variant of TNFRSF1B is not likely to 
be the link between TNF and bone formation, as TNF inhibition in AS cases does not 
accelerate bone growth (184).  However in a mouse model, dual blockade of DKK-1 and 
TNF promoted osteophyte formation (26).  The nature of these signals at growing 
syndesmophytes is clearly complex, and may involve regulation by other pro-inflammatory 
cytokines.  MRI studies suggest that osteoproliferation is more likely to occur at vertebral 
corners with persistent osteitis or where osteitis has resolved (13).  Perhaps in these 
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circumstances the balance of pro-inflammatory and bone repair signals reduces the ability 
of TNF to inhibit Wnt via DKK-1.  The involvement of the TNF pathway in bone formation is 
complex, but the fact that TNF is an innate pro-inflammatory cytokine ties inflammation 
with bone formation.  The uncoupled theory of bone formation in AS postulates that bone 
formation is independent of inflammation.  The uncoupled theory is supported by studies of 
mouse models that show no change in bone formation in the presence of TNF inhibitor 
(17).  The association of two TNF receptors, TNFRSF1A  and TNFRSF1B, and the RANK 
receptor TNFRSF11A with AS implies a close connection between inflammation and 
osteoproliferation.  It provides further evidence that the innate inflammatory pathways of 
TNF and RANK influence bone formation in AS.  This finding is an important contribution 
to our understanding of AS pathogenesis and implies that the TNF-Wnt pathway is 
responsible for osteoproliferation in AS. 
 
NLRP7 and the NLRP family of NOD Like Receptors detect Pathogen Associated 
molecular Patterns (PAMPs) and regulate the inflammasome (185).  NLRP7 detects 
microbial acylated lipopeptides, and can activate or inhibit caspase-1 in inflammasomes 
(186, 187).  Variants of NLRP family members have been associated with Crohn’s 
disease, atopic dermatitis and vitiligo (188).  The NLRP family has not previously been 
associated with AS susceptibility, despite multiple GWAS and a candidate SNP study that 
examined three SNPs in NLRP3 (189).  Mouse models of NLRP3 overactivity demonstrate 
excessive inflammasome activation, dramatically increased IL-1β production and multi-
organ inflammation.  The mice develop inflammatory arthritis and a Th17 predominant 
response (190, 191).  The involvement of IL-1 in AS was previously suggested by the AS 
Immunochip study, which found IL-1R1 and IL1-R2 to have suggestive associations, p < 5 
x 10-7 (22).  IL-1β is linked to bone formation by its induction of the Th17 response, which 
is known to promote bone formation at entheses (25).  Excessive activity of IL-1β in AS is 
also suggested by the strong association signal at VRK2, which modulates expression of 
IL-1β and other cytokines (179).  Hence association of the NLRP associated 
inflammasome and VRK2 in AS provide a theoretical mechanism for bone formation via IL-
1β and IL-17/23. 
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NLRP inflammasomes also influence and are influenced by the gut microbiome.  Presence 
of commensal bacteria amplifies the IL-1β dependent Th17 response (192).  NLRP6 
regulates gut mucosal immunity and microflora.  NLRP6 knockout mice develop 
inflammatory colitis and dysbiosis of gut microbiota, due to impaired clearance of enteric 
pathogens (193, 194).  These mice have a higher abundance of Prevotellaceae, gram 
negative bacteria that elicit a strong inflammatory response from the gut mucosa (193).  
When transferred from NLRP6 knockout mice to healthy wild-type mice, Prevotellaceae 
induce colitis.  A recent study by Costello et al. found that human AS cases also have a 
higher abundance of Prevotellaceae compared to healthy controls (195).  Loss of function 
variants in NLRPs causing impaired clearance of Prevotellaceae is a possible mechanism 
to explain the change in abundance and consequent colitis in AS.  Chronic colitis with 
inflammasome activation would produce IL-1β, causing an IL-17/23 response which would 
promote chronic bone formation.  Variation in NLRP function is a potential mechanism of 
innate immune system overactivity in AS.  It provides a theoretical template for 
understanding the mechanism for excessive acute inflammation, intestinal dysbiosis, 
colitis, the Th17 response and bone formation. 
 
Previous research has not identified the mechanisms that trigger the innate immune 
response in AS.  A candidate SNP study suggested CARD8, and not NLRP3 were 
associated with AS susceptibility. This study only compared one SNP in CARD8 and three 
SNPs in NLRP3 (189).  AS susceptibility studies have identified involvement of 
inflammasome components (eg CARD9) but not genes in the pathways that activate the 
inflammasome (22, 36).  NLRPs may activate the innate immune system in AS.  
Deleterious NLRP7 variants may promote to inflammasome overactivity, promoting a Th17 
phenotype and changes to the intestinal microbiota, resulting in colitis and arthritis.  Once 
intestinal dysbiosis is established, the inflammatory phenotype would be maintained by 
aberrant host-microbiota interactions from NLRP7.  NLRP7 therefore provides another 
potential pathway for innate immune system activation and chronic inflammation in AS. 
 
Confirmation of the involvement of the NLRP family in AS pathogenesis would strengthen 
the notion that AS involves aberrant activation of innate inflammation by pathways similar 
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to IBD.  Modulation of these innate pathways should influence severity of inflammation and 
osteoproliferation.  For example in AS and Crohn’s disease, TNF inhibitors are effective at 
reducing inflammation by blocking TNF, an innate pro-inflammatory signal.  This GWAS 
provides further evidence that innate pathways drive inflammation and bone formation in 
AS.   
 
FGF4 is involved in cartilage and bone metabolism and wound repair.  It regulates skeletal 
formation and chondrogenesis during development and is also expressed in adult mice 
(196-199).  Gene therapy with FGF4 has also been shown to improve soft tissue wound 
repair and to stimulate fibroblast proliferation (200).  The closely related FGF2 promotes 
endochondral ossification in fracture repair, and acts synergistically with BMP2 to increase 
ossification by periosteal cells via canonical Wnt signalling (201-203) .  Case reports of 
patients with craniosynostosis (premature ossification of cranial sutures), have found 
duplication of the 11q13.3 region containing FGF3 and FGF4 (204).  The process of 
syndesmophyte formation in AS is believed to involve erosion of cartilage and bone, which 
is replaced by cartilaginous repair tissue which later ossifies (11).  Similar to 
craniosynostosis, osteoproliferation in AS may be caused by overactive FGF pathways, 
initiated to repair erosions.  This would provide a link between the events of bone erosion 
and bone formation in AS, and would support the coupled hypothesis.  The association 
between the skeletal growth factor FGF4 with syndesmophyte formation should be 
investigated as it may provide the link that couples erosion to osteoproliferation in AS. 
 
A suggestive association exists at BMP2, a gene that stimulates osteogenesis, skeletal 
homeostasis and fracture repair (205).  The suggestive association was only present at 
markers with MAF < 0.1.  The association was present at low levels of significance in 
common genotyped SNPs from both cohorts.  The previous candidate gene study by 
Cortes et al. (116) included ten SNPs within BMP2, three of which had p<0.05 for either 
cervical, lumbar or total mSASSS.  No SNP in BMP2, BMP3, BMP4, BMP6, BMPR2, 
BMPR1A or BMPR1B met experiment wide significance.  Together these features make 
the significance of this locus uncertain.  Similar to FGF4, overactivity of BMP2 would be 
expected to cause excessive bone formation following bone injury or resorption from 
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normal bone turnover.  Aberrant BMP2 activity in AS would also provide a link between 
erosion and osteoproliferation.  The fact that this study as well as the study by Cortes et al. 
found some degree of association at BMP2 could be attributed to overlapping cohorts and 
the association of low frequency variants only.  Despite this uncertainty, the known 
relevance of BMP2 to bone metabolism makes it a target worthy of investigation. 
 
The suggestive associations at OFCC1, VRK2, 3p24.1, 4q21.23 are at loci with poorly 
defined functions.  There is also a suggestive association at HTR5A which has no evident 
involvement in spondyloarthropathy, inflammation or osteoproliferation.  OFCC1 is 
believed to cause an orofacial cleft malformation but its role in skeletal development and 
metabolism has not been ascertained.  VRK2, a protein kinase, has been linked to 
transcription of IL-1 β and is expressed in monocytes and neutrophils (179).  Its activity 
could therefore influence a range of autoimmune conditions.  It has not been identified as 
significant by association studies of any IL-1β related autoimmune disease, making its 
significance tied to the involvement of other IL-1β related signals.  The suggestive 
association in an intergenic region at 3p24.1 could be from a regulatory sequence for a 
predicted transcript 216 bp in the 3’ direction or for the EOMES which is 255kb in the 5’ 
direction.  EOMES is a transcription factor implicated in AS and Multiple Sclerosis that is 
associated with variation in CD8+ lymphocyte counts (22).  If the association signal is from 
EOMES, it would be the only suggestive association with any element of acquired 
immunity.  The suggestive association at 4q21.23 may be from a predicted lincRNA 
expressed in muscle, leucocytes, fibroblasts and chrondrocytes.  It may have regulatory 
functions related to wound repair, or metabolism of cartilage or bone. 
 
No loci with suggestive associations in this study were identified by previous candidate 
gene studies, as apart from BMP2 these loci were not investigated.  Candidate causal 
variants identified by previous studies (eg PTGS1, HLA alleles, NELL1, LMP2) were not 
found to be associated by this study.  These candidate gene studies were vastly different 
analyses in terms of genotyping, imputation and phenotype modelling.  It could be argued 
that this study, as the first genome wide study, and the first study to attempt complex 
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phenotype modelling has used the best approach to date.  The suggestive associations 
found by this GWAS require confirmation by future candidate gene studies or GWAS. 
 
GWAS suggests that genes related to the innate immune system, microbial interaction and 
bone repair are related to bone formation in AS.  These genes provide clues about the link 
between bone erosion and bone formation in AS, and the initiation and prolongation of the 
innate immune response and the Th17 response.  Future study should investigate the 
function of these genes and their pathways in AS cases, and compare the microbiome of 
risk variants. 
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3.4.3  HLA Association 
 
This was the first association study to compare the entire HLA region with the phenotype 
of radiographic severity.  Similar to the vast majority of previous studies, the phenotype 
was found to be independent of HLA-B27 status.  No other HLA allele or amino acid 
polymorphism was significantly associated with the phenotype. 
 
A previous candidate gene study by Ward et al. (71), identified numerous HLA alleles as 
predictors of radiographic severity.  In the combined TASC and SPARCC cohort, no HLA 
alleles listed by the previous study were significant predictors.  All candidate alleles 
identified by the study were low frequency variants (MAF < 0.1) with six out of eight being 
rare variants (MAF <0.05).   
 
Considering the results of the previous study by Ward et al. and this larger entire HLA 
analysis, there is no evidence to suggest that any polymorphism within HLA strongly 
contributes to radiographic severity.  This finding contrasts with the established role of HLA 
alleles in disease susceptibility.  AS susceptibility causal variants in the HLA probably 
contribute to inflammation without affecting syndesmophyte formation over time.  
Osteoproliferation is probably more strongly influenced by other pathways, such as innate 
inflammatory or bone repair pathways than acquired immunity initiated by HLA signalling. 
The lack of strong association between HLA alleles and radiographic severity is an 
indication that osteoproliferation in AS is driven by factors outside HLA related pathways. 
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3.4.5  Genome Wide Complex Trait Analysis 
 
GCTA demonstrates that variation in radiographic severity is strongly associated with 
genetic variation across the genome.  Similar to other diseases, SNPs that do not pass the 
stringent genome wide significance level do make a significant contribution to the 
phenotype (45, 206).  Apart from Chromosomes 5 and 3, the per chromosome analyses 
were not significant, likely due to the limited number of examined SNPs on each 
chromosome and therefore the proportion of genetic variance captured by the genotypes 
available. 
 
This is the first study using genome wide data to demonstrate the heritability of 
radiographic severity in AS.  It conservatively estimates the heritability to be at least 0.33, 
meaning that at least this proportion of variation in the phenotype is from genetic factors.  
Previous estimates of determinants of radiographic severity have attributed at least 23-
38% of phenotypic variation to non-genetic factors (Table 2.12, (3)), and 56% to genetic 
factors (6).   Given the limitations of this GCTA, and the limited contribution of non-genetic 
factors identified by many previous studies, heritability probably contributes more than 
non-genetic factors to the variability of this phenotype.  The true value of broad sense 
heritability is likely to approach two-thirds.  The simpler BASRI score of AS severity was 
estimated to have a broad sense heritability of 0.56 by a pedigree study (6).  It could be 
argued that this BASRI value, calculated by a pedigree study, is an overestimate due to 
the shared environment of family members.  A shared environment should not influence 
this GCTA as it compares specific genetic variants present in a population of 1020 
subjects (with related individuals removed) rather than a small number of families.  An 
improved GCTA estimate could be obtained with a sample size of 10 000 subjects, an 
approach used by prominent GCTA studies of quantitative phenotypes (47, 168, 207). 
 
The GCTA findings are promising for the role of genetics in the clinical management of AS.  
They suggest causal genetic variants are present and measurable.  Once identified, a 
prognostic score could be created to guide long term pharmacotherapy and aid patients in 
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life decisions.  The results also suggest that multiple loci with small effect sizes influence 
radiographic severity.  These are important drug targets, even if their effect size is small.  
In the case of AS susceptibility, pathological relevance is not proportionate to locus effect 
size.  The TNF pathway is an excellent therapeutic target, yet TNFRSF1A has OR 1.13 
compared to HLA-B27 with OR 60 (22).  The GCTA findings suggest unidentified causal 
variants are present, which should be investigated for clinical use. 
 
A particularly interesting finding of GCTA was that almost half of the whole genome VG/VP 
was present in Chromosome 5.  This finding was based on a large degree of variation in 
18 070 SNPs examined from Chromosome 5 and was highly significant.  There were no 
suggestive associations from Chromosome 5 on the GWAS, with no SNP having p < 1 x 
10-5.  AS susceptibility loci present on chromosome five include ERAP1, ERAP2, LNPEP, 
PTGER4, IL-12B and IL-7R.  None of these loci have been directly linked to bone 
formation, although PTGER4 encodes a prostaglandin receptor, and IL-12B encodes a 
subunit of the IL-23 receptor, which promotes bony spur formation (25).  The variation 
detected in this chromosome may be from these loci or from unidentified AS related loci.  
The presence of this strong signal in this relatively small GCTA sample suggests this 
chromosome is deeply involved in AS pathogenesis and should be examined for variants 
associated with osteoproliferation. 
 
Despite thorough genotyping of the HLA region with the Illumina Immunochip platform, the 
variation in Chromosome 6, which includes the HLA, was not found to be positively 
associated with the phenotype.  This adds to the findings of the HLA association testing, 
which do not demonstrate any contribution of the HLA region. 
 
GCTA can only compare the genetic variation presented to the software.  In this case, 
almost 400 000 SNPs were examined in over 1000 subjects.  Other GCTA studies 
commonly use over 5 000 subjects, and often use over 10 000 (47, 169).  The SNPs 
examined in this analysis are only a fraction of the genetic variation present in each 
subject.  An ideal analysis would include millions of genotyped SNPs from each subject, 
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with all causal variants tagged.  Because some causal genetic variation was probably not 
tagged in this study, the narrow sense heritability is probably higher than the GCTA 
estimate.  Additionally GCTA uses an additive genetic model so cannot assess heritability 
from other genotype-phenotype relationships, such as dominance, gene-gene interactions 
and gene-environment interactions.  For these reasons the estimate of narrow sense 
heritability by GCTA will always be lower than the true broad sense heritability.  Given the 
limitation of this analysis, the heritability of AS radiographic severity is at least 0.33. 
 
GCTA demonstrates that the phenotype of radiographic severity in AS is determined to a 
large degree by genetic variants that did not reach genome wide significance on GWAS.  
The phenotype is polygenic and is probably influenced by genetic variants more than 
environmental factors.  Further characterisation of these genetic variants would improve 
clinical management. 
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3.4.4  Allelic Risk Score 
 
To date no loci associated with AS susceptibility has been associated with AS radiographic 
severity.  The most apparent cause of failing to find loci with association would be an 
insufficient sample size to detect the effect size.  The allelic risk score analysis provides 
some ability to find a relationship between multiple loci with small effect sizes and the 
phenotype.  Once causal variants have been established, it can also be used for risk 
prediction.  The allelic risk score approach is most useful for polygenic traits with small 
effect sizes that are not highlighted by association testing of multiple independent loci by 
GWAS. 
 
An AS susceptibility allelic risk score assessed the contribution of forty AS susceptibility 
loci to radiographic severity.  Similar to the genome wide and HLA association testing, this 
polygenic analysis did not find association between loci known to cause AS susceptibility 
and radiographic severity.  HLA-B27 had to be removed from the score as its weighting 
(OR 60) made other loci irrelevant.  The score created from other AS susceptibility loci 
was not predictive of radiographic severity.  If inflammation is closely linked to bone 
formation in AS, inflammation related AS susceptibility loci might also be determinants of 
radiographic severity.  The allelic risk score analysis provided no evidence to support this.  
The AS susceptibility allelic risk score did not identify the expected relationship between 
AS susceptibility loci and osteoproliferation. 
 
Genes involved in bone metabolism are candidates for genetic determinants of 
syndesmophyte formation.  Individuals with bone maintenance or repair pathways that are 
prone to more bone deposition would presumably have a higher risk of syndesmophyte 
formation.  This analysis found no consistent evidence of the involvement of osteoporosis 
related genes in osteoproliferation.  If this finding were replicated on a larger scale it would 
be an indication that the processes that affect BMD over a lifetime differ to the processes 
that contribute to syndesmophyte formation.  This is unlikely given the involvement of 
inflammatory mediators such as RANK in both BMD and AS, and the connection between 
TNF and the bone forming Wnt pathway by DKK-1 (27, 116, 176).  The BMD based allelic 
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risk score did not identify the expected relationship between bone metabolism genes and 
osteoproliferation in AS. 
 
SNPs associated with human height were examined as previous studies have suggested a 
connection between bone growth loci and human height.  Analysis of height GWAS have 
identified numerous height associated SNPs in or near known bone or skeletal genes, 
including BMP3, BMP6, WNT6, WNT3A, WNT9A, MEF2C and STARD3NL (174).  The 
height based allelic risk score was not found to be predictive of radiographic severity.  The 
score may be misdirected in a number of ways.  It may focus on loci responsible for bone 
formation early in development, or may include alleles that predispose to bone formation in 
healthy individuals but not in AS.  Importantly the phenotype of human height is not the 
same as the osteoproliferative phenotype.  Human height is based on many factors, 
including the length of long bones.  Osteoproliferation in AS is more likely to involve genes 
related to bone mineralisation, bone repair and endochondral ossification.  
Osteoproliferation related alleles in the height score may be diluted beyond significance by 
alleles related to height only.  Despite the relationship between bone metabolism and 
human height, the role of height loci in the dysfunctional bone metabolism of AS remains 
to be established. 
 
Cigarette smoking is an established predictor of radiographic severity in AS (71, 79).  
Individuals with an increased risk of nicotine dependence are expected to be at risk of 
radiographic progression.  This analysis found no association between the nicotine 
dependence allelic risk score and radiographic severity.  Alleles associated with nicotine 
dependence are an indirect measure of smoking, which is influenced by many 
environmental and cognitive factors.  As the relationship between smoking and 
radiographic severity is strong, yet the risk score has no relationship, cognitive and 
environmental factors are probably the main predictors of smoking in this cohort.  
 
The allelic risk score analysis is a simple system with multiple limitations.  The most 
important requirement is that the SNPs included in the score must contain causal variants, 
or variants in LD with causal variants, of the phenotype being tested.  Another fundamental 
assumption of the weighted allelic risk score is that each loci's risk score effect size is 
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similar to its radiographic severity effect size.  It has been repeatedly established that the 
effect size of HLA-B27 on AS susceptibility is very different to its effect size on 
radiographic severity. It is therefore reasonable to assume that the effect sizes for other 
loci may differ greatly in their contribution to susceptibility and radiographic severity.  Loci 
included in this analysis may contribute to AS radiographic severity but if weighted 
incorrectly the effect may not be visible.  An alternative approach is to weight all loci 
equally, but again if these equal weights differ greatly from the actual effect size of each 
locus the relationship will be lost.  Similarly, if only a small fraction of loci included in the 
score are causal variants, the association will be diluted beyond significance.  Another 
shortcoming of this technique is that it estimates the risk from each locus by including only 
the risk from the lead SNP, not from all risk SNPs.  The allelic risk score is useful tool to 
investigate polygenic traits, but has major limitations, which is the likely reason it was 
unable to link these related phenotypes. 
 
The allelic risk score analysis was performed in an attempt to capture the possible 
contribution of many loci with small effect sizes.  Using four scores based on phenotypes 
related to AS, no connection was established. 
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3.5  Conclusion 
 
This study was the first genome wide comparison of genotype and radiographic severity in 
AS.  It was the first study to compare all HLA types with radiographic severity and to 
investigate the contribution of common genetic variants with low effect sizes to this 
phenotype. 
 
The GCTA study indicates that at least one third of phenotype heritability is from genetic 
variation.  This is the first genetic marker based study to confirm that a large proportion of 
AS radiographic severity is determined by genetic factors.  The conservative GCTA 
approach estimated phenotype heritability to be 33%, but given the lack of other predictors 
of radiographic severity, and the strong genetic component of AS susceptibility, the 
expected narrow sense heritability of AS is probably significantly higher than this.  The true 
value is probably at least as high as the estimated broad sense heritability of radiographic 
severity in AS using the BASRI score, 56%.  A broad sense heritability for this phenotype 
of 60% would be consistent with the phenotype modelling (Chapter 2) which attributed up 
to 39% of phenotypic variance to environmental factors and symptom duration.  The 
source of heritability identified by GCTA  is likely to be common variants of low effect size 
rather than low frequency variants, as these are not captured as well by the genotyping 
approaches used.  GCTA confirms the heritability of this phenotype, but the relative 
contributions of common and rare variants will need to be elucidated by large GWAS. 
 
The main clinical implication of this heritability finding is that AS severity appears to be 
more strongly influenced by genetic factors than environmental factors.  Phenotype 
modelling (Table 2.12) found <4% of variation was attributable to smoking, which is far 
smaller than that attributed to risk variants by GCTA.  Therefore, disease modification in 
AS should focus on treating aberrant cell biology rather than environmental exposures of 
limited influence. 
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This study suggested differing roles of acquired and innate immunity in AS pathogenesis.  
Highly accurate HLA imputation of more than 1000 cases did not associate any HLA type 
with radiographic severity.  Similarly GCTA did not find evidence that variation in 
chromosome 6 was significantly associated with the phenotype.  If replicated in a larger 
cohort, this would mean that HLA variation has little or no influence on bone formation in 
AS which suggests that acquired immunity does not influence it either.  Instead the GWAS 
findings suggest innate inflammatory pathways including TNF and inflammasomes are 
involved in osteoproliferation.  If confirmed, this study’s findings would suggest that while 
acquired immunity is a strong contributor to disease susceptibility, progressive bone 
formation in the spine is probably influenced by other factors, including innate 
inflammation.   
The GWAS findings also contribute to the discussion of mechanisms of bone formation in 
AS.  The GWAS results suggest an association between the innate immune system 
involvement and bone formation in AS.  NLRP7 containing inflammasomes and the TNF 
pathway and were associated with mSASSS.  This links acute innate inflammation with 
bone formation.  The anatomical location of the innate inflammation that drives bone 
formation is not clear.  The NLRP family are known to be act as microbial sensors and 
regulators within leucocytes in gut mucosa.  Activity of this family of genes at entheses or 
during bone repair has not been described.  NLRP7 variants may simply stimulate and 
maintain the Th17 pathway in the gut, causing colitis and systemic inflammation.  The link 
between NLRP7 and Th17 has not been established, but overactivity of the closely related 
NLRP3 stimulates a Th17 response (191).  An intestinal Th17 response has been shown 
to trigger inflammatory arthritis with bony spur formation in a spondyloarthritis mouse 
model (208).  Thus the NLRP family are a potential link between innate inflammation and 
Th17 induced bone formation in AS.   
 
Another innate inflammatory pathway, TNF, is known to be active in both colitis and 
osteitis.  The results of this GWAS suggest that the TNF-Wnt pathway contributes to bone 
formation in AS.  The role of TNF as a regulator of bone formation is controversial given 
the conflicting findings that TNF inhibition does not appear to increase syndesmophyte 
formation in cases, may inhibit bone formation in cases, and did not affect bone formation 
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a mouse model (17, 79, 184).  The mechanism by which the TNF-Wnt pathway promotes 
bone formation has not been established, but this GWAS finding suggests that TNF does 
influence bone formation in AS.  The suggestive association of two innate inflammatory 
pathways (NLRP and TNF) implies inflammation is tightly linked to bone formation in AS.  
These suggestive associations require replication and confirmation of effect size.  Activity 
of NLRPs could be compared between AS cases with and without active bone formation.   
 
Two bone metabolism loci, FGF4 and BMP2 had suggestive associations in this GWAS.  
These genes are involved in wound repair, and may be activated by bone erosion in AS.  
Overactivity of these genes would cause excessive bone formation in response to erosion.  
These loci could be investigated by examining their level of expression at sites of 
osteoproliferation or by known down studies.  
 
This GWAS did not associate known AS susceptibility loci with the phenotype.  This 
analysis used a dramatically different approach to susceptibility studies and consequently 
highlighted different loci that contribute to the related phenotype of radiographic severity.  
The method of quantitative phenotype analysis and the differing effect sizes that AS 
susceptibility loci have for susceptibility and severity are the likely reason why this GWAS 
identified new AS related loci in similar pathways to the AS susceptibility GWAS. 
The allelic risk score analysis did not find evidence that AS susceptibility loci, bone 
metabolism loci, nicotine dependence loci or height loci contribute to the phenotype of 
radiographic severity.  While the allelic risk score method provides only a snapshot of each 
subject’s genome, it was an attempt to create a simple clinically applicable prognostic 
score.  Presumably the causal variants are in loci related to the risk score loci, but were 
not tagged by SNPs used in the risk scores. 
 
This study had major acknowledged limitations which affected the statistical significance of 
the results.  The sample size and phenotype modelling were the best available to the 
researchers but both limited the study’s ability to detect causal variants.  The GCTA 
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estimate may have been limited by the small sample size.  Small GCTA studies include 1 
000 to 3 000 subjects, but prominent GCTA studies have sample sizes of 10 000 subjects 
(47, 168, 169, 207).  For the GWAS, HLA association testing and the allelic risk score 
analysis, the sample size only provided adequate power to detect common variants with a 
large effect size.  GWAS with low power have limited ability to detect causal variants in low 
LD with tag SNPs.  The allelic risk score analysis which relies on causal variants being in 
high LD with tag SNPs was significantly hindered by the low power.  The complex 
phenotype of syndesmophyte formation and ankylosis was difficult to model using a cross-
sectional approach.  A complex ZINB model was used as too few subjects had multiple 
radiographs to allow longitudinal analysis.  The adequacy of the ZINB modelling is difficult 
to assess.  Diagnostic model tests and sensitivity testing found the model to be adequate 
and the use of ZINB models by previous authors to model radiographic scores, including 
AS, is an indication that it is the best approach available.  An intrinsic limitation of the NB 
and ZINB models was the propensity to underestimate mSASSS in subjects with severe 
disease, resulting in the increased weighting of subjects with ankylosis.  This effect was 
clearly seen in the SPARCC cohort but was only a minor effect in the much larger TASC 
cohort.  The scoring of films by multiple readers is another potential source of error.  Minor 
inter-rater variation may have been present as most films were not scored by multiple 
readers.  The effect of inter-rater variation was probably minimal as the most subjective 
element of mSASSS, scores for erosions, sclerosis and squaring, were removed.  Inter-
rater variation would be minimised if films were scored by multiple readers or a single 
reader, or if longitudinal scores were analysed.  Longitudinal modelling with more 
extensive environmental exposure data, including disease activity, occupational and 
treatment data would enable more precise phenotype modelling.   Patient recall of disease 
symptom onset is likely to be a cause of error, which would be avoided using longitudinal 
studies.  Obtaining an adequate number of paired radiographs with a sufficient interval 
between them is challenging.  Further, such data would be subject to reader error with two 
sets of measurements, not just the one as is the case in cohort studies.  Other unidentified 
predictors of cross-sectional severity may also exist.  A larger cohort would also improve 
modelling, and if more than 3000 subjects were included, the GWAS power would improve 
dramatically, providing increased certainty regarding significant loci and improved 
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detection of low frequency variants.  This study had major limitations which should be 
considered by the next study into radiographic severity. 
 
The findings of all the genetic investigations suggest that genetic factors make a significant 
contribution to AS radiographic severity, probably more than all environmental factors 
combined.  No common risk alleles with large effect sizes were identified, but GCTA 
suggests that common variants with small effect sizes make a significant contribution, with 
at least one third of phenotype variation attributable to genetic variation.  HLA alleles and 
acquired immunity in general do not have a major influence bone formation in AS.  While 
HLA alleles are the main determinants of AS susceptibility, they do not appear to exert 
significant influence on bone formation over years.  Causal variants appear to be present 
in innate immune system pathways which suggests a close link with bone formation.  A 
possible new link between the Th17 response in the gut mucosa and bone formation in AS 
has been suggested.  These findings require replication in a larger cohort, but highlight 
areas of cell biology which with further characterisation may provide valuable therapeutic 
targets.  Future research should focus on identifying: common causal variants, the link 
between the suggestive GWAS associations and bone formation, and the potential role of 
the NLRP family and Prevotellaceae in the IL-17/23 response of AS. 
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Thesis Conclusion 
 
Ankylosing Spondylitis is a function limiting condition with few effective pharmacological 
agents.  Currently clinicians have a limited ability to predict or prevent future ankylosis.  
Identification of modifiable environmental or biological factors that influence ankylosis is an 
important goal in the management of this disease.   
 
This study identified and quantified the major known contributors to radiographic severity - 
gender, smoking and disease duration.  Smoking duration was found to be a more 
influential predictor of the phenotype than pack year history.  Common variants with small 
effect sizes were found to contribute to at least 30% of phenotype variation.  No signal was 
identified to link known contributors to AS susceptibility, including the MHC region, with 
radiographic severity.  Known AS susceptibility, BMD and height loci were not associated 
with severity, meaning that their effect size for severity was small or zero.  Genes in the 
same pathways as AS susceptibility loci, including the TNF pathway, were associated with 
radiographic severity.  A new suggestive association linking bone formation to immune-
microbiota interactions in the gut was made, which may explain observed patterns of 
microbiota in human AS cases.   Genetic associations also suggested that bone 
metabolism and inflammation related loci are related to the phenotype, although findings 
were not definitive.  Reasons for the study failing to identify definite genetic associations 
include its low power, errors in phenotype modelling from to a cross-sectional approach 
and lack of correction for other non-genetic predictors of severity such as medication. 
 
As the first comprehensive study of the relationship between genotype and radiographic 
severity, this study confirms that genetic factors make a significant contribution.  Multiple 
epidemiological studies have searched for non-genetic determinants, yet have not been 
able to attribute more than one third of variation to specific factors.  The genetic findings 
indicate that common variants, the innate immune system, bone metabolism and perhaps 
the microbiome all affect the phenotype.  The male gender is by far the largest genetic 
determinant of severity.  These contributors should all be investigated with much larger 
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genetic association studies as well as expression and functional profiling of the new 
candidate genes in AS cases.  Once replicated, significant genetic determinants of 
radiographic severity would make attractive targets for therapeutic intervention.  
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Appendix 
 
A.1  Symptom Score Details 
Visual Analogue Scale Stiffness  
 How much stiffness has the patient had because of the illness in the past week?   
Early Morning Stiffness  
 If the patient is stiff in the morning, about how long does the stiffness last (in 
minutes)? 
Exercise number per week 
 How many times does patient exercise in a typical week? 
Exercise minutes per week 
 How long does each exercise session typically last? 
Back Exercises days per week 
 Does patient do any back stretching or strengthening exercises? 
 
 
A.2  R Output for NB model of TASC contracted mSASSS  
 
Call:  glm.nb(formula = round_any(Tot_012, 1) ~ DISDUR + GENDER, data = full.xr,       
link = log) 
Deviance Residuals:   
 Min       1Q   Median       3Q      Max   
-1.8513  -1.3488  -0.5946   0.1888   3.0889   
 
Coefficients: 
            Estimate Std. Error z value Pr(>|z|)     
(Intercept) 0.314014   0.110914   2.831  0.00464 **  
DISDUR      0.048185   0.003146  15.317  < 2e-16 *** 
GENDERM     1.020703   0.105119   9.710  < 2e-16 *** 
--- 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
(Dispersion parameter for Negative Binomial(0.379) family taken to be 1) 
 
Null deviance: 1775.1  on 1391  degrees of freedom 
Residual deviance: 1481.5  on 1389  degrees of freedom 
AIC: 8381.3 
 
Number of Fisher Scoring iterations: 1 
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              Theta:  0.3790  
          Std. Err.:  0.0171  
 
 2 x log-likelihood:  -8373.3460 
 
Calculation of Dispersion Parameters for NB model 
φ = NB model deviance / residual degrees of freedom in NB model = 1481.465/1389 = 
1.067 
α = 1 / thetaNB model   = 1 / 0.379 = 2.639 
 
A.3  ZINB R OUTPUT of chosen model  
 
This model is listed as ‘Model A’ from Table 2.12. 
 
Call: 
zeroinfl(formula = Tot_012.success ~ GENDER + READER + DISDUR * 
smoking.duration,  
    data = full.xr.smkdur, dist = "negbin", EM = FALSE) 
 
Pearson residuals: 
    Min      1Q  Median      3Q     Max  
-0.9403 -0.5927 -0.3550  0.3161 10.0629  
 
Count model coefficients (negbin with log link): 
                          Estimate Std. Error z value Pr(>|z|)     
(Intercept)              1.2808113  0.2014353   6.358 2.04e-10 *** 
GENDERM                  0.5751680  0.1089477   5.279 1.30e-07 *** 
READER2                  0.1224244  0.1574228   0.778  0.43676     
READER3                  0.3590427  0.2142943   1.675  0.09384 .   
READER4                  0.2191919  0.1773103   1.236  0.21638     
READER5                  0.3070046  0.2068312   1.484  0.13772     
READER6                  0.5375261  0.3456145   1.555  0.11988     
READER7                 0.1522920  0.1886301   0.807  0.41946     
DISDUR                   0.0276956  0.0039376   7.034 2.01e-12 *** 
smoking.duration         0.0230824  0.0072838   3.169  0.00153 **  
DISDUR:smoking.duration -0.0003600  0.0001798  -2.002  0.04524 *   
Log(theta)              -0.0379427  0.0771288  -0.492  0.62276     
 
Zero-inflation model coefficients (binomial with logit link): 
                          Estimate Std. Error z value Pr(>|z|)     
(Intercept)              1.1264424  0.4499395   2.504   0.0123 *   
GENDERM                 -1.0244977  0.2011589  -5.093 3.52e-07 *** 
READER2                  1.0309194  0.4328975   2.381   0.0172 *   
READER3                  1.1706588  0.5519414   2.121   0.0339 *   
READER4                  0.7876221  0.4974656   1.583   0.1134     
READER5                  0.8532399  0.6534593   1.306   0.1916     
READER6                  0.0423468  0.9628321   0.044   0.9649     
READER7                  0.1915973  0.5020500   0.382   0.7027     
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DISDUR                  -0.1001037  0.0100910  -9.920  < 2e-16 *** 
smoking.duration        -0.0978515  0.0193117  -5.067 4.04e-07 *** 
DISDUR:smoking.duration  0.0023821  0.0006067   3.926 8.62e-05 *** 
--- 
Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1  
 
Theta = 0.9628  
Number of iterations in BFGS optimization: 29  
Log-likelihood: -3214 on 23 Df 
 
 
A.4   Goodness-of-fit plots for NB model (glm.nb function in MASS package) 
 
Standard goodness-of-fit tests to assess  homogeneity, independence of X and Y, outliers 
and influential observations.  Outlier subjects 1345, 1137 and 955 were checked for invalid 
observations, and none were found.  The histogram and QQ plot of residuals suggest an 
excess of smaller residuals than expected.  The plot of NB model residual vs observed 
values demonstrates that the model underestimates higher scores, and overestimates 
lower scores (causing the negative residual).  A zero-inflated model should address the 
latter issue.  NB model fitted values range up to 141, about three times the maximum 
cmSASSS value of 48. The abrupt upper and lower bounds of datapoints on the residual 
vs fitted plot are due to observed cmSASSS ending abruptly at 0 and 48. 
Standard goodness-of-fit tests to assess normality of residuals, homogeneity, 
independence of X and Y, outliers and influential observations.  Outlier subjects 1345, 
1137 and 955 were checked for invalid observations, and none were found.  The 
histogram and QQ plot of residuals suggest an excess of smaller residuals than expected.  
The plot of NB model residual vs observed values demonstrates that the model 
underestimates higher scores, and overestimates lower scores (causing the negative 
residual).  A zero-inflated model should address the latter issue.  NB model fitted values 
range up to 141, about three times the maximum cmSASSS value of 48. The abrupt upper 
and lower bounds of datapoints on the residual vs fitted plot are due to observed 
cmSASSS ending abruptly at 0 and 48. 
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Figure A.4.1  Pearson residual plot vs symptom duration plot. This demonstrates 
independence of the residuals from symptom duration  (the model predictor with the 
largest r2). 
 
Figure A.4.2  Pearson residual plot vs  fitted plot.  This demonstrates adequate 
homogeneity and is distributed as expected (See A.4.3 for expected distribution). 
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Figure A.4.3 Typical Pearson residual vs fitted plot for a ZINB model.  Reproduced from 
Hilbe (Figure 9.3) with permission from Cambridge University Press (113).  Pearson 
residuals of Generalised Linear Models are not expected to be normally distributed.  As 
Zuur et al. note (p230) "However, it should be noted that we are not looking for normality 
from the Pearson or deviance residuals.  It is all about lack of fit and looking for patterns in 
the deviance or Pearson residuals." 
 
Figure A.4.4  Predicted vs observed boxplot.  This demonstrates that predicted cmSASSS 
increases as observed mSASSS increases.  The size of predicted values are 
proportionately lower than the observed values.  For example the median predicted value 
for observed cmSASSS of 20 is 14.   
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A.5  Goodness-of-fit plots for ZINB model (zeroinfl() function, pscl package) 
 
Compared to the goodness-of-fit plots for NB, the final ZINB model has more normally 
distributed raw residuals which have a more random pattern when plotted against 
symptom duration.  The ZINB model also has smaller raw residuals which remain in the 0-
48 range of the cmSASSS scale.  The Pearson residual vs fitted plot is as expected 
(variance decreases with higher fitted values), and the predicted value increases as the 
observed value increases.  Covariates such as symptom duration have no remaining 
relationship with the Pearson residuals.  A QQ plot of Pearson residuals with an expected 
residual envelope confirmed an adequate model fit and robustness against influential 
outliers. 
 
Notably predicted vs observed plots demonstrate predicted values are lower than 
observed, especially at higher observed values.  This may be due to the fact that the 
negative binomial distribution does not include a peak for completely ankylosed individuals 
with a maximum mSASSS  (as demonstrated in Figure 2.11). 
 
Equation A.5.1.  Definition of Pearson Residuals.  Pearson residuals are calculated by 
dividing observed minus fitted values by the square root of the variance function.  Notably 
the NB distribution has a large variance at zero which decreases dramatically as x 
increases.  Small Pearson residuals indicate that the difference between observed and 
fitted values is small compared to the variance of the NB distribution at this point.   
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Figure A.5.1.  Pearson residual plot vs fitted values.  Figure A - The distribution of 
residuals is uneven with many small Pearson residuals, including many less than zero.  
Figure B is the same plot as Figure A, with observed cmSASSS values <=5 in green, and 
those >5 in red.  This demonstrates that the many low Pearson residuals are produced 
from the hundreds of subjects with observed cmSASSS <5.  Following modeling with fixed 
effects and the binomial and NB distributions in the ZINB model, the predicted (fitted) 
values are less clumped under 5 cmSASSS points.  Observations with a high fitted value 
have a higher Pearson residual, while many observations with a low fitted value have a 
small, negative Pearson residual.  Negative Pearson residuals indicate that the expected 
(fitted) value is higher than the observed.  These occur because the ZINB model 
underestimates the number of zeros (and low values) as the count model adds fixed 
effects for gender and Scorer.  For example, all males are given a fixed effect of 0.6 units, 
so a male with an observed cmSASSS of zero and a symptom duration of zero would have 
a predicted cmSASSS score slightly higher than zero, producing a negative residual.  
Small Pearson residuals indicate a small ratio between the difference in observed and 
fitted values compared to the variance function. The variance function is greatest 
approaching zero, so low variance of the residuals at this point will generate small Pearson 
residuals.  Thus the significant number of small and negative Pearson residuals is a result 
of many small observed cmSASSS, small differences between observed and expected 
values for low fitted values (due to fixed effects), and the higher variance of the NB 
distribution than the residuals as values approach zero. 
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Figure A.5.1. A 
 
Figure A.5.1. B 
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Figure A.5.2  Predicted vs observed plot.  This demonstrates that predicted values 
increase with observed values.  Similar to the NB model, predicted values are 
proportionately lower than observed values.   
 
Figure A.5.3  Pearson residual plot. Pearson residuals demonstrate indepence from 
symptom duration.  
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Figure A.5.4   QQ plot of Pearson residuals, with expected residual envelope.  Comparison 
of the residual (black) with the 95% confidence interval estimate (grey) generated by 
bootstrapping is an established test for ZINB models (114, 115). As the residuals are well 
contained within the bootstrapped estimate, the model fits adequately and is robust to 
influential outliers. 
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A.6 Modelling of SPARCC mSASSS 
 
As per the TASC cohort, the radiographic scores of the SPARCC cohort were 
approximated by the negative binomial (NB) distribution.  The NB model using SPARCC 
data was overdispersed, similar to the TASC data.  Correctible causes of real and 
apparent overdispersion were investigated.  Overdispersion due to excessive counts of 
zero were addressed by using a ZINB model.  The NB and ZINB models were compared 
using Vuong’s test, AIC and goodness-of-fit plots.  The ZINB model was superior.  
Goodness of fit plots for the ZINB model using SPARCC cohort data confirmed an 
adequate fit, independence of X and Y, and robustness against outliers. 
 
Standard assessment of negative binomial model fit involves examination of standardised 
‘Pearson residuals’ (112, 113).  
 
Overdispersion Calculations 
φ = NB model deviance / residual degrees of freedom in NB model = 1.19 
α = 1 / theta NB model =  1.29 
 
NB vs ZINB model comparison 
  
Table A.6.1  Goodness-of-fit tests of NB vs ZINB models.  Vuong’s test and AIC favour the 
ZINB model.  Lower AIC indicates superior fit. 
Model Vuong’s test AIC 
NB ZINB superior  
p < 0.013 
2055 
ZINB 2048 
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Figure A.6.1 Goodness of fit tests: QQ plot with residual envelope.  The QQ plot of 
Pearson residuals with expected envelope demonstrates adequate fit and robustness to 
outliers.   Comparison of the residual (black) with its 95% confidence interval estimate 
(generated by bootstrapping) is an established test of model fit for ZINB models (114, 
115).  As the residuals are well contained within the bootstrapped estimate, the model fits 
adequately and is robust to influential outliers. 
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Figure A.6.2  Goodness of fit tests: independence.  This plot of Pearson residuals from 
SPARCC ZINB model.  The residuals are independent of symptom duration (the predictor 
with the largest r2).  This demonstrates that the model adequately adjusts for symptom 
duration. 
 
 
 
Figure A.6.3  Goodness of fit tests: homogeneity. The Pearson residual vs fitted plot 
demonstrates adequate homogeneity of the model.  There is adequate spread across the 
residuals for each value of fitted.  The distribution of this residual vs fitted plot is as 
expected for a negative binomial model (See Figure A.4.3, reproduced from Hilbe (113)) 
 
  
166 
 
Figure A.6.4  Goodness of fit tests: predicted vs observed plot (SPARCC cohort).  
Appropriately, predicted mSASSS increases as observed mSASSS increases, however 
predicted mSASSS is proportionately lower than observed values.  Importantly all values 
are proportionately reduced, preserving the relative differences between subjects.  Notably 
predicted mSASSS plateaus at observed mSASSS over 40.  This is an intrinsic deficiency 
of the negative binomial distribution, where higher scores are less probable, meaning that 
the model under-predicts the number of subjects with severe disease (See Figure 3.1).  
The consequence of this deficiency is that subjects with ankylosis will have 
disproportionately higher residuals, weighting them the most strongly.  This is not 
necessarily an undesirable effect.  mSASSS is right censored, where no scores can be 
higher than 72.  The disproportionate weighting of individuals with severe disease may 
offset the effect of no mSASSS being greater than 72.  Another notable feature of the 
predicted vs observed plot is the fact that for an observed mSASSS of 0, the predicted 
value is 10.  This occurs because the model is describing an average subject - the majority 
of subjects are male smokers.  Addition of fixed effects for the male gender and a smoking 
history makes the predicted value >0, even though many males have an mSASSS of 0.  
The alternative would be to have a negative fixed effect for females, which would give 
female non-smokers a negative predicted mSASSS.  In the context of this condition, a 
negative predicted mSASSS cannot exist and is the less favourable choice. 
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Figure A.6.5  Predicted vs observed plot for TASC cohort.  The plateau effect is present 
but far smaller in the larger TASC model. 
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Figure A.6.6  Residual vs Observed Plots for each cohort.  In both cohorts, residual 
values, which were used as a corrected phenotype, increased with observed values.  The 
consequence of the plateau seen in Figure A.6.4 is that the most severe scores in the 
SPARCC cohort have disproportionately higher residuals, demonstrated by the larger 
increases between each box once observed mSASSS is greater than 40.  The TASC 
cohort does not display this effect as there is minimal plateauing of predicted values. 
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